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ABSTRACT 
Polymeric Materials for Controlled Ophthalmic Drug Delivery. 
Proliferative vitreoretinopathy, a potentially blinding condition, involves excessive 
proliferation of retinal pigment epithelium (RPE) cells and is the main complication 
following retinal detachment (RD). Complicated cases of RD are treated with 
silicone oil (SiO) tamponades which can potentially be used as drug reservoirs. The 
aim of this study was to investigate different methodologies to develop a sustained 
and controlled drug release of anti-proliferative and anti-inflammatory drugs from 
SiO tamponades using all-trans retinoic acid (atRA) and ibuprofen (Ibu).   
In detailed studies of atRA and Ibu, including atRA degradation behaviour, the drugs 
were found to be non-toxic to an adult RPE cell line (ARPE-19) below 10-5 M. The 
solubility of both drugs in SiO was assessed using radioisotope techniques. Prodrugs 
of atRA and Ibu were synthesised via conjugation to polyethylene oxide (PEO), and 
cleavage of the resulting ester bond, toxicity towards RPE cells, solubility in SiO and 
release into media were assessed. Prodrug cleavage was successful in vitro for Ibu 
but not achieved in the case of atRA due to its highly conjugated nature. Cytotoxicity 
assays showed PEO attachment had no effect on cytotoxicity and PEO-prodrug 
solubility in SiO followed the expected trend of decreasing solubility with increased 
PEO chain length. Overall the saturation concentration of drug in SiO achieved 
through the use of PEO-prodrugs was too low for an effective therapy.   
Lipophilic prodrugs with a poly(dimethylsiloxane) (PDMS) pro-moiety were 
synthesised and investigated. Their cleavage was problematic due to PDMS being 
highly hydrophobic and cleavage could only be achieved in vitro when a small 
hydrophilic spacer was added between PDMS and the drug. The effects of PDMS 
prodrugs as additives in SiO were investigated and the presence of PDMS-atRA in 
SiO was shown to have a positive effect on both atRA solubility and longevity of 
release. The clinically-relevant release period (6-8 weeks) was independent of atRA 
starting concentration but dependant on the PDMS-atRA concentration within the 
blend. This has potential for further development into tamponade drug reservoirs for 
future patient benefits. 
A series of linear and branched amphiphilic copolymer architectures were also 
evaluated as additives for SiO. Monomer selection included oligoethylene oxide 
methacrylate (OEGMA), 2-hydroxyethyl methacrylate, PDMS-methacrylate 
(PDMSMA) and the brancher PDMS-dimethacrylate (PDMSDMA). SiO solubility 
of p(OEGMA-co-PDMSDMA) was investigated and copolymers which contained 
the smallest hydrophilic and largest lipophilic components only achieved small 
solubility (0.1 % v/v). To overcome these solubility issues, hydrophobic PDMSMA 
monomer was utilised. Both linear p(PDMSMA-co-OEGMA) and branched 
p(PDMSMA-co-OEGMA-co-PDMSDMA) were successfully synthesised and 
displayed high solubility within SiO, up to 40-50 % v/v. 
The potential for SiO tamponades as long-acting drug reservoirs has been 
demonstrated after inclusion of a novel end-modified PDMS additive leading to long 
term release of atRA. The formation of novel polymer architectures that show 
considerable miscibility with SiO also shows the scope of the opportunity for further 
additive development to tailor release profiles. 
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1.1 THE EYE 
 
The eye is the structure in the body which receives light signals and converts them 
into neural signals, which the brain then transforms into visual images.1  
 
1.1.1 Structure  
 
The eye (Figure 1.1) consists of two partial spheres, the anterior chamber which is 
the region between the cornea and the lens containing aqueous humour, and the 
larger posterior region between the lens and the retina containing the vitreous 
humour.  The sclera is the tough white outer layer which protects the eye, fuses with 
the cornea anteriorly and is attached to the optic nerve posteriorly, whilst being 
nourished by a blood supply from the choroid. 
 
 
Figure 1.1 An illustration of the human eye, and its structure. 
 
1.1.2 Light Pathway  
 
Light enters the eye through the cornea, which is clear and convex in shape, causing 
the light to refract.  The light then passes through the aqueous humour (which 
provides nutrients and oxygen to the eye, as well as removing waste products), to the 
pupil.2  The amount of light which enters the pupil (a gap in the iris) is controlled by 
the contraction and expansion of the muscular iris.  Light is further refracted by the 
lens which is an important structure in focussing light; the lens adjusts its thickness 
via the ciliary muscles attached to it.  If an object is nearby the lens bulges but if the 
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object is far away the lens flattens. Then, the light passes through the vitreous 
humour which not only helps maintain the shape of the eye but also helps to focus.  It 
finally reaches the macula area of the retina surrounding the fovea.  The fovea is the 
thinnest area of the retina which contains the most photoreceptors and no capillaries.  
Once the retina processes the inverted and reversed image of the object being 
viewed, it is sent through the optic nerve to the visual cortex where the image is 
rearranged, enabling us to view the object as it is in reality. 
 
1.1.3 The Retina 
 
The retina is a light sensitive layer which is approximately 30-40 mm in diameter 
and lines the back of the interior of the eye.  The main function of the retina is to 
detect an inverted image via a light signal which is then converted into a 
communicable chemical signal by photo-transduction.  The ordered pattern is then 
sent to the brain through the optic nerve.   
 
The structure of the retina can be divided into two layers, the inner neuroretina and 
the outer epithelial monolayer consisting of retinal pigment epithelium (RPE), as 
depicted in Figure 1.2.  The neuroretina is made up of 9 layers including the inner 
limiting membrane (ILM) which is the structure of the retina closest to the lens and 
front of the eye.     
 
 
Figure 1.2 An illustration of the organisation of the retina. Adapted from ref: 
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Light travels through the majority of the retina before photons of light are absorbed 
by visual pigment within the photoreceptors (rods and cones).  The light activates the 
photoreceptors to produce a biochemical message which is sent synaptically to 
bipolar cells as an image by patterned excitation.  The photoreceptors are surrounded 
by horizontal and amacrine cells which modify the electrical signal before relaying it 
to the ganglion cells.  These spiking discharge patterns produced by both rods and 
cones are intermixed and combined when they are transmitted to the brain by the 
ganglion cells to produce a representation of the external environment.  
 
The outer epithelial layer consists of hexagonally packed cuboidal RPE which supply 
nutrients to the inner retinal visual cells and transports metabolic waste to the 
choroid.   The innermost layer of the choroid is the Bruch’s membrane which 
thickens with age, therefore, slowing down the transport of metabolites.    
  
1.1.4 Retinal Pigment Epithelium 
 
In humans the monolayer of RPE cells is situated at the back of the eye with its 
apical membrane facing the subretina, whilst the basolateral membrane is in contact 
with the Bruch’s membrane attached to the choroid.  There are approximately 3.5-6.1 
million RPE cells per eye.4 They are hexagonally close packed with simple cuboidal 
and columnar morphology, and vary in size depending on which area of the retina 
they are located.  Near the macular region they are narrower but taller (10-12 µm 
wide, 14 µm tall), however, near the periphery they are flatter and broader (60 µm 
wide and 10-14 µm tall).5  The RPE and neural retina are very closely linked; from 
embryonic development RPE cells and photoreceptor cells co-differentiate during the 
evolution of the eye.  Vitamin A (retinol) acts as a differentiation signal for both 
cells. The RPE cells express receptors such as the retinoic acid receptor beta-2 
(RAR-ß2) for retinoic acid (RA), a vitamin A derivative which is secreted by the 
developing retina.  The exchange of RA between primitive RPE and the neuroretina 
promotes the differentiation.4, 6 
 
Initially it was thought that the sole purpose of the RPE was to absorb scattered light.  
In fact, RPE cells have multiple functions including light absorption, epithelial 
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transport, spatial buffering of ions, visual cycle, phagocytosis, secretion and immune 
modulation, all of which are illustrated in Figure 1.3. 
 
 
Figure 1.3 Diagram of the major functions of RPE.
6
 
 
The retina is at high risk of photo-oxidative stress due to the high concentration of 
photo-oxidative energy within its environment.  This energy is created by the lens 
concentrating light radiation onto the macula, as well as the choroid supplying a high 
oxygen flow.7, 8  Photo-oxidation leads to damage of the photoreceptor outer segment 
tips which then require constant renewal.  This renewal process involves 
phagocytosis, which is the ingestion of solid particles into a phagosome within the 
cell; this is then removed by lysosomes.  The damaged photoreceptor outer segments 
near the RPE undergo phagocytosis which in turn leads to the release of free radicals 
to the high photo-oxidative environment.9 Therefore, the RPE has to be able to 
maintain the structural integrity of the retina by combating free radicals, 
photo-oxidative exposure and light energy.  The melanin present in the RPE 
contributes to removing the risk of photo-oxidative stress on other cells.   
 
RPE cells are also responsible for epithelial transport (Figure 1.3).  Metabolites and 
water accumulate in the subretinal space due to the retina having the highest cell 
density of any tissue in the body, as well as the intraocular pressure moving water 
from the anterior of the eye towards the retina.10  RPE cells, which form tight 
junctions that lead to the formation of the outer blood retinal barrier (BRB), are 
responsible for supplying nutrients and removing metabolites and water via active 
transport from the subretinal space.11  
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RPE cells regulate the spatial buffering of ions which is necessary due to the fast 
changes in ion concentration, and at this rate cannot be compensated for by normal 
transepithelial transport.  Mechanisms such as transduction of light by cells require 
the RPE to capacitatively compensate for the change in ion concentration.12   
Without this, the cells would no longer be excitable, therefore, the electrical signals 
produced would be halted and the pattern sent to the brain disjointed, resulting in 
incorrect image perception. 
 
RPE cells play a key role in the visual cycle via retinoid metabolism.  When a photon 
of light is absorbed by chromophores in a photoreceptor, chemical reactions such as 
the isomerisation of rhodopsin to meta-rhodopsin as well as 11-cis retinal to all-trans 
retinal are initiated.13  Phosphorylation determines the rate at which rhodopsin 
reforms; rhodopsin then requires the exchange of all-trans retinal to 11-cis retinal in 
order to be reactivated by another photon.  Photoreceptors do not express 
re-isomerase for all-trans retinal, so this takes place in RPE cells for rods and RPE 
and Muller glia cells for cones.14   
 
RPE cells must interact with both subretinal cells15 and cells on their basolateral 
side.16  RPE cells secrete numerous growth factors such as transforming growth 
factors beta (TGF-ß) and fibroblast growth factor (FGF) as well as transcription 
factors and signalling molecules.6 These are then directed to cells which have 
important physiopathogenic roles such as maintaining the integrity of surrounding 
tissues. 
 
The eye is an immune privileged space which, due to the BRB, is disconnected from 
the blood stream and therefore, the body’s immune system.17   As the eye is 
separated from the immune system, the RPE cells must communicate with each other 
and other cells via a variety of chemical and mechanical signals to provoke an 
immune response such as inflammation, if the eye becomes diseased, but ensure 
silence in a healthy eye.18    
 
1.2 RETINAL DETACHMENT 
 
Retinal detachment (RD) is a potentially blinding condition when the inner 
neuroretina becomes detached from the supporting RPE.  RD has become one of the 
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most common ophthalmic emergencies in the UK.19 Population-based studies from 
around the world have found annual incidence rates ranging from 6.8 to 17.9 per 
100,000 population,20-23 whereas within the UK the figures range from 6.3 to 13.6 
per 100,000 people.19, 24, 25 
 
1.2.1 Types of Retinal Detachment 
 
There are 3 different types of RD (Figure 1.4): rhegmatogenous RD (RRD, Figure 
1.4 B), exudative RD (ERD, Figure 1.4 C) and traction RD (TRD, Figure 1.4 C). The 
most common is RRD, which occurs when there is a tear in the retina.26   
 
Figure 1.4 Diagram of A: Tear in the retina, B: rhegmatogenous retinal detachment and C: exudative 
and tractional retinal detachment. 
 
Retinal tears (Figure 1.4 A) can be triggered by numerous causes including trauma, 
such as those experienced during boxing and bungee jumping, advanced diabetes, 
myopia, inflammatory eye diseases, retinal disorders or complications following 
cataract surgery.27-29  Myopia is the most common cause of non-traumatic RRD and 
accounts for 55 % of cases.27 Ageing also increases the risk of RRD to 20 in 100,000 
for middle aged/elderly people with the greatest risk in the age range 55-70 years30 
due to the retina becoming thinner as well as a change in vitreous.  The vitreous 
humour is a gel (97 % by weight of water) made up of a network of long collagen 
fibres with glycoprotein such as hyaluronic acid which non-covalently binds the 
water.  The vitreous moves as a single entity and is normally loosely attached to the 
back of the lens, the retina and the optic nerve; with age the consistency of the 
vitreous can shrink or become more fluid-like as the collagen network collapses.  
The vitreous then becomes detached from the optic nerve and the posterior retina 
whilst remaining attached to the anterior.  With eye movement the vitreous and the 
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retina move relative to each other and can result in forces that cause the retina to tear 
and detach. All of these factors can lead to the vitreous separating from the retina 
with enough force to cause a tear.  Vitreous humour then may leak through the tear 
and accumulate underneath the retina separating it further from the RPE.31  
 
Both TRD and ERD result in RD without a tear in the retina (Figure 1.4 C).  TRD is 
the second most common form of RD, and usually occurs as a complication of other 
diseases or conditions such as diabetic proliferative retinopathy and proliferative 
vitreoretinopathy (PVR), discussed in more detail in Section 1.4.  Scar tissue forms 
on the rods and cones and contracts, pulling the neurosensory retina away from the 
supporting RPE.32 
 
ERD occurs following the build-up of fluid from blood vessels into the space 
between the retina and the RPE.  ERD is triggered by other retinal diseases and 
conditions which cause abnormal development in blood vessels behind the retina, 
such as severe macular degeneration, very high blood pressure, certain cancers such 
as choroidal melanoma and rare blood vessel disorders.31   
 
1.2.2 Symptoms  
 
Patients with RD usually experience symptoms, however, some RDs are found 
following routine eye checks where the patient’s vision is perceived as normal.  
Common symptoms include the appearance of floaters or the increase number of 
floaters in the field of vision; these are caused by debris within the vitreous humour 
blocking the retina from receiving light signals.  6 out of 10 people with RD 
experience photopsia, i.e. flashing lights in vision even when eyes are closed or in a 
darkened room.  Patients also experience vision loss either centrally or from shadows 
in the peripheral, which can be described as a “curtain effect” where a portion of 
their visual field slowly progresses in being blocked out. 
 
1.2.3 Treatments  
 
There are numerous treatments available for RD, all with the aim of reattaching the 
retina to the RPE and fixing any tears present (Figure 1.5).  It is crucial for RD to be 
treated urgently for a successful outcome.  The longer RD is left untreated, the more 
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widespread the detachment may become and more severe, especially if the macula 
region is reached. Ideally RD is treated within 24 to 72 hours.  The procedure carried 
out is determined by a number of factors including size, location, severity and type of 
RD.  However, a combination of treatments can be used at the same time.30    
 
Figure 1.5 Images of different treatments for RD.  A: pneumatic retinopexy, B: scleral buckle surgery 
and C: vitrectomy with tamponade replacement. Adapted from refs:
33, 34
  
 
1.2.3.1 Pneumatic Retinopexy 
 
To treat a retinal tear where no fluid has seeped through between the retina and RPE, 
laser or cryotherapy may be used.  This creates a small amount of scar tissue to seal 
the break and prevent RD progressing.  Laser or cryotherapy can be used in 
conjunction with other treatments such as pneumatic retinopexy.  Pneumatic 
retinopexy involves the injection of a gas bubble into the vitreous cavity forcing the 
retina back against the RPE (Figure 1.5 A), the RPE will then remove any build-up 
of subretinal fluid.35  The gas used is either air or perfluorocarbon gases such as 
sulphur hexafluoride (SF6), perfluoropropane (C3F8) or perfluoroethane (C2F6).  Air 
has a short residency time (days) within the vitreous cavity due to diffusion into the 
surrounding tissues, therefore, cannot be used for a long period of time to support the 
retina reattaching.  Perfluorocarbon gases are utilised because they have a longer 
residency time than air (a few weeks), they are inert within the vitreous cavity due to 
steric hindrance, their volume increases after insertion and they are poorly water 
soluble.36-38  This treatment is usually used for people with RD in the top segment of 
the retina as the head must be kept in a set position for the majority of time over a 2 
week period, the most common position being head down and forward. However, 
this positioning means it is not suitable for all, as some people find it too 
uncomfortable to maintain the correct position leading to the failure of retinal 
reattachment.  Incorrect positioning results in pneumatic retinopexy having the 
lowest success rate of the treatments available.     
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1.2.3.2 Scleral Buckle Surgery  
 
Scleral buckle surgery is performed by stitching a small piece of silicone or hard 
plastic onto the sclera which pushes the sclera inwards against the detached segment 
(Figure 1.5 B).  Sometimes a circumferential band is used when multiple, wide or 
anterior breaks are present, and encircling buckles are used either when breaks cover 
a large area or are undetectable.39, 40  These are usually permanent but cannot be 
seen.  Fluid build-up may either be surgically removed or left to be absorbed by the 
RPE.  Pneumatic retinopexy and laser or cryotherapy may be used in conjunction 
with this technique depending on the severity of detachment.   
 
1.2.3.3 Vitrectomy/ Tamponade Replacement 
 
The final type of treatment is a vitrectomy followed by the insertion of a tamponade 
which fills the vitreous space.  This is the most common treatment in complicated 
cases or severe RD.  The surgical procedure involves the removal of the vitreous 
which is then replaced with saline followed by the replacement with a gas or silicone 
oil (SiO) tamponade.  The tamponade causes the closure of the retinal tear, forces the 
retina back into the correct position against the RPE and prevents access of any 
remaining aqueous to the tear, therefore, inhibiting migration of the aqueous into the 
subretinal space, excluding any inflammatory factors and initiating retinal 
reattachment.   
 
1.2.3.3.1 The Tamponade Effect  
 
The ideal tamponade agent would have an “efficient” tamponade effect. The 
efficiency is dictated by the amount of tamponade contact with the retina and 
aqueous in the eye.  Figure 1.6 shows that both SiO and air float above the aqueous 
whilst perflurorohexyloctane and Densiron® fill the inferior space but not the 
superior.  Air and perflurorohexyloctane have a flattened top surface and fit into the 
recess whereas SiO and Densiron® have a rounded top surface and do not fit into the 
recess space.  The interfacial energy of the tamponade determines how the 
tamponade acts in the vitreous cavity.  The hydrophobic nature of the tamponade 
means it forms a bubble in the aqueous to minimise the surface contact it has with 
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the aqueous; this also prevents the tamponade agent from migrating through the tear 
in the retina and acts as a plug instead.   
 
Figure 1.6 Model eye chamber with  indents at either side, filled with various tamponade agents (a: 
air, b: SiO, c: perflurorohexyloctane and d: Densiron®).  The white arrows point to filling efficiency 
of the tamponade agent by the indent and the black arrows point to the top of the bubble.  
 
A total tamponade effect is desirable as this would ensure support of the retina to the 
RPE for reattachment to occur, however, this is difficult if not impossible to achieve.  
This is not because of the tamponade itself but because of under filling during 
surgery, if the eye is considerably under filled this could result in failure of retinal 
reattachment.41   
 
1.2.3.3.2 Gas Tamponade  
 
Currently a number of substances are used as tamponade agents including air, or 
perfluorocarbon gases.  The tamponade effect from gas is reduced quickly due to the 
short residency time as discussed in Section 1.2.3.1.42  Perfluorocarbon gases have an 
advantage over air in that they expand once injected due to diffusion of other gases 
from the bloodstream, however, if they expand too much this can cause damage to 
the optic nerve.43  Perfluorocarbon gases have a longer residency time than air, 
however, it is still approximately only 2-3 weeks.42   As with pneumatic retinopexy, 
gases used as tamponades require patient positioning for a 2 week period during 
recovery.  However, this positioning can be too uncomfortable for patients and can 
lead to failure of the retinal reattachment.   
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1.2.3.3.3 Silicone Oil Tamponade 
 
SiO has been used clinically since 1958 as a tamponade agent due to its transparency, 
low toxicity and chemical inertness within the vitreous cavity, as well as high 
interfacial surface energy.43, 44  SiO is highly hydrophobic, therefore, forms an 
interface with the aqueous and the hydrophilic retina resulting in exclusion of 
aqueous from the tear.  SiO has a 75 % anatomical success rate which increases to 
85 % for posterior RD; this is relatively high as it is the tamponade agent most often 
used when long-term retinal support is required, particularly when RD/tears are quite 
complicated, severe or where PVR (see Section 1.4) is present.45-47   The treatment of 
inferior RD with SiO has been questioned in relation to the coverage of the tear and 
some surgeons prefer to perform scleral buckle surgery in parallel.  However, studies 
have found that solely performing a vitrectomy with SiO tamponade replacement is 
sufficient in treating inferior RD.48, 49 Development of a heavier-than-water SiO 
tamponade (Densiron®) has provided a much more successful treatment option.50  
The chemistry of Densiron® is discussed in Section 1.2.3.3.4. 
 
SiO is the only long term tamponade agent available as its tamponade effects do not 
dissipate over time, this does mean removal of the SiO is required 2-8 months after 
the initial surgery.  Disadvantages of SiO include the possibility of oil migrating into 
the anterior chamber which can lead to damage of the corneal endothelium51 or cause 
glaucoma.52 Oil can induce cataract formation53 which is why the lens is replaced in 
the majority of vitrectomies with SiO tamponade replacements.  
 
Forces at the interface of the SiO with the aqueous or the movement of the retina can 
cause dispersion, i.e. the breakup of SiO into droplets.  Emulsions can then form if 
surfactants or cellular debris are present as these will stabilise the SiO droplets.  This 
can lead to two problems: the tamponade no longer being effective and, if the 
droplets are small enough, macrophages will be activated and the oil will be engulfed 
by cells inducing an inflammatory response.54  
 
Work is being carried out to reduce the tendency of SiO to emulsify, through 
tailoring rheological (the higher the shear viscosity, the greater the shearing force 
required to disperse a tamponade agent into small droplets) and interfacial properties.  
The viscosity of different types of SiO is expressed in centistokes (1 cSt = 10−6 m2/s), 
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and arises from both the molecular weight (MW) and the length of the polymer; 
increasing SiO molecular weight results in an increased polymer chain length and 
consequently an increased viscosity.  SiOs currently used clinically have a viscosity 
ranging from 1000 (SiO1000, MW = 37,000 gmol
-1) to 5000 cSt (SiO5000, MW = 
65,000 gmol-1) with the majority of clinicians preferentially using a SiO with 
kinematic viscosity of 1000 cSt.  A retrospective study of 24 patients, where a 
SiO1000 tamponade was used, was carried out to determine emulsification rates.
55  It 
was determined 6 patients had emulsification after 3 months, which increased to 9 
patients after 6 months. Another study that investigated emulsification of higher 
viscosity SiO, found SiO5000 to be the most stable with no difference in 
emulsification when using SiO up to SiO10,000.  However, SiO1000 is usually used as it 
offers ease of manual injection.56 The injectability of various SiO, e.g. 1000, 2000 
and 5000, as well as blends 56/44 w/w SiO1000/SiO5000 and 90/10 w/w SiO1000/SiO 
423 000 gmol-1, has been studied and it was found that even a small percentage of 
high MW additive makes it easier to inject than single grade oils with equivalent 
shear viscosity.57  This could lead to the development of different varieties of SiO 
blends for clinical use (fluorinated SiO and semi-fluorinated alkane blends are 
discussed in Section 1.2.3.3.4).  Scott et al. investigated the difference between 
SiO1000 and SiO5000 in terms of anatomical success and visual acuity.
58  No significant 
difference was seen between the oils at 6 months, apart from a slight increase in 
retinal re-detachment when SiO1000 had been used to treat RD following trauma.  
 
The advantages of using SiO far outweigh the disadvantages, due to it being the only 
available long-term tamponade and the normality of day-to-day life during recovery 
compared with gas tamponades, where patients are required to remain in a set 
position for up to 2 weeks.  No positioning is required due to the specific gravity of 
SiO being slightly lower than water (0.98 g cm-3) resulting in the SiO floating on top 
of the remaining aqueous; the buoyancy forces are minimal so it is still an effective 
treatment for retinal tears in the inferior section of the vitreous cavity.  
  
1.2.3.3.4 Modified SiO  
 
Alternatives to SiO have been investigated to find a material which has a better 
tamponade effect such as copolymers of SiO with fluorinated SiO (SiO-FSiO).  The 
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specific gravity of SiO-FSiO can be tailored depending on the ratio of FSiO/SiO; 
materials ranging from 1.16 – 2.03 g cm-3 were studied.41  Histological changes to the 
outer plexiform layer (thinning/loss) and migration of photoreceptor nuclei towards 
RPE were observed.  It was argued that an increase in pressure caused these changes, 
however, another study investigating intraocular pressure (IOP) with a range of 
materials found no significant difference compared to normal IOP.59 Therefore, it is 
possible that the histological changes observed are due to the exclusion of water.  
Also, SiO-FSiO with low viscosity (<200 cSt) cause a macrophagic response; 
however, it is not automatically safe to use highly viscous SiO-FSiO as white 
deposits on the retina were observed with materials of 1750 mPa.s.60   
 
Semifluorinated alkanes (SFA) are being investigated as an additive to SiO; they are 
transparent and immiscible with water.  SFAs act as an amphiphilic surfactant as the 
hydrocarbon end is highly hydrophobic whereas the fluorocarbon end is less so.  The 
specific gravity of SFAs can be determined by the length of the alkane.  Histological 
studies have been carried out using a rabbit model and no abnormalities were 
observed with regards to the retina over 3 months.61  However, the clinical use of 
SFAs as the sole tamponade agent is restricted because dispersion, which can induce 
a macrophagic response, occurred within the first 15 days.  Therefore, mixtures of 
SFA with SiO were studied.  The solubility of SFA is determined by the viscosity of 
the SiO and the MW of the SFA and increasing either will reduce SFA solubility.  A 
mixture of SiO5000 and perfluorohexyloctane (Densiron®) causes an egg-shaped 
tamponade to form with the SiO on top and SFA underneath, resulting in good 
contact only with the inferior retina (Figure 1.6 d).62  It is hoped that the SiO cap may 
reduce the tendency of SFA to disperse. Densiron® underwent a successful 
multicentre clinical trial in Liverpool and Rotterdam with positive outcomes.  Kocak 
and Koc compared Densiron® with SiO1000 and observed 84 % and 74 % success 
rates respectively in terms of retinal reattachment.50  As this is a heavy SiO (density 
= 1.06 g cm-3) it can be used to treat inferior RD much more successfully than 
unmodified SiO.     
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1.3 RETINAL PIGMENT EPITHELIUM IN PROLIFERATIVE 
DISEASES 
 
RPE cells make up a critical tissue in the eye and play multiple roles in retinal 
homeostasis as outlined in Section 1.1.3.  Dysfunctional RPE is a key cause of a 
number of retinal diseases which ultimately lead to visual disruption and/or 
irreversible vision loss.  Diseases involving the RPE may be classified into 3 
categories: degenerative, dystrophic and proliferative; however, proliferation of the 
RPE cells can occur in all categories.63  A number of different diseases resulting 
from abnormality in RPE function are described below. 
 
1.3.1 Degenerative Proliferative Disease 
 
Degenerative diseases result from ageing of the eye and include a decline in tissue 
cellularity and blood flow.  In the retina, degenerative effects can result in 
neurosensory retinal deterioration and RPE cell dysfunction.  The most common 
sight-threatening degenerative disease in developed countries is age-related macular 
degeneration (AMD), of which there are two different types: dry and wet.64  Dry 
AMD occurs as a consequence of the accumulation of cellular debris and metabolic 
by-products, which then interfere with the photoreceptors in the macular.  Wet AMD 
develops via  the formation of abnormal blood vessels underneath the macular, 
leading to cellular dysfunction.65, 66  
 
1.3.2 Retinal Dystrophy 
 
Retinal dystrophy is a term which describes a broad (and growing) group of hereditary 
disorders affecting the retina. It is a term which can be used to describe a number of 
diseases including pattern dystrophy (PD) and adult-onset foveomacular vitelliform 
dystrophy (AOFV).  PD of the RPE involves the development of a variety of patterns 
of deposits of yellow, orange, or grey pigment in the macular area.67  AOFV is a 
condition that presents completely differently to PD with bilateral, symmetrical, 
lesions within the macular area in the RPE or between the RPE and photoreceptor 
layer.68   
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1.3.3 Proliferation of RPE Cells 
 
Proliferation of RPE cells only occurs during foetal development in a healthy eye, 
however, proliferation can be reinitiated in response to trauma, inflammation or 
ageing.  Proliferation, dedifferentiation and migration of the RPE cells depend on a 
number of factors: the size of the initial injury, the condition of the RPE-choroid 
complex, the state of the neuroretina and the interaction with different growth 
factors, cytokines and proteins.69-71 Following minor injury to the RPE and 
photoreceptors, macrophages remove cellular debris.  The RPE cells at the edge of 
the wound proliferate and if they re-establish a continuous monolayer over the 
Bruch’s membrane, proliferation stops.  If the injury involves other layers of the 
neuroretina and RPE, such as RD, the RPE cells in the vicinity of the wound 
dedifferentiate to mobile proliferative cells of a fibroblastic-like or macrophage-like 
phenotype and function.72   
 
1.4 PROLIFERATIVE VITREORETINOPATHY 
 
Proliferative vitreoretinopathy (PVR) is a condition that can follow a break in the 
retina where scar-like membrane formation occurs, analogous to dynamic wound 
healing with respect to inflammation, proliferation and modulation of scar tissue (see 
Figure 1.7).73  Formation of epiretinal and subretinal membranes and traction of this 
scar tissue leads to TRD.   
 
Figure 1.7 Overview of proliferative vitreoretinopathy (PVR) cycle following a tear in the retina: 
inflammation, proliferation, cell migration and contraction leading to retinal detachment.  Adapted 
from ref:
74
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Traumatic PVR is a consequence at the vitreoretinal interface of a perforating trauma 
to the posterior segment of the eye, or can happen following surgical intervention.75 
Idiopathic PVR is a complication that follows RRD, especially if there has been a 
severe retinal tear.  PVR occurs in approximately 5-10% of all RRD and re-
detachment after surgery occurs in 75 % of these cases making it the most common 
cause of failure of RRD surgery.76, 77   
 
1.4.1 Pathology of PVR 
 
During trauma or RRD, the RPE loses contact with adjacent cells, and consequently 
loses cellular signalling. RPE then comes into contact with different growth factors 
and cytokines, triggering the cells to proliferate, de-differentiate and migrate to repair 
the defect.  Dedifferentiation is triggered by the separation of the RPE from the 
neuroretina and the absence of adjacent RPE.  The RPE cells undergo epithelial-
mesenchymal transition where the microvilli retract causing a loss of adhesion to the 
neuroretina and their extracellular matrix (ECM).  The cells then round up and 
detach from their basement membrane.12, 77, 78  RPE cells then dedifferentiate into a 
wound repair phenotype, similar to fibroblasts and macrophages which construct a 
membrane, as they migrate towards the vitreous.69  This differentiation is regulated 
by various growth factors (platelet-derived growth factor [PDGF], TGF-ß, epidermal 
growth factor [EPGF], tumour necrosis factor alpha, FGF and others) as well as 
cytokines (interleukin-1, 6, 8, 10 [IL-1, IL-6, IL-8, IL-10] and interferon-gamma 
[IF-γ]).69, 72, 78-80  RPE cells are the main component of the membranes, however, 
other cells involved include fibroblasts, which are responsible for tissue repair, in 
particular scar formation, myofibroblasts and macrophages, as well as minor 
amounts of glial cells.79, 81  The resulting membranes contract and distort/pull on the 
retina leading to TRD.73, 78 
 
1.4.2 Current Treatments for PVR 
 
To combat the inflammatory response caused by a break in the retina, corticosteroids 
are usually administered intravitreously, however, there are no prophylactic measures 
for the proliferation and migration phase.82, 83  Surgery called membrane peeling can 
be performed to remove  scar tissue formed during PVR and relieve tractional forces 
CHAPTER 1 
18 
 
as well as closing the retina.  A vitrectomy is usually performed at the same time as 
membrane peeling.  This type of surgery has a 60-80% anatomic success rate and, of 
this, 40-80% have functional success.73, 84, 85 Sigler et al.86  investigated the use of 
SiO1000 in 33 patients where recurrent RD (on average 2.4 previous RD surgeries per 
patient) had occurred due to PVR.  Reoperation under SiO during the initial 6 
months, to remove the membranes, resulted in complete success in 29 patients at the 
24 month follow up, with visual acuity improved in 25 of these patients.  
  
The reason why there are currently no effective preventative treatments for PVR is 
partially due to the difficulty of achieving therapeutic drug levels in the vitreous 
cavity and retina through conventional and systemic routes; this will be discussed 
later in Section 1.5.  It is possible to administer drugs intravitreally or 
subconjuctivally, however, PVR is a long term complication which requires a 
treatment period of 4-6 weeks and the half-life of most drugs in the vitreous cavity 
and subconjuctival is short.87  Repeated injections could be performed but this can 
cause complications such as infections, inflammation an elevated intraocular 
pressure and/or a build-up of drug to toxic levels.   
 
1.4.3 Prospective PVR Treatments 
 
Various pharmacological agents have been investigated to reduce and/or prevent 
PVR.  The two main categories are anti-inflammatory and anti-proliferative drugs, 
however, antioxidants, antineoplastic and antigrowth factors have also been studied, 
as well as combination therapies of two or more drugs.    
 
1.4.3.1 Anti-inflammatories  
 
Corticosteroids were among the first anti-inflammatories investigated for PVR.  They 
exert most of their anti-inflammatory response in early stages of inflammation, 
therefore, before the disease has fully developed.83, 84  Triamcinolone acetonide 
(TAA) has been administered intravitreously in a number of in vivo studies. 88, 89  
Liang et al. induced PVR by the injection of macrophages in a rabbit model, and 
treatment with 1 mg TAA, showed a reduction in  PVR by up to 64%.90  TAA has 
also been used in collaboration with 5-fluorouracil (5-FU) as both a co-drug powder 
injected intravitraeously and a co-drug pellet implanted intravitreally.  Yang et al. 
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used a rabbit model and observed both therapies (a 10 mg co-drug injected and a 3.3 
mg pellet) had no cytotoxic effects and decreased PVR incidence.91 In human clinical 
conditions, 100 mg TAA was administered systemically for 5 days, followed by 50 
mg for 10 days and 50 mg every other day for 40 days, resulting in weaker effects 
than experimental conditions where 1 mg intravitreal injections were used.92   
 
Other corticosteroids investigated for the treatment of PVR using a rabbit model 
include: Adriamycin, methotrexate and trifluorothymidine. Adriamycin (1 mg) 
inhibited proliferation and prevented the formation of membranes, whereas 1 mg of 
both methotrexate and trifluorothymidine had no beneficial effect.93  Dexamethasone 
is another anti-inflammatory which is useful in reducing the BRB breakdown, 
therefore, allowing an increased amount of drug to pass through to the targeted 
area.94 An in vitro study with human RPE showed a biphasic effect with respect to 
stimulating growth at low concentrations (10-7-10-6 M) but inhibiting growth  at high 
concentrations (10-4 M).95 
 
Ibuprofen 
 
Ibuprofen (Ibu, Figure 1.8), chemically known as (±)-(R, S)-2-(4-isobutylphenyl)-
propionic acid, is a non-steroidal anti-inflammatory drug (NSAID).   
 
 
Figure 1.8 Chemical structure of Ibuprofen. 
 
Ibu has been found to be more effective than other NSAIDs, such as aspirin, in pain 
relief and has a very mild blood-thinning effect in comparison.  Ibuprofen has yet to 
be studied in the context of PVR but its characteristic anti-inflammatory response 
makes it a candidate of choice to be studied throughout the project. 
 
A double-blind trial of Ibu and aspirin was carried out in 60 soft-tissue injuries in 
professional footballers. Ibu significantly reduced the severity of pain and allowed 
training, on average, two days earlier, allowing players to reach match fitness earlier 
than the controls taking aspirin.96 Although the exact pathway of how Ibu works as 
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an anti-inflammatory is unknown, it involves the non-selective inhibition of 
cyclooxygenase.97 Rabbit models were used to determine the efficacy of topical 
administration of Ibu onto the eye.  In one study, inflammation was induced by IL-1 
and it was found that Ibu inhibited vascular permeability, however, it did not inhibit 
infiltration of IL-1 into the cells.98  In another, model paracentesis was induced and it 
was found that treatment with Ibu reduced inflammation.99  Ibu is also a nonselective 
prostaglandin synthetase inhibitor and has been shown to decrease vascular 
endothelial growth factor (VEGF) signalling when dosed to early postnatal rats at 50 
mg/kg.  This indicates it could be used as a possible therapy for PVR. 
 
1.4.3.2 Anti-growth Factors and Growth Factor Inhibitors 
 
As discussed in Section 1.4.1, the differentiation of RPE is regulated by growth 
factors as well as cytokines.69, 72, 78-80  It is possible to block these growth factors, 
therefore, altering the pathogenesis and stopping the progression of PVR.73   
 
TGF-ß levels in the eye can be correlated with the severity of PVR and is known to 
be released by RPE cells.  TGF-ß has a complex and multifunctional role, and is 
involved in the regulation of ECM production, membrane contraction and 
inflammation of RPE. Vitreous aspirates from eyes, with intraocular fibrosis 
associated with PVR, were studied and more than three times the amount of TGF-ß 
was measured than in eyes with uncomplicated retinal detachments without 
intraocular fibrosis.100  There are three different TGF-ß isoforms TGF-ß1, TGF-ß2 
and TGF-ß3. Anderson et al. studied the location of the different isoforms within 
mammalian retinas and found it was the distribution of TGF-ß2 which determined 
fibroblast formation.101  TGF-ß inhibitor therapies have shown inhibition of 
proliferation of RPE cells in numerous animal models as well as humans.102 Porcine 
RPE cells were grown on top of bovine corneal ECM to form confluent monolayers.  
These monolayers were then co-cultured with first passage porcine RPE cells in the 
presence of various volumes of the confluent cell media as well as different amounts 
of TGF-ß neutralising antibody (0.1-100 µg/mL). Growth rates of the RPE cells were 
calculated 72 hours after plating and found it decreased when RPE cells were bathed 
with the fractions of medium from an adjacent confluent RPE monolayer, and was 
abolished by adding TGF-ß neutralising antibody (0.1-5 µg/mL). Blocking greater 
amounts of TGF-ß in the medium with higher doses of antibody (>10 µg/mL) also 
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inhibited the growth of the newly plated RPE cells, irrespective of media from a 
confluent cell layer being present or not.103 
 
Other inhibitors such as FGF and collagen inhibitors have been explored and found 
to have dose dependant and time dependant effects on RPE cells.  Wang et al.104 
investigated the relationship of cell proliferation with basic FGF (bFGF) and EPGF 
on human RPE (hRPE) cells cultured in vitro.  They found both regulate cell 
proliferation but the proliferation effect of EGF was stronger than bFGF when the 
concentration was above 4 ng/mL.  Yasukawa et al.105 investigated the effects of a 
collagen inhibitor, cis-4-hydroxyproline (CHP), on PVR in a rabbit model.  The rate 
of RD decreased from 89 % to 57 % at 28 days in the presence of 1.7 mg CHP.     
 
1.4.3.3 Antiproliferative Drugs 
 
Antiproliferative drugs are being investigated to inhibit the cell cycle and cellular 
proliferation which follow retinal damage.  Cytotoxic levels have been established as 
well as antiproliferative effects for a number of drugs such as 5-FU, α-tocopherol, 
dasatnib, daunorubicin, daunomycin, doxorubicin, mitomycin and RA.  
 
5-FU is one of the most commonly researched compounds as it was one of the first to 
be tested to stop PVR.  It was originally developed as an anticancer drug as it works 
by altering DNA synthesis through inhibition of thymidine formation.106  5-FU has 
been shown to reduce fibroblastic proliferation, and has a toxic level of 7.7 10-6 M.  
However, 5-FU is rapidly eliminated from the vitreous cavity (t1/2 < 3.5 hours for 1 
mg)107, and its effect slows down after 2 to 4 days of exposure.95 Therefore, multiple 
doses are required leading to potential risks as well as dangers of reaching a toxic 
level.  An alternative administration route is the use of a medical device.  Borhani et 
al. evaluated a sustained-release using a biodegradable device in a rabbit model of 
PVR.108  Devices containing 0.5 mg and 1 mg 5-FU showed significant efficacy in 
preventing PVR, with the higher-concentration implant being 100% effective in 
preventing  TRD.108  The use of 5-FU as co-drugs with low molecular weight heparin 
(an anticoagulant which binds to fibronectin and growth factors) has also been 
explored and conflicting results reported.109  Asaria et al. carried out a randomised, 
double-blind, controlled clinical trial and found adjuvant 5-FU and heparin prevented 
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PVR,110 whereas Wickman et al. carried out a randomised control trial and found no 
difference between control and treated groups.111 
 
Mitomycin is a drug that has been used as a chemotherapeutic and is a DNA cross-
linker which arrests the cell cycle without killing cells.  Cytotoxic effects have been 
investigated on RPE cells and it has been found that even 10-9 M has significant 
effects on RPE cell proliferation after 4 days and 10-8 M has very significant effects 
without any toxicity.95    
 
Daunorubicin is a topoisomerase inhibitor which prevents DNA and RNA synthesis 
and inhibits mitotic activity.112  The toxicity and efficacy of daunorubicin for the 
prevention of PVR has been investigated by a randomised, controlled clinical trial. It 
was found that although anatomical success was higher, no significant difference in 
visual acuity was observed.113  However, other research has found there to be both 
anatomical and visual improvements.114-117  An alternative topoisomerase inhibitor to 
daunorubicin, which is more appealing due to its decreased toxicity, is aclcainomycin 
(ALM).  Additionally, ALM has no carcinogenic effect compared to 5-FU and 
daunorubicin making it a good alternative. Morphologic studies of eyes treated with 
30 and 60 nmol for 3 days revealed no damage to the retina.118 Glucosamine has 
been reported to inhibit growth of many different cell types and have anti-
inflammatory effects in ocular disorders making it an ideal candidate for the 
prevention of PVR.119-121  Glucosamine has been shown to block TGF-ß signalling, 
therefore, preventing PVR as discussed in Section 1.4.3.2.122-124   
 
Retinoic Acid 
 
The second drug of choice used within this project is all-trans retinoic acid (atRA) 
(Figure 1.9) due to promising results reported by others in the reduction of PVR and 
RPE cell proliferation.125-127 
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Figure 1.9 Chemical structure of all-trans retinoic acid (atRA). 
 
RA belongs to a family of retinoids including active metabolites of vitamin A as well 
as a diverse spectrum of synthetic derivatives, which are not closely related to retinol 
but elicit biological vitamin A or retinoid activity.  Vitamin A has many important 
functions such as: role in vision, immune competence, reproduction, embryonic 
growth and development and maintenance of epithelial surfaces.128 Vitamin A plays 
a crucial role in 2 fundamental processes in vision: phototransduction and the visual 
(retinoid) cycle of RPE cells (see Figure 1.10).  These processes involve photon 
signals being transformed into electrical signals within the photoreceptor cells (rods, 
cones and ganglion cells) in the retina as was briefly discussed in Section 1.1.4.  
 
 
Figure 1.10 Retinoid flow in the visual cycle.  Adapted from ref:
129
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Phototransduction involves the photosensitive derivative of vitamin A: 11-cis retinal, 
which covalently links to opsins to form an inactive, but photosensitive conformation 
of the retinyldene protein rhodopsin (visual pigment).129 In humans there are 3 
different types of cone photoreceptors that are sensitive to red, green and blue light, 
these contain slightly different opsins which have a unique interaction with 11-cis 
retinal, and are sensitive to a specific wavelength (colour) of light.130 The 
chromophore in 11-cis retinal leads to the photosensitivity of the opsin which 
absorbs a photon and photoisomerises to all-trans retinal which no longer fits in the 
binding site and changes the configuration of the opsin.  This leads to a cascade of 
signal transduction and hyperpolarisation of the photoreceptor cells.  Following 
dissociation of all-trans retinal from opsin it travels into the outer segment and is 
transferred to the rods and cones via a retina-specific ATP-binding cassette 
transporter called ABCA4 (see Figure 1.10) where it is reduced to all-trans retinol; a 
process catalysed by NADPH-dependant all-trans retinal dehydrogenase enzyme 
(RDH8).131  All-trans retinol is rapidly released by photoreceptor cells to the 
extracellular space and transferred to the RPE by interphotoreceptor retinoid-binding 
proteins which contain binding sites for both 11-cis- and all-trans-retinoids and 
protect the retinoids from both oxidation and isomerization.  All-trans retinol is also 
taken up from the bloodstream through the basal membranes of RPE cells. 
 
All-trans retinol regenerates 11-cis retinal by a process catalysed by at least 3 
enzymes associated with smooth endoplasmic reticulum.  All-trans retinol esterified 
by lecithin retinol acyltransferase is then transformed to 11-cis retinol by retinoid 
isomerhydrolase (RPE 65) or esterified to form an 11-cis-retinyl ester which stores 
the pre-isomerized chromophore precursor.  The 11-cis retinal travels back to the 
outer segment of rods and cones where it conjugates with opsin to form rhodopsin, 
and the cycle can start again.131-133   
 
Vitamin A and 11-cis retinal deficiency can lead to short- or long-term visual 
impairment.  A short-term shortage is an uncomfortable but common event, for 
example, the inability to see at night after passing an oncoming car's bright lights is 
partially due to the depletion of 11-cis retinal in rods. Long-term deficiency, 
however, can lead to permanent visual impairment.   
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Vitamin A also has many other important functions such as: immune competence, 
reproduction, embryonic growth and development and maintenance of epithelial 
surfaces.128  The identification of RA receptors within the RPE, such as RPE65 and 
RAR-ß2, makes it feasible to develop useful drugs to treat retinal and macular 
degeneration whilst avoiding substantial side effects.  Giguere et al.134 and Petkovich 
et al.135 individually discovered nuclear receptor sites that are specific to RA whilst 
most had a high affinity for atRA and 9-cis RA, but not 13-cis RA.  There are also 
some receptors that are site specific for atRA which regulate gene expression by 
binding to short DNA sequences in the vicinity of the target area.     
 
Many studies have shown RA to act as an antiproliferative agent to RPE cells.  The 
cytotoxic effects of RA on RPE cells in vitro was investigated and found to be in the 
range of 10-5 M but there are contradicting and imprecise values reported with 
dependence of the isomer; less than 1 x 10-5 M – 3.33 x 10-5  M (3 µg/mL) and as low 
as 6.66 x 10-7 M (2 µg/mL) for atRA. 102, 136-138  
 
Oral doses of RA have been investigated in vivo.  Chang et al. administered 10 mg 
RA to human subjects twice daily for 8 weeks and found the treated group had 
significantly lower rates of membrane formation and significantly better rates of 
ambulatory vision (able to see large objects at close range).139  Whilst in another 
study administering 13-cis RA at 40 mg twice daily for 4 weeks, the rate of retinal 
reattachment was much greater.140   However, the oral administration of 13-cis RA 
used for the treatment of acne is linked to mental health issues including increased 
risk of depression and suicidal tendencies.141  Oral administration of drugs for 
treatment of conditions in the eye also have the characteristic disadvantages of any 
systemic treatment, as well as the added complication of passing through the BRB 
(see Section 1.1.3 for details).   
 
RA delivered directly to the eye intravitreously or within a SiO tamponade has been 
investigated in many different animal cell lines such as porcine, bovine, chick, rabbit 
and cultured primary human RPE cells.125-127, 136, 137, 142, 143  All studies showed a 
reduction in PVR when RA is administered.  In chick RPE cells it was found that 
concentrations of 10-6-10-7 M for 10 days had an anti-proliferative effect and that 
there was no difference in viability of the treated and control groups.  RA (10-5 M) 
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significantly inhibited PVR membrane formation and TRD (80 %), and significantly 
inhibited the migration (80 %) and invasion (65 %) behaviours of wound healing 
human RPE cells.136  Studies have demonstrated that RA can inhibit proliferation of 
RPE cells by disrupting some integrin functions such as blocking TGF-ß expression 
by up to 41 %.144  Studies by Wu et al. involved an in vitro model using RPE from 
excised membranes of PVR and treatment with 10-6 M atRA or 13-cis RA; after 12 
days only 6.7 % and 9.3 % RPE cells proliferated within a 5 hour time period, 
respectively,126   indicating atRA was more effective than 13-cis RA.  However, 
Ariaz et al. found that when atRA was administered to cells in vitro at 37 °C in light, 
60 % had isomerised to 13-cis RA within 1 week.137 
 
Many studies have also been performed in vivo using rabbit models.  Groups that 
were dosed with 5 or 10 µg (10-5 M) RA had significantly less progressed PVR.137  
Nakagawa et al.125 found that 6 µg/mL (2 x 10-5 M) atRA and 9 µg/mL (3 x 10-5 M) 
13-cis RA inhibited PVR to the same extent, therefore concurred with the in vitro 
study performed by Wu et al.126 showed that atRA to be more effective.  
  
1.5 ADMINISTRATION OF DRUGS 
 
In this next section common pathways of drug administration for eye diseases will be 
discussed, including common topical and systemic administration as well as the more 
unfamiliar iontophoresis.  
 
1.5.1 Systemic 
 
Systemic administration is a route where the whole body is exposed to the drug, as it 
is delivered orally or intravenously.  Due to the tight junctions within the BRB, most 
of the administered drug does not pass through into the eye, therefore, high doses are 
usually required which may have serious side effects on non-target tissue.43  
 
1.5.2 Topical  
 
Topical administration involves drug being delivered to surfaces of the body, and 
eye-drops are a prime example of topical administration to the eye.  Advantages of 
topical drug delivery to the eye are the ease of application and the lack of 
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invasiveness.  Topical application has the disadvantage of poor ocular bioavailability 
with only 5 % lipophilic drugs and 0.5 % hydrophilic drugs reaching the aqueous 
humour and even less reaching the retina, but the ease of administration means 
repetitive dosing is not a problem.145  Topical administration is primarily used to 
treat diseases in the anterior or on the surface of the eye as it is an ineffective route 
for treating diseases in the posterior of the eye, as one of two pathways would need 
to be taken, i.e. corneaaqueous humourintraocular tissue or 
conjunctivasclerachoroid/RPE.146  Eye drops are widely used and repetitive 
dosing is required as there is rapid clearance by tear drainage which is induced upon 
administration.147  Corneal permeability reduces efficacy of eye-drops, however, if 
the cornea is damaged this could lead to toxic amounts entering the posterior 
chamber, especially with the variability in dispensing of eye drops.148  The 
alternative route to the cornea is via the sclera which also has issues of permeability 
especially with high MW molecules.146  Eye drops are still widely prescribed despite 
problems of patient adherence, due to the lack of invasiveness of this route of 
administration.   
 
1.5.3 Intravitreal Injections 
 
Intravitreal injection is the most common method of drug delivery to treat diseases in 
the posterior of the eye.  An intravitreal injection involves an injection of medicine 
into the vitreous of the eye. Despite a short drug half-life (only several hours for 
most low MW drugs) in the vitreous, intravitreal injections are much more efficient 
than topical or systemic delivery.  However, due to the nature of this technique, there 
are some (low) risks of injuries to the lens, retinal detachment or endophthalmitis 
(inflammation in the eye).149  Although it is an invasive technique, current methods 
of pre-injection of anaesthetics reduce pain for the patient, therefore, it is a much 
more pain-free and efficient route of drug administration than alternate methods. 
 
1.5.4 Iontophoresis  
 
Iontophoresis provides a local, non-invasive technique to deliver precise amounts of 
drug to a target area.150  A specially designed probe generates an electric field which 
aids penetration of ionised topical drugs across the sclera and cornea.151  This method 
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is applicable to a broad range of drugs, however, it is most effective for hydrophilic, 
negatively charged, low MW drugs.152   As for the other delivery methods multiple 
administrations may be required, which usually leads to low patient adherence, while 
mild pain is caused in some cases.153 
 
1.6 DRUG DELIVERY DEVICES 
 
There are many different drug delivery devices (DDD) currently available for 
treatments in the eye.  However, there is still a need to develop DDD that target 
diseases in the posterior segment of the eye such as PVR.  There is also a need for a 
controlled therapeutic release for a sustained time period to overcome the need of 
multiple administrations.  Consequently, both implantable and non-implantable 
devices are currently the object of extensive research.  An ideal DDD would improve 
drug efficacy, attenuate adverse effects, be biocompatible, be easy to sterilise and 
would not distort visual acuity.154  In this next section a few of the current DDDs 
available will be discussed as well as those being developed.  
 
1.6.1 Contact lenses 
 
Contact lenses could potentially provide a long term DDD without any modification.  
It has been shown that soft hydrogel lenses can incorporate drugs upon hydration in 
an aqueous drug solution.  Drug release from the lenses is dependent on the affinity 
of the drug to the lens; if it is too high the drug will remain on the lens, if it is too low 
the drug will be released very quickly.  Collagen corneal shields are similar to 
contact lenses in the way they are administered, however, the drug is trapped within 
the collagen matrix when hydrated in an aqueous drug solution.  The drug is only 
released upon degradation of the collagen, leading to much longer drug exposure 
time than topical administration or when hydrogel lenses are used.155, 156  Contact 
lenses and corneal shields administer drugs topically, therefore, have all the 
characteristic disadvantages of topical administration to the eye and those previously 
discussed for eye drops (see Section 1.5.2).  
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1.6.2 Inserts 
 
Inserts usually lie in the conjunctival cul-de-sac of the eye between the lower eyelid 
and the eye so that they are exposed to tears.  Inserts have the advantage of increased 
contact time, therefore improved bioavailability, and possible increased release 
period with the potential of delivering accurate amounts. 
 
There are three different types of inserts: erodible, soluble and insoluble.  Erodible 
inserts consist of a biodegradable, hydrophobic polymer surface; erosion of this 
surface determines the release.  Soluble inserts consist of a hydrophilic water soluble 
polymer; if the drug is also hydrophilic the release is controlled by diffusion, but if 
the drug is hydrophobic, release is restricted by dissolution.  Insoluble inserts are 
made from hydrophobic, water insoluble polymers that will need to be removed once 
the drug has been released.  Two more release systems based on inserts have been 
described: an osmotic system where drug molecules are dispersed within a polymer 
matrix and as tears enter the matrix the drug is dissolved and released, and a 
membrane controlled release system where a drug core is surrounded by a 
hydrophobic membrane which controls diffusion.157  
 
Inserts usually treat conditions in the anterior of the eye.  Infection and inflammation 
would require a high dose for a short period of time whereas glaucoma would require 
a low dose over a sustained period of time.  The first controlled release ocular insert 
that entered the market was Ocusert® in 1975.158 Ocusert® is a reservoir model 
(drug coated with an ethylene vinyl acetate membrane) used to treat glaucoma by 
releasing pilocarpine hydrochloride over 7 days. However, clinical use is not 
widespread due to complications with insertion and removal as well as side effects 
arising from continuous drug exposure.   In Russia, a soluble ophthalmic drug insert 
SODI® is used to treat a variety of diseases with antibiotics or anti-inflammatories.  
It consists of a thin film of acrylamide, N-vinylpyrrolidone and ethyl acetate 
copolymer which degrades and releases drugs over several hours; due to this short 
release time scale SODI® is restricted to Russia and the East.159  As well as 
delivering drugs to the eye, inserts can provide platforms for the release of materials 
to combat keratitis (dry eye).  In 1981 Lacrisert® became commercially available.160  
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It consists of hydroxypropyl cellulose which dissolves into the tear film, thickening it 
and providing lubrication and protection for the eye. 
 
1.6.3 Colloidal Drug Carriers 
 
Colloidal drug carriers discussed here include liposomes and micro/nano-particles.  
The benefits of using a colloidal drug carrier are: stabilisation of drug, increased drug 
half-life, localised delivery, and decreased toxicity by minimising the burst release 
profile seen for many drugs.  In recent years there has been an exponential growth in 
the number of patents filed for the application of nanotechnology in ophthalmic drug 
delivery.161 
 
1.6.4 Implants 
 
Intraocular implants require either surgery or an injection to place the DDD 
intravitreally. The benefits of implants include avoiding the BRB to deliver drug 
directly to the area required, and avoiding side effects related to systemic treatments 
or repeated administration. Implants aim to provide a prolonged controlled drug 
release from a polymeric material. There are 3 different categories of implants: 
monolithic, binding polymer hydrogel and reservoir structure (Figure 1.11).   
 
Figure 1.11 Schematic of implants. From left to right: A:monolithic, B: binding polymer hydrogel 
and C: reservoir structure. 
 
The monolithic type contains a homogenous mix of polymer and drug.  A binding 
polymer hydrogel (three dimensional network of cross-linked hydrophilic polymer) 
chemically or ionically binds to drugs which are then released by enzymatic 
hydrolysis of inter- and intramolecular bonds of the polymer.157  Finally the reservoir 
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structure consists of an outer shell of polymer coating an inner drug core.  Implants 
can be in an injectable form of colloidal or gelling solutions or an implantable plug, 
disc, pellet, rod or sheet.   
 
The ocular implants can either be synthesised from non-biodegradable or 
biodegradable polymers.  Non-biodegradable implants can provide a more constant 
prolonged drug release period than biodegradable equivalents, however, they require 
surgical removal.  Non-biodegradable polymers often used include poly(hydroxyl 
ethyl methacrylate) (pHEMA), polyvinyl acetate (PVA), ethylene vinyl acetate, 
methylcellulose and polyacrylamide, due to their biocompatibility.162-166  
Biodegradable polymers frequently used in implants include polylactic acid (PLA), 
polylactic-co-gycolic acid (PLGA), polyanyhdrides, or polyorthoesters, and 
hydrogels that mainly consist of collagen, gelatin, albumin, chitosan, starch or 
dextran.165  The hydrolysis of these polymers produce carbon dioxide (CO2) and 
water, via  the Kreb’s cycle, which are then adsorbed by the surrounding tissue.167  
Intravitreal implants currently available on the market include non-biodegradable 
Vitrasert® which delivers ganciclovir for 8 months, Retisert® which delivers 
fluocinolone for up to 2.5 years and Illuvien® which delivers fluocinolone acetonide 
for 3 years.168-170  Ozurdex® is a biodegradable implant which delivers 
dexamethasone for up to 6 months.171  Stimuli responsive implants are currently 
being investigated, which are light activated, mini pump or magnetically modulated. 
172-176  Implants that are not placed intravitreally include punctal plugs which are 
implants that are inserted in the tear duct to prevent liquid drainage from the eye.177  
 
Gene therapy is an option where genetically modified cells release different 
therapeutic proteins and growth factors; these cells are isolated within a device and 
inserted intravitreally. NT-501 is a device currently undergoing phase II clinical 
trials within the EU and US, in which genetically modified cells are grown onto a 
poly(ethylene terephthalate) scaffold to secrete ciliary neurotrophic factor, for the 
potential treatment of retinitis pigmentosa and age-related macular degeneration.178  
 
1.6.4.1 Microparticles and Nanoparticles 
 
Microspheres, microcapsules and their nanoscale equivalents are made from 
micro/nano particles, respectively.  They have been investigated for ocular drug 
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delivery via implantation into the vitreal cavity. Micro/nano spheres involve the 
physical homogeneous dispersion of drug within a polymer matrix whereas 
micro/nano capsules consist of a drug core surrounded by a polymer coating (Figure 
1.12).  These colloidal drug carriers were initially used to prolong release of topically 
applied drugs and overcome solubility issues, however, with the use of microspheres 
the increase in bioavailability was insignificant,147 therefore, research progressed to 
intraocular administration.   
 
Figure 1.12 Schematic of micro/nanoparticles. From left to right: A: sphere with drug dispersed B: 
sphere with drug absorbed, C: capsule, D: capsule with drug dispersed. 
 
Biodegradable polymers with bio-adhesive properties such as PLA, polyglycolic acid 
(PGA) and the PLGA have been used in this context.  They attach to biological 
tissues leading to the drug being released close to the target area and have been 
shown to be intravitreally biocompatible over a 12 week period.179  The 
encapsulation technique used to synthesise micro/nano-spheres depends on the 
hydrophilic/lipophilic nature of the drug.180   Drug release can then occur by two 
different mechanisms: diffusion through the polymer matrix and polymer 
hydrolysis/bulk erosion.  For PLGA, drug release is affected by drug solubility, fast 
degradation of short polymer chains and change in water content of PLGA.  These 
result in a burst release followed by a lag phase then a pulsatile flow as erosion 
occurs.  A 24-hour burst release of sodium fluorescein, which is highly hydrophilic, 
was observed,181 whereas RA, a lipophilic drug, had a constant release from PLGA 
microspheres over 30 days.138  The release profile from PLGA can be tailored upon 
variation of MW and degrees of polymerisation (DPn).
159   The ratio of PLA to PLG 
within a 5,000 gmol-1 PLGA copolymer has been investigated using rhodamine as a 
model drug over a 30 day time period.  It was observed that a 50/50 copolymer led to 
a much faster burst release with 80 % of the rhodamine released after 15 days whilst 
the 25/75 copolymer had only released 60 % at 30 days. 
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There have been many animal studies investigating the use of colloidal carriers 
injected intravitreously which provided non-toxic, therapeutic amounts of drug to 
suppress inflammation, proliferation and infection.182-185 Evidence for potential 
intracellular drug delivery to RPE cells has been shown using a rat model where 
nanoparticles were found to be in the cytoplasm of the RPE cells, 4 months after an 
intravitreal injection.154  In another study, microspheres coated in gelatine have been 
phagocytosed by RPE cells (phagocytosis is one of the functions of RPE cells, see 
Section 1.1.4).186  A particular concern of utilising nanotechnology for drug delivery 
in the eye is that the nanoparticles may be cleared relatively quickly via the 
periocular circulation route, even before drug release has occurred.  It has been found 
that nanoparticles of 20 nm have a very rapid clearance whilst those of 200 nm are 
cleared only after several weeks.187   
 
1.6.4.2 Liposomes 
 
Liposomes are biocompatible, amphiphilic vesicles made of a lipid bilayer as 
depicted in Figure 1.13. They can transport both hydrophilic and lipophilic drugs in 
the aqueous compartment and membrane respectively. Liposome properties can be 
tailored to different size, lipid content and surface charge; it is the surface charge 
which seems to determine uptake by the cornea.188  Liposome uptake by the cornea is 
greater for positively charged liposomes and least for neutral materials.    It has been 
reported that transport within a liposome helps increase drug efficacy up to 10 fold, 
while leading to a better control of release rate at the same time.189-192   Habib et al. 
reported a 36 % increase in the delivery of fluconazole across the cornea when 
liposome drug carriers were used. 193  The inclusion of markers and receptors within 
the liposome membrane is currently being investigated to allow active targeting of 
different cells as well as laser or heat induced release.194, 195   
 
Figure 1.13 Schematic of a liposome. 
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1.6.5 Explants 
 
Explants are DDDs attached to the outside of the eye, an example of which is a 
scleral buckle modified to release drugs; a solid non-biodegradable silicone band 
which can be removed after 1 year has been used.196, 197  A hydrogel buckle made 
from poly(methyl acrylate-co-2-hydroxyethyl acrylate) which has the advantage of 
swelling in water, therefore, can act as a reservoir for hydrophilic drugs could also be 
used.197-199 
 
1.6.6 Vitreous Substitute 
 
An ideal vitreous substitute must meet a number of requirements: be transparent, 
have long term biocompatibility, have a high water/tamponade interface surface 
tension, be able to conform to irregular surfaces, have a low viscosity and properties 
which lead to low (if any) emulsification; many of these properties are often 
mutually incompatible.44  Lin et al. saw a synthetic foldable vitreous substitute go to 
a 3 month clinical trial with positive results in flexibility, effectiveness and safety.200 
A vitreous substitute could also be used as a drug reservoir.  Zheng et al. loaded a 
foldable vitreous substitute with 5-FU and saw a sustained release for up to 56 days 
both in vivo and in vitro.201  
 
An alternative to vitreous substitutes are tamponade agents such as gas and SiO 
which were discussed in Section 1.2.3.3 for the treatment of RD. A SiO tamponade 
could be an ideal candidate for drug delivery to the posterior of the eye, as it could 
act as a drug reservoir. However, the majority of drugs such as triamcinolone and 
daunomycin as well as antigrowth factors and growth factor inhibitors are water 
soluble, therefore, do not have high (if any) solubility in SiO.  Studies investigating 
the use of SiO as a reservoir for the extended delivery of many lipophilic drugs such 
as 5-FU, RA, α-tocopherol and acetylsalicylic acid have been carried out.  Lipophilic 
5-FU has been shown to rapidly clear from SiO with t1/2 < 3.5 hours for 1 mg.
107  N1-
alkoxycarbonyl prodrugs with 5-FU which are soluble in SiO have been synthesised.  
A prodrug is a compound that upon administration must undergo chemical 
conversion by a metabolic process to become an active pharmacological agent, 
ideally at efficacious levels without adverse effects (prodrugs will be discussed in 
more in detail in Section 1.8).202  The release of drug is prolonged in this case as the 
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prodrug has to diffuse to the edge of the bubble and hydrolyse to release the drug; 
release of 5-FU was prolonged but was still under 2 days.107  Co-drugs of 5-FU and 
RA have also been developed which have a t1/2 release of 5.8 days which is promising 
but would need further modification to reach the desired 6-8 week treatment period 
for PVR.203 Animal studies with α-tocopherol204 and acetylsalicylic acid205 dissolved 
in SiO have resulted in higher and prolonged retinal concentration of both drugs 
compared to delivery via a intravitreal injection.   
 
1.6.7 Limitations of DDDs 
 
Although all the DDDs discussed have many advantageous properties, there are still 
some disadvantages and more developments which need to be made.  The limitations 
of the DDDs are summarised in Table 1.1. 
 
Table 1.1 Table to summarise the limitations of different drug delivery devices. 
 
 
1.6.8 Current PVR DDD Research 
 
PVR requires a treatment period of 4-6 weeks which makes it an ideal candidate for 
treatment using a DDD.87  This section will discuss some of the DDDs previously 
discussed with the aim of prevention/treatment of PVR.   
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Rabbit models with antiproliferative drugs encapsulated in liposomes have shown a 
significant improvement of the intravitreal drug half-life, therefore, improving drug 
efficacy as well as generating a decrease in toxicity.  These studies also showed 
flaws in liposomal drug delivery such as cloudiness in the vision due to the size of 
the liposomes, possible cause of cataracts as well as risks of infection when 
administered and inflammation, which could induce PVR.   Sustained delivery of RA 
from microspheres of 50/50 PLGA was seen in a rabbit model for up to 40 days.138  
Giordano et al. also demonstrated that the same amount of drug injected directly 
would have a toxic effect whereas when injected within the microspheres there were 
no histological abnormalities or cytotoxic effects.138  
 
Scleral plug implants have been used to release drugs with beneficial impacts of 
reducing PVR within rabbit models. Yasukawa et al. investigated the use of a scleral 
plug synthesised with PLGA incorporating the antiproliferative drug cishydroxy 
proline for the treatment of PVR in rabbits.  After 28 days they found a 48 % 
decrease in the prevalence of PVR compared with equivalent intravitreal injections 
of the drug.105   
 
Utilising a SiO tamponade as a drug reservoir for treatment would be ideal as it is 
usually used in complicated RD where PVR is more likely to occur or already exists.  
It has also been suggested that the ideal drug delivery system is not only intravitreal 
but has a double benefit as it acts as a tamponade agent.206  Many studies have 
already taken place solubilising lipophilic drugs into SiO (see Section 1.6.6), 
including 5-FU and RA, where the drug diffuses to the interface of SiO and is 
released into the surrounding aqueous.107, 137  However, 98 % of RA, and the 
majority of 5-FU, is cleared from SiO within 1 week,137, 207 therefore, drug 
modification is required to develop a truly sustained release. 
 
1.7 RESEARCH OBJECTIVES 
 
The work presented here focuses on developing a sustainable drug delivery system 
for the treatment of PVR utilising the SiO tamponade agent as a drug reservoir. SiO 
is the only long term tamponade agent clinically available, therefore, can be present 
in the eye for the 4-6 week treatment time PVR requires.  Lipophilic drugs must be 
chosen for this project as water soluble drugs do not have high (if any) solubility in 
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oil.  The two drugs chosen to be investigated throughout this research are Ibu and 
atRA.  Ibu was chosen as its characteristic anti-inflammatory response may be able 
to reduce PVR, and Ibu has yet to be studied in the context of PVR. atRA was chosen 
due to the promising results previously reported by others in the literature in reducing 
PVR and RPE proliferation, as well as previously being administered via a SiO 
tamponade.125-127 To develop a long term release system prodrugs will also be 
studied, and these are discussed in Section 1.7.1. 
 
1.7.1 Prodrugs 
Albert208 and Harper209 introduced the concept of a prodrug as a compound that on 
administration must undergo chemical conversion by a metabolic process to become 
an active pharmacological agent ideally at efficacious levels and without adverse 
effects (see Figure 1.14).202 The model involves a parent drug molecule attached to a 
pharmacologically inactive pro-moiety deeming the whole system inactive.  Prodrugs 
aim to overcome pharmaceutical problems (poor solubility, chemical instability of 
drug molecule, unacceptable taste or odour), pharmacokinetic issues (insufficient 
absorption/permeability, dosing frequency, toxicity) and pharmacodynamics 
problems such as lack of selectivity at the site of requirement.210, 211  
 
Figure 1.14 A schematic illustration of the prodrug concept. 
 
The prodrug can be bio-activated either intracellularly or extracellularly by an 
enzymatic or chemical transformation.  
 
1.7.2 Prodrug Bond 
 
Release of drugs solubilised in SiO is primarily determined by the diffusion rate of 
drugs through the oil.  Araiz et al. reported 98 % clearance of atRA from the eye 
(using a rabbit model) within 7 days.137 Prodrugs could prolong drug release as the 
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rate of release will be determined by the cleavage of the bond linking the drug to the 
non-drug component.212  Many different bonds are currently used in prodrug 
synthesis and the most common bonds used with drugs such as atRA and Ibu, that 
contain carboxylic acid functional groups are shown below in Figure 1.15.   
 
Figure 1.15 Common functional groups within prodrugs when a carboxylic acid is present on parent 
drugs. 
 
As well as those shown above, some other linkages which can be utilised in various 
prodrugs include: 
i. Schiff Bases - Müller et al213 investigated acid sensitive Schiff bases which 
are stable at pH 7.4 but for which acid-catalysed hydrolysis occurs at pH 5 to 
release drug.210  Kratz et al reviewed acid-sensitive drug-polymer conjugates 
recently developed and future aims within this research field.214 
ii. Peptide linkers - enzymatically degraded to parent drug molecule and 
carrier.215  
iii. Disulphide bridges - Bio-activate via intracellular disulphide exchange with a 
thiol such as glutathione.216, 217 
iv. Hydrazone linkers - Display stability under a wide range of conditions yet 
undergo covalent exchange reactions in the presence of an acid or nucleophile 
catalyst such as in endosomal and lysosomal compartments which have a pH 
of 4 - 6.5.218 
v. Hydrolysable Linkers - amide212, 219, 220, anhydride221-224 and ester211, 212, 225-227 
bonds bio-activate when they are exposed to water. 
 
In this project, prodrugs bio-activated extracellularly will be investigated, as 
activation is hypothesised to take place at the SiO/aqueous humour interface and 
within the aqueous humour itself.  Figure 1.16 shows the proposed drug release 
mechanisms for this project when a hydrophilic pro-moiety (poly ethyleneoxide 
 
Carbonate Esters Esters Anhydrides Amides Carbamates 
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[PEO]) is used.  The PEO will drive the diffusion of the drug towards the aqueous 
interface, the rate of the bio-activation (cleavage of the bond) will then determine the 
rate of release of drug from SiO into the aqueous humour, or within the aqueous 
humour with the hope of a prolonged time period.   
 
Figure 1.16 Proposed mechanism of the PEO prodrug and the bio activation of the drug at the 
SiO/aqueous humour interface and within the aqueous humour. 
As the cleavage of the covalent bonds is expected to take place at the SiO/aqueous 
humour interface and within the aqueous humour it is important to try and determine 
the composition of the aqueous humour and determine the potential cleavage factors 
present.  
  
1.7.2.1 Aqueous Humour 
 
Aqueous humour flows around the eye and contributes to the homeostasis of the eye 
by providing nutrients, removing metabolites, transporting neurotransmitters and 
stabilising the ocular surface (see Figure 1.1).228   There are very limited reports in 
the literature about the composition of aqueous humour, due to a general reluctance 
to take samples of aqueous humour from patients in case harm is caused; 
unfortunately the information which is available is contradictory.229  General 
consensus of composition is: amino and ascorbic acid, bicarbonates, carbohydrates, 
carbon dioxide, chlorides, glucose, glutathione, inorganic ions, lactic acid oxygen, 
proteins, urea and water.228, 230-233  Flow rates of approximately 3 µL/min in the 
morning and 2.4 µL/min in the afternoon have been reported, while during sleep it 
slows to 1.5 µL/min.234 This may affect the cleavage of bonds within prodrugs if the 
presence of a certain concentration of cleavage factor is required. The literature also 
states that aqueous humour is different in healthy eyes and eyes with pathological 
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diseases,235 in particular those with PVR.236  As the amount of information available 
for the composition of aqueous humour for patients with PVR is minimal and 
contradictory, it was decided a simple ester linkage would be used within these 
prodrug studies.  This allows solely the presence of water to bio activate the prodrug.  
 
An ester is usually prepared by reacting an hydroxyl functional group with an acid 
group.  While both our drugs bear a carboxylic acid, the polymers chosen as the 
pro-moiety either contain a hydroxyl function by nature, like PEO, or can be 
purchased already functionalised, like polydimethylsiloxane (PDMS), which 
removes the need for any modification prior to the esterification step.  Ester prodrugs 
are also the most common ophthalmic prodrugs, as esterases (types of enzymes 
responsible for cleaving ester bonds within the body) are known to be present in the 
eye.227  The use of an anhydride as the linker was not considered as these bonds are 
extremely water sensitive (more so than an ester bond), therefore making it difficult 
to carry out future experiments without degradation; this would become particularly 
problematic if the prodrug was chosen to be used clinically, as sterilisation (see 
Chapter 2, Section 2.3 autoclave degradation) may also need to be carried out.     
 
1.7.3 PEO 
 
The ideal polymer to incorporate into a prodrug should be biocompatible (non-toxic, 
non-immunogenic, contained within FDA approved medicines for internal 
consumption and preferably biodegradable), able to transport required drug dosage, 
inexpensive, protect the drug against premature metabolism, display active/passive 
targeting and be able to bio-activate at a rate appropriate to the desired dosing 
frequency.237, 238 PEO is a “popular” polymer with a broad range of uses in everyday 
products, industrial applications and within biomedical drug delivery systems and its 
structure is presented below in Figure 1.17.   
 
Figure 1.17  Structure of poly(ethylene oxide) (PEO).  
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PEO products have been on the market for 25 years and it is the most commonly 
used non-ionic polymer in the field of polymer based drug delivery.239  Table 1.2 
gives some examples of PEO based prodrugs currently available on the market 
including Macugen and Zioptan™ which are used ophthalmically.  
 
Table 1.2 PEO based prodrugs currently available on the market and some being developed.  Includes 
ophthalmic prodrugs Macugen and Zioptan™. Table adapted from refs: 239, 240 
 
PEO is synthesised by an anionic polymerisation of ethylene oxide, initiated by 
nucleophilic attack of a hydroxide ion on the epoxide ring, resulting in a very narrow 
dispersity polymer.240  The narrow dispersity is important for reproduction of the 
polymer and examination of clearance pathways.  Low number average molecular 
weight (Mn) PEO is preferred, below 40,000 gmol
-1 but above 400 gmol-1, as 
oxidation leads to a diacid and hydroxyl-acid metabolites, which can cause toxicity 
problems and clearance issues.239  PEO has been shown to be removed from the body 
via a combination of renal and hepatic pathways as long as it is below 
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40,000 - 50,000 gmol-1; above this Mn it would compromise the renal filtration 
system.241, 242  When using a hydrophobic drug, the hydrophilic-lipophilic balance of 
a polymer conjugate can be varied depending on the Mn of the PEO.  Increasing Mn 
increases solubility in water and most organic solvents,243  and the terminal hydroxyl 
groups provide a labile site for covalent attachment to drugs as discussed in Section 
1.7.1. 
 
1.7.4 atRA in Prodrugs 
 
atRA is susceptible to degradation in light, air, high temperatures and when in 
solution, therefore, synthesising an atRA prodrug can be problematic.  Currently 
there are a number of methods in the literature to synthesise atRA-conjugates with 
condensation reactions, however, only a 40-48% yield is achieved,244 also reported 
are acyloxyalkyl245 and acyl chloride esterifications.246  The Steglich esterification 
method (discussed in more detail in Chapter 3, Section 3.3.2) was used by Wang et 
al.247 to synthesise a methoxy-poly(ethylene glycol)-b-poly(lactide-co-2,2-
dihydroxymethyl propylene/atRA/cisplatin) esters and drug release was investigated.  
Micelles were prepared at a 1:1 ratio of atRA and cisplatin conjugates and release 
was measured via UV-Vis spectroscopy.  Although both atRA and cisplatin were 
released at neutral, acidic and basic pH, release of atRA was always slower.   
 
1.7.5 Ibuprofen in Prodrugs 
 
Ibu has been used to produce anhydride and ester linked prodrugs.224, 248, 249  Abu 
Zanat et al.249 synthesised two Ibu prodrugs: Ibu-2-hydroxylethyl ester and the co-
drug: 2-(2-(4-isobutylphenyl) propanoyloxy) ethyl nicotinate hydrochloride via an 
acyl chloride esterification. It was observed that the rate of hydrolysis of co-drug and 
Ibu-2-hydroxyethyl ester is influenced by pH. The co-drug’s susceptibility to 
hydrolysis increased as pH increased toward the alkaline range, however, the 
opposite was true for the hydrolysis of Ibu-2-hydroxyethyl ester which was more 
reactive at low pH values.  A prodrug of PEO-Ibuprofen was synthesised utilising the 
coupling agent 1,1’-carbonyldiimidazole (CDI) to form a diester (Ibu was attached to 
both ends of the PEO) with various Mn of PEO including 1,000 and 2,000 gmol
-1, 
with yields of 75 and 88 % respectively.248 
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1.7.6 Project Challenges 
 
Key principles requiring investigation during this project include: toxicity of drugs 
on RPE, determination of an accurate method to measure drug solubility within SiO 
and release of drugs, and development of a tailored release of therapeutic amounts of 
drug over a prolonged treatment period of 4-6 weeks. 
 
Drug characterisation and biological evaluation of atRA and Ibu on RPE to 
determine toxic thresholds and antiproliferative effects of the drugs will require 
studying using cultured RPE cells.   
 
Synthetic aims include the investigation of linear end group modification of 
polymers to form prodrugs.  The use of both a hydrophilic and lipophilic pro-moiety 
within prodrugs will be investigated as well as different amounts of substitution and 
different DPn of the pro-moiety.  The solubility of the prodrugs will be investigated 
as well as the cleavage of drugs from the prodrugs and release from SiO.  Solubility 
of both atRA and Ibu in SiO will need to be accurately determined to be able to 
compare the effects of using the prodrugs to free drug.  The objectives of this project 
are illustrated in Figure 1.18.  
 
Figure 1.18 Illustration of the objectives of this project A: detached retina, B: treatment with SiO 
tamponade, C: drug dispersed within SiO, D: Prodrug with hydrophilic (PEO) pro -moiety dispersed 
within SiO, E: Prodrug with hydrophobic (PDMS) pro-moiety dispersed within SiO, F: mixture of 
drug and prodrug with PDMS pro-moiety within SiO tamponade. 
 
As discussed, a detached retina (Figure 1.18 A) can be treated with a vitrectomy 
followed by insertion of a SiO tamponade (Figure 1.18 B).  The solubility of drug on 
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its own within SiO (Figure 1.18 C) will be investigated so a comparison can be made 
when prodrugs are used, with the aim to determine if drug concentration increases or 
decreases when attached to both a hydrophilic and hydrophobic pro-moiety.  Release 
profiles of free drug from SiO will also be determined so effects of prodrug on 
release can be investigated.  Figure 1.18 D represents the prodrug with a PEO pro-
moiety; the proposed mechanism for the bio-activation of the drug was shown in 
Figure 1.16.  The PEO will drive the drug to the SiO/aqueous interface where it will 
either cleave leaving some drug within the SiO to diffuse out, or cleavage will occur 
within the aqueous humour.  In both of these scenarios PEO would be a side-product 
of the drug delivery system within the aqueous humour.   The rationale to use a 
hydrophobic pro-moiety came from this as a hydrophobic component would remain 
within the oil, and cleave at the interface, leaving only the drug to travel into the 
aqueous humour.  The pro-moiety would then surgically be removed along with the 
SiO tamponade.  Figure 1.18 E represents the lipophilic prodrug, and Figure 1.18 F 
represents drug dispersed within SiO in the presence of the prodrug; the effects of the 
hydrophobic pro-moiety with respect to solubility of drug will be investigated as well 
as the effects on release.  
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2.1 INTRODUCTION 
 
As mentioned in Chapter 1 the drugs of choice for use throughout this thesis are 
atRA (all-trans retinoic acid) and Ibu (ibuprofen).  atRA has been proven to be 
sensitive to light, air and temperature, and will isomerise/oxidise under these 
conditions,1-3 whereas Ibu is stable.  A full characterisation of atRA was carried out 
in order to confirm the purity of the product commercially obtained.  1H and 13C 
nuclear magnetic resonance (NMR) spectroscopy, mass spectroscopy, high-
performance liquid chromatography (HPLC) and melting point analysis were utilised 
to assess purity.  The degradation of atRA, under conditions which would be used in 
subsequent work, was also studied.   
 
The cytotoxicity of the two different drugs was evaluated using MTT, Resazurin, 
Phalloidin and BrdU assays on ARPE-19 cells (ATCC® Number: CRL-2302™, 
adult retinal pigment epithelium cells from the normal eyes of a 19 year old male 
donor, who died in a motor vehicle accident). This cell line was chosen because 
ARPE-19 cells are an established but non-immortalised human cell line which model 
the structure and functionality of RPE cells in vivo and as such provide a good 
system to study interactions of drugs encountering the RPE.4, 5  BrdU incorporation 
was also used to investigate the anti-proliferative effects of atRA and Ibu on 
ARPE-19 cells.   
 
Overall the aims of this chapter are to characterise and evaluate the degradation of 
the sensitive atRA, under conditions relevant to the subsequent research that will be 
carried out, as well as the biological evaluation of both atRA and Ibu, in order to 
determine toxic thresholds and antiproliferative effects of both drugs.   
 
2.1.1 Cellular Assays 
 
There are many different assays that can be carried out to determine the cytotoxicity 
and antiproliferative effects of a drug to a cell.  In this section the assays used 
throughout this research to biologically evaluate the drugs are discussed. 
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2.1.1.1 MTT Assay 
 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
measures the mitochondrial activity of a cell, and is therefore indicative of 
cytotoxicity.  Mitochondria have many functions with the most prominent being 
energy conversion and regulation of cell metabolism.6  MTT is a colorimetric assay 
where the mitochondria metabolise MTT via the reduction to formazan crystals, 
which reside within the cell, therefore the metabolic activity of the cell can be 
monitored (Scheme 2.1). 
 
Scheme 2.1 MTT reduction to formazan. 
 
The cells are broken down and the formazan crystals solubilised in acid then 
measured on a spectrophotometer.  The more active the mitochondria are within the 
cell, suggesting the cell is healthy, the more formazan will be produced; therefore a 
stronger absorbance will be seen on the spectrophotometer (See Figure 2.1).   
 
 
Figure 2.1 MTT plate showing variation of formazan crystal formation, typical of healthy cells  with 
deep purple colour (left) and unhealthy/dead with a lilac colour (right). 
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2.1.1.2 Resazurin Assay 
 
The resazurin assay is similar to the MTT assay in that it measures the mitochondrial 
activity of a cell. In this assay the mitochondria reduce resazurin to the fluorescently 
active resorufin presented in Scheme 2.2; the fluorescence is then measured on a 
fluorescent plate reader.  The advantages of this assay over MTT is that the cells 
remain alive after the assay is performed, therefore, further studies can be carried out 
on the same samples, including staining. 
 
Scheme 2.2 Resazurin reduction to resorufin. 
 
2.1.1.3 Phalloidin Assay 
 
Phalloidin belongs to a family of phallotoxins that are derived from the death cap 
mushroom which, as the name suggests, is highly toxic and is responsible for most 
fatal mushroom poisoning worldwide.7  Phalloidin is conjugated to a fluorophore and 
used to stain the F-actin of the cellular cytoskeleton so the structural integrity can be 
determined via fluorescent microscopy.  Figure 2.2 shows an image of ARPE-19 
cells stained with phalloidin.  The nuclei of the cells have also been stained with 
dianidine-2-phenylindole (DAPI).  DAPI is a blue fluorescent DNA stain which 
binds to DNA base pair adenine-thymine rich areas, so is ideal for nuclei staining.8  
Another advantage of using DAPI is that it can pass through membranes without 
causing any damage.    
 
Figure 2.2 ARPE-19 cell stained with phalloidin (green) and the nuclei 4', 6-diamidino-2-
phenylindole (DAPI) (blue).  Scale bar represents 50 µm. 
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2.1.1.4 BrdU Assay 
 
Bromodeoxyuridine (BrdU) is a synthetic analogue of thymidine (Figure 2.3) and is 
usually used to determine the rate of cellular proliferation.9-11  BrdU replaces 
thymidine in newly developed DNA of replicating cells.  To stain the incorporated 
BrdU, the cells need to be fixed into an immobile biological state, the membrane 
permeabilised, as well as the nuclei, to allow penetration of the dye.  A blocking 
agent is then applied and antibody staining for BrdU (anti-BrdU) is performed. Only 
the nuclei of cells which have incorporated BrdU are stained during this process 
which indicates the rate of proliferation of the cells.  Another dye, such as Hoechst 
33342 which has been used in ARPE-19 cells previously12 and is similar to DAPI as 
it is a blue fluorescent DNA stain, is used to stain the nuclei of all the cells which did 
not incorporate BrdU. 
 
 
 
 
Figure 2.3 BrdU and thymidine structures and an image of ARPE-19 cells which have been incubated 
with BrdU for 4h.  The nuclei which have incorporated BrdU are stained red and the nuclei of cells 
which didn’t stained with Hoechst (blue). 
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2.2 RETINOIC ACID CHARACTERISATION 
 
atRA was analysed by 1H and 13C NMR spectroscopy, chemical ionisation (CI) mass 
spectroscopy, HPLC and melting point analysis to determine isomeric purity.  It is 
possible for each double bond in the hydrocarbon chain to undergo isomerisation to 
mono-cis or multiple-cis forms of RA.  However, due to steric hindrance some of 
these isomers are not thermodynamically stable at ambient temperature and, 
therefore, isomerise into a stable form.2 Possible isomers of atRA and oxidation 
products can be seen in Figure 2.5.  
 
Mass spectrometry analysis (Figure 2.4) confirms the MW of RA; however, this 
technique cannot differentiate the isomers but can confirm no oxidation products are 
present.  
 
 
Figure 2.4 Mass Spectra (CI-MS) of atRA. 
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Figure 2.5 Isomers of retinoic acid and oxidation products all-trans epoxy retinoic acid and 13-cis 5,6 epoxy retinoic acid.
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The 1H NMR spectrum of RA is shown in Figure 2.6 with all peaks assigned.  Only 
the chemical shifts characteristic of the all-trans isomer are present indicating 
isomeric purity. In particular, there is absolutely no trace of the most common 13-cis 
isomer (see Figure 2.5) for which the chemical shift attributed to the CH named (l) 
would be shifted to 7.73 ppm.13 
 
 
Figure 2.6 
1
H NMR (CDCl3, 400 MHz) of atRA. 
 
Further confirmation that no other isomer is present was obtained from the 13C NMR 
spectrum of the RA sample (presented in Figure 2.7), where no carbon environment 
characteristic of isomers other than atRA was observed.  Similar to 1H NMR, there is 
no trace of the most common 13-cis isomer for which the chemical shift attributed to 
the carbon labelled (18) would be shifted to 168.6 ppm compared to 172.7 ppm 
observed.14  
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Figure 2.7 
13
C NMR (CDCl3, 400 MHz) of atRA. 
 
The melting point of RA was measured via an Optimelt Automatic Melting Point 
System.  The melting temperature range was determined to be 179.8-181.5 °C which 
is characteristic of atRA whereas, 9-cis RA and 13-cis RA are characterised by 
melting points of 184-187 °C and 175 °C respectively.15  
 
Finally RA was characterised by HPLC (UV-Vis detection: details in Section 6.1.4).  
The separation of RA cis- and trans- isomers by HPLC has been the subject of many 
investigations.2, 13, 16   Using an eluent composed of 95% acetonitrile (ACN), 5% 
methanol (MeOH) and 0.6% acetic acid, a narrow peak was observed, with no 
lagging or tailing (see Figure 2.8). The presence of a single narrow peak confirms 
that only one isomer is present, concluding the atRA purity for later experiments. 
The peak located at 1.2 minutes is due to the detectors response to the mobile phase 
within the sample. 
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Figure 2.8 HPLC chromatogram of atRA (Eluent: 95% ACN; 5% MeOH; 0.6% Acetic Acid). 
 
2.3 RETINOIC ACID DEGRADATION 
 
As atRA has been proven to be light, heat and oxygen sensitive, it was essential to 
the project to study its degradation under the proposed experimental conditions 
which would be utilised throughout this research. The different conditions tested are 
summarised in Table 2.1.  
 
Table 2.1 Various conditions and time points at which the degradation of atRA was studied. 
 
Solid atRA 
atRA in 
EtOH 
(1mg/mL) 
atRA in 
DMSO 
(66.6mg/mL) 
atRA in SiO 
(suspension) 
atRA in 
DCM 
(1mg/mL) 
-20 °C Argon 1, 7, 28, 
548d 1, 7, 28d - - - 
  
-20 °C Air 1, 7, 28d 1, 7, 28d 1, 7d - -   
37 °C Light, Air - - 1, 7d 1, 7, 28d -   
37 °C Dark, Air - - 1, 7d 1, 7, 28d -   
Ambient T, 
Light, Argon 1, 7d - - - - 
  
Ambient T, 
Light, Air 1, 7d 1, 7d - 1, 7, 28d - 
  
Ambient T, 
Dark, Argon 1, 7d - - - 1, 4, 7d 
  
Ambient T, 
Dark, Air 1, 7d 1, 7d - 1, 7, 28d - 
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The possible and expected atRA degradation products (isomers, photoisomers and 
oxidation induced epoxide formation) can be seen in Figure 2.5.  Degradation of 
atRA was monitored by HPLC, 1H NMR and mass spectroscopy (CI for solid 
samples and electrospray (ES) for solutions) for all conditions apart from atRA in 
SiO due to incompatibility of the SiO with these methods.  
 
As a yellow solid powder, atRA is normally stored under argon at -20 °C in the dark.  
Under these conditions no degradation was observed and atRA stability was assessed 
up to 548 days (3.5 years) after receipt of the product (Appendix Figure A1 and A2).  
When a solid sample was stored under the same conditions (-20 °C, in the dark) but 
in the presence of air, oxidation products began to show in CI-MS after 28 days 
(Figure 2.9).  Increasing temperature as well as exposure to light also leads to the 
presence of other isomers (Appendix Figure A3-A8). 
 
 
Figure 2.9 CI-MS of atRA stored at -20 °Cunder air for 28 days.  
 
There was an increase in degradation when atRA was in solution, particularly upon 
exposure to light.  Ethanol solutions were studied as EtOH would need to be used 
throughout the project.  Samples were analysed at 1 and 7 days, and although some 
very minor degradation was observed upon storage at -20 °C (see Appendix Figure 
A9-A14), most degradation occurred when the temperature was increased and the 
samples were stored in the presence of light (see Appendix Figure A15-A17).  Figure 
2.10 shows the HPLC chromatograms of the ethanol solutions stored at ambient 
temperature, under air, in both light and dark.  The appearance of a signal at 2 
minutes elution compared to the atRA peak at 2.4 minutes indicates the presence of 
an impurity.  This signal is much stronger when the sample is exposed to light and 
increases from 1 to 7 days.  
 
Epoxy RA 
(-CH3) +Na 
RA(-COOH) 
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Figure 2.10 HPLC chromatograms of ethanol solutions of retinoic acid stored at ambient temp erature 
in both light and dark, at 1 and 7 days. 
 
atRA degradation was also investigated in DMSO solutions, as DMSO would be 
used later in the project to help solubilise atRA into media.  Oxidation occurred 
within these samples when stored in the freezer after only one day, as evidenced by 
ES-MS, where an MH+ peak at 315 m/z, indicative of a 5,6-epoxide, can be seen 
(Figure 2.11).   
 
Figure 2.11 ES-MS of atRA stored in a DMSO solution at -20 °C in air for 1 day. 
 
1H NMR analysis in DMSO-d6 showed a change of the multiplicity of the peak at 
6.15 ppm attributed to CH-CH(CH3)-CH-, (highlighted in Figure 2.12), as well as an 
increase of the integration values compared to the 1H NMR of atRA (peaks j,k in 
Figure 2.6). This clearly indicates that isomerisation has occurred as well as 
oxidation.   
 
M+MeOH 
M
+
 
Epoxy RA 
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Figure 2.12 
1
H NMR (DMSO-d6,  400MHz) of atRA after storage in a DMSO solution at -20 °C in 
the presence of air for 1 day. 
 
As anticipated, samples stored in DMSO at 37 ºC degraded to a greater extent than 
those stored at -20 °C, particularly in the presence of light (see Appendix Figure 
A18-A23).  Furthermore, visual inspection showed a colour change from a yellow to 
orange solution.   
 
For DCM, which is the solvent of choice for the synthetic reactions that were 
planned for this project, degradation was assessed under argon and in the dark.  
Isomerisation occurred under these conditions after 4 days, as evidenced by the 
presence of new peaks in the HPLC chromatograms (see Figure 2.13).  Furthermore, 
as the 1H NMR spectra was unchanged (see Appendix Figure A24) for that period of 
time, the extent of degradation was considered to be at a level acceptable for further 
study.  Time periods of future reactions in DCM will be kept in mind.   
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Figure 2.13 HPLC chromatograms of atRA stored in DCM at ambient temperature in the dark for 1 
(red), 4 (black) and 7 (blue) days. (Eluent: 95% ACN; 5% MeOH; 0.6% Acetic Acid). 
 
Studying the degradation of atRA in SiO was essential as the ultimate aim of the 
project is to solubilise atRA into SiO for the treatment of PVR.  Only 1H NMR was 
used to analyse this as  neither HPLC nor mass spectroscopy can be carried out in the 
presence of SiO, and extraction methods of atRA from the SiO could potentially lead 
to degradation, therefore, making it impossible to determine whether degradation 
occurred before or after extraction.  Studies of atRA in SiO was not carried out at 
concentrations where atRA is solubilised, as even at the saturation concentration, 
signals in the 1H NMR spectra were not intense enough to analyse atRA compared to 
the SiO peaks.  Instead samples of 1 mg/mL atRA in SiO were used.  The 1H NMR 
spectra of the samples exposed to the harshest conditions, i.e light, air and 37 ºC, can 
be seen in Figure 2.14. From the 1H NMR analysis there was no degradation of atRA 
over 28 days in SiO. 
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Figure 2.14 
1
H NMR (CDCl3, 400MHz) of atRA in SiO at 1 mg/mL after 1, 7 and 28 days, upon 
storage under light, air and at 37°C. 
 
2.3.1 Degradation in Media 
 
Cell culture experiments will be carried out in this project, therefore the effects of 
culture media on atRA needed to be studied.  The classic conditions for incubating 
ARPE-19 cells were used, i.e. 37 °C with 5 % CO2 and in the dark.  Direct analysis 
of atRA in media could not be carried out, as media is not a suitable solvent for any 
of the analytical techniques available, therefore, atRA had to be extracted (see 
Section 6.4.1 for details). To ensure the extraction method was not degrading the 
atRA and confounding the results, a t=0 time point was taken which included 
extraction.  Solutions of atRA in media were prepared at a concentration of 10-3 M 
(using DMSO at 1 % to achieve solubility) as this is the maximum concentration 
currently dosed in the literature.17 Figure 2.15 shows the HPLC chromatograms of 
samples taken at different time points along with the sample at t=0.  A degradation 
CHAPTER 2 
75 
 
product eluting at 1.9 minutes is present after day 1 (absent at t=0) and increases 
from 7.9 % of the atRA peak after 1 day to 18.6 % at 7 days study.   
 
 
Figure 2.15 HPLC chromatograms of RA extracted from media at t=0 (green), 1 (red), 3 (black) and 7 
(blue) day. (Eluent: 95 % ACN; 5 % MeOH; 0.6 % Acetic Acid). 
 
The media is usually changed every 3-4 days when cultivating ARPE-19 cells, 
however, this degradation study suggests that when studying release of atRA, 
samples must be taken more frequently, preferably every day.   
 
2.3.2 Autoclave Degradation 
 
One of the companies which currently supplies medical grade SiO for eye 
tamponades is Fluoron GmbH.18  The commercial oil is subjected to sterilisation by 
autoclave at a temperature of 121 °C for 21 minutes.  Solutions of atRA in SiO (1 
mg/mL) were prepared, then autoclaved under the same conditions.  1H NMR and 
UV-Vis spectroscopy were carried out to analyse degradation by solubilising the SiO 
solutions in CDCl3 and THF respectively.  No isomerisation was observed in either 
spectrum (1H NMR spectrum in Appendix Figure A25).  Figure 2.12 shows the 
comparison between the UV-Vis traces of SiO, atRA and atRA solution in SiO 
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before and after treatment by autoclave.  There is no difference in absorbance of 
atRA in THF or atRA in SiO solubilised in THF before and after being autoclaved. 
The difference in intensity observed is due to samples being at different 
concentrations. Overall the treatment by autoclave doesn’t seem to affect atRA when 
in SiO. 
 
Figure 2.16 UV-Vis spectra of atRA compared to atRA in SiO before and after autoclave; all 
solubilised in THF. 
 
2.4 BIOLOGICAL EVALUATION 
 
As discussed in Section 2.1, the assays used to determine drug toxicity were MTT, 
resazurin, phalloidin staining and BrdU.  BrdU assays were also used to investigate 
the anti-proliferative effects of atRA and Ibu on ARPE-19 cells.  Various conditions 
of both culture time (pre- and post-confluent; cells cultured for 1 and 7 days 
respectively) and drug exposure times (1 and 7 days) were studied. 
 
2.4.1 Controls 
 
For each assay three technical replicates of each condition were carried out as well as 
controls, to confirm the assay was working correctly and ensure the validity of the 
experiment.  These included: 
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 Negative Control- represents healthy cells solely treated with culture media, 
expecting to observe no adverse effects 
 Positive Control- cells treated with 20 % DMSO to induce cell death 
 1 % DMSO- higher concentrations of drug require the presence of 1 % 
DMSO to become soluble in culture media. 
 
For MTT and Resazurin assays, the above controls were studied as well as the 
following additional experiments to ensure no background signals were observed in 
the spectrophotometer or fluorescent plate reader: 
 Media 
 Media plus cells 
 Media plus MTT/resazurin. 
 
Results from both MTT and resazurin assays are presented in Figure 2.17 where no 
significant difference between the negative controls and cells treated with 1 % 
DMSO was observed.  This indicates that this concentration of DMSO does not 
affect the metabolic activity of the mitochondria and is not toxic to RPE cells.  
Therefore, the drugs can be solubilised in 1 % DMSO and put into the media without 
affecting cytotoxicity studies.  There was a significant difference between both the 
negative control and 1 % DMSO dosage, against the positive control, and the 
background measurements of media, cells and MTT/resazurin, therefore indicating 
no interference from these additional components and resulting in confidence of a 
good experimental set up.   
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Figure 2.17 Controls studied by MTT (top) and resazurin (bottom) assays (mean, error bars represent 
± 1 standard deviation); n=3 . *, Significance by ANOVA and Dunnett’s T3 post-hoc evaluation 
(p≤0.05). 
 
Phalloidin staining was carried out on the negative and positive control samples as 
well as cells treated with 1 % DMSO (representative images of the controls are 
presented in Figure 2.18).  Staining confirmed that the cellular structure was intact 
for the negative control and cells treated with 1 % DMSO.  However, the majority of 
cells in the positive control had died, those that were still attached to the base of the 
well were stained and could be seen to be rounded and/or not resembling a healthy 
cell. 
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Figure 2.18 Fluorescent phalloidin (green) marked F-actin in ARPE-19 cells and DAPI (blue) stained 
nuclei.  A: Negative control, B: positive control and C: cells exposed to 1 % DMSO. Scale bar 
represents 50 µm. 
 
2.4.2 Retinoic Acid 
 
The metabolic activity and morphology of ARPE-19 cells were studied at multiple 
time scales.  Both pre- and post-confluent cells (1 day and 7 days growth 
respectively) were exposed to atRA for 1 and 7 days.  MTT and resazurin were the 
initial assays carried out followed by phalloidin staining on the cells from the 
resazurin assays.  Finally cell counts were performed to assess the toxicity.   
 
MTT and resazurin assays were in concordance with one another with respect to the 
amount of atRA that affected the metabolic activity of the cell (Figure 2.19).  For 
pre- and post-confluent cells after 1 day exposure to atRA, cytotoxicity was observed 
at concentrations above 10-5 M.  After 7 days exposure, cytotoxicity for post-
confluent cells was also observed for concentrations above 10-5 M, however, for pre-
confluent cells the toxic limit decreased by a factor of ten, to concentrations above 
10-6 M.  
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Figure 2.19 Overall cytotoxicity of atRA determined from MTT and resazurin assays.  ARPE-19 cells 
were exposed to different concentrations of atRA, from 10
-3 – 10-10 M, grown and treated for different 
time scales.  Pre-confluent cells (grown for 1 d) were exposed to atRA for 1 d (black) and 7 d (red).  
Post-confluent cells (grown for 7 d) were also exposed to atRA for 1 d (blue) and 7 d (green).  (mean, 
error bars represent ± 1 standard deviation ); n=3. *, Significance by ANOVA and Dunnett’s T3 post- 
hoc evaluation (p≤0.05). 
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Phalloidin staining confirmed these cytotoxic concentrations with images of healthy 
cytoskeletons when pre-confluent cells were exposed to atRA for 7 days at 
concentrations 10-5 M or 10-6 M. Figure 2.20 shows pre-confluent cells exposed to 
different concentrations of atRA for 1 day.  Many cells exposed to 10-3 M atRA have 
died, therefore, there were very few cells to image.  Cells exposed to 10-4 M still look 
unhealthy whereas cells exposed to 10-5 M are comparable to those imaged in the 
negative control (healthy cells).   
 
Figure 2.20 Images of pre-confluent ARPE-19 cells with F-actin stained by phalloidin (green) and 
nuclei by DAPI (blue) exposed to different concentrations of atRA. A: 10
-3
, B: 10
-4
 and C: 10
-5
 M. 
Scale bar represents 50 μm. 
 
BrdU incorporation assays allow for both cytotoxicity and anti-proliferative effects 
to be studied.  Cell number was determined as all nuclei were stained after drug 
exposure and counted; a decreased cell number compared to the negative control 
indicated an increase in drug toxicity. This assay followed the same trend as the 
previous assays (see Figure 2.21); no cytotoxic effects were observed below 10-5 M 
for post- and pre-confluent cells when exposed for 1 day or 10-6 M for pre-confluent 
cells with a longer exposure time of 7 days. However, the cell number is 
approximately 25 % of the cell number usually seen when cells are cultured for 8 
days.  Also the samples subjected to longer culture time (8 days) present larger 
variations, as evidenced by the standard deviation; this is because the cells grow in 
clusters and for analysis random areas of wells are counted to determine overall cell 
number.  Therefore, some images would have a larger number of cells than others 
where there were large areas devoid of cells. 
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Figure 2.21 Cell number upon exposure to atRA determined from BrdU assay.  ARPE-19 cells were 
exposed to different concentrations of atRA, from 10
-3 – 10-7 M,  grown and treated for different time 
periods.  Pre-confluent cells (grown for 1 day) were exposed to atRA for 1 day (top) and 7 days 
(middle).  Post-confluent cells (grown for 7 days) were also exposed to atRA for 1 day (bottom).  Bars 
represent mean number of BrdU-positive cells per field of view. (Error bars represent ± 1 standard 
deviation); n=9.  
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The anti-proliferative effect of atRA was also studied using this assay (see Section 
2.1.1.4). After the cells were exposed to atRA for the desired time they were 
incubated with BrdU for 4 hours.  Only the cells which proliferated during this time 
incorporated BrdU. Cells were fixed and stained, then imaged by fluorescence 
microscopy.  Both the Hoechst stained nuclei and anti-BrdU stained nuclei were 
counted and a percentage of proliferation determined.  Table 2.2 summarises the 
percentage of proliferation observed for all the different concentrations tested.  A 
decrease in proliferation was observed when cells were exposed to increasing 
concentrations of atRA.  Pre-confluent cells exposed to atRA for 1 day showed the 
most dramatic effect.  In this particular case the cells were still proliferating at a 
faster rate to form a monolayer, compared to subsequent assays when cells were 
cultured for 8 days and a monolayer had already formed.  Proliferation percentage 
went from 49 % in the negative control (where proliferation should be consistent 
with normal cellular rate) to 22 % when exposed to 10-5 M atRA.  No BrdU 
incorporation was observed within the 4 hour incubation period for post-confluent 
cells when exposed to atRA for 7 days as a monolayer of ARPE-19 cells had already 
formed and proliferation was no longer occurring at a steady rate.   
Table 2.2 Proliferation calculated as a percentage of cell nuclei with incorporated BrdU compared to 
Hoechst stained nuclei, when cells were exposed to atRA 10
-5
-10
-7 
M (10
-5 
M excluded for pre-
confluent cells with 7 days exposure as this concentration determined to be toxic) as well as controls 
where proliferation shouldn’t be affected. 
 
 
2.4.3 Ibuprofen 
 
Cytotoxic responses of ARPE-19 cells were also studied upon exposure to varying 
amounts of Ibu, from 10-3 to 10-10 M.  The same time scales and experimental set-up 
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were used as in Section 2.4.2 to study both pre- and post-confluent cells at different 
exposure times.   
 
MTT and resazurin assays were in concordance with one another with respect to the 
amount of Ibu which affected the metabolic activity of the cell, see Figure 2.23. For 
pre-and post-confluent cells and 1 day exposure to Ibu, cytotoxicity was observed at 
concentrations above 10-4 M.  Upon 7 days of exposure, cytotoxicity for post-
confluent cells was also observed at concentrations above 10-4 M.  However, for pre-
confluent cells the toxic limit decreased to concentrations above 10-5 M. All 
cytotoxicity observed for Ibu occurred at a concentration a factor of 10 higher than 
atRA for the same culture and exposure times. 
 
Phalloidin staining confirmed these cytotoxic amounts with images of healthy 
cytoskeletons in the case of pre-confluent cells exposed to Ibu for 7 days, at 
concentrations below 10-4 M or 10-5 M.  Figure 2.22 shows pre-confluent cells 
exposed to Ibu for 1 day; cells exposed to 10-3 M Ibu have died and those that remain 
do not exhibit a healthy epithelial morphology, therefore, there were not as many 
cells to image whereas cells exposed to 10-4 M Ibu are comparable to those imaged in 
the negative control (healthy cells).   
 
Figure 2.22  Fluorescent imaging of pre-confluent ARPE-19 cells with F-actin stained by phalloidin 
(green) and nuclei by DAPI (blue) exposed to different concentrations of Ibu. A: 10
-3
, B: 10
-4
 and C: 
10
-5 
M. Scale bar represents 50 µm. 
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Figure 2.23 Overall cytotoxicity for Ibu determined from MTT and resazurin assays.  ARPE-19 cells 
were  exposed to different concentrations of Ibu,  from 10
-3 – 10-10 M, grown and treated for different 
time scales.  Pre-confluent cells (grown for 1 day) were exposed to Ibu for 1 day (black) and 7days 
(red).  Post-confluent cells (grown for 7 days) were also exposed to Ibu for 1 day (blue) and 7 days 
(green).  (mean, error bars represent ± 1 standard deviation); n=3. *, Significance by ANOVA and 
Dunnett’s T3 post- hoc evaluation (p≤0.05). 
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BrdU incorporation assay allowed for both cytotoxicity and anti-proliferative effects 
to be studied.  Cell number was determined and followed the same trend as the 
previous assays (see Figure 2.24).  No cytotoxic effects were observed below 10 -4 M 
for post- and pre-confluent cells upon 1 day exposure, or 10-5 M for pre-confluent 
cells with a longer exposure time of 7 days.  
 
Figure 2.24 Cell number upon exposure to Ibu, determined from BrdU assay .  ARPE-19 cells were 
exposed to different concentrations of Ibu, from 10
-3 – 10-7 M, grown and treated for different time 
scales.  Pre-confluent cells (grown for 1 day) were exposed to Ibu for 1 day (top) and 7 days (middle).  
Post-confluent cells (grown for 7 days) were also exposed to Ibu for 1 day (bottom).  Bars represent 
mean number of BrdU-positive cells per field of view. (Error bars represent ± 1 standard deviation); 
n=9.  
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The anti-proliferative effect of Ibu was also studied.  After the cells were exposed to 
Ibu for the desired time period they were incubated with BrdU for 4 hours. Table 2.3 
shows Ibu had no effect on proliferation, apart from when pre-confluent cells were 
exposed to Ibu for 1 day at 10-4 M.  Here the proliferation rate was less than half of 
what was seen for the controls and the other treatment concentrations.  
Table 2.3 Proliferation calculated as a percentage of cell nuclei with incorporated BrdU compared to 
Hoechst stained nuclei, when cells were exposed to Ibu 10
-4 – 10-7 M (10-4 M excluded for pre-
confluent cells with 7 d exposure as this concentration determined to be toxic) as well as controls 
where proliferation shouldn’t be affected. 
 
 
2.5 CONCLUSION 
 
The characterisation of atRA was accomplished by 1H and 13C NMR spectroscopy, 
CI mass spectroscopy, HPLC and melting point analysis, all of which confirmed 
isomeric purity of the sample as being the all-trans material.  A degradation study of 
the atRA isomer was carried out under various conditions relevant to experimental 
conditions to be used within the thesis.  The ideal storage conditions were 
determined to be atRA as a solid at  -20 °C in the dark with an inert argon 
atmosphere so no degradation can occur.   
 
Biological evaluation of both atRA and Ibu was carried out on ARPE-19 cells via 
MTT, resazurin, phalloidin and BrdU assays. For pre-and post-confluent cells and 1 
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day exposure to atRA, cytotoxicity was observed at concentrations above 10-5 M 
whilst exposure to Ibu under the same conditions resulted in cytotoxic results above 
10-4 M.  Upon 7 days exposure, cytotoxicity in the case of post-confluent cells was 
observed at the same concentrations, however, for pre-confluent cells the toxic limit 
decreased by a factor of ten for both atRA and Ibu to concentrations above 10-6 M 
and 10-5 M respectively. All cytotoxicity observed for Ibu occurred at a concentration 
a factor of 10 higher than atRA for the same culture and exposure times, therefore it 
was determined that Ibu is less toxic to ARPE-19 cells than atRA.  Overall, the 
cytotoxic limits of atRA and Ibu on ARPE-19 cells determined from these assays 
will lead to the concentrations of drug used for future loading and release studies 
within the project. 
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3.1 INTRODUCTION  
 
The synthesis of a drug delivery system (DDS) which releases non-toxic 
concentrations of drug (determined in chapter 2) over a prolonged period of time, for 
the prevention and treatment of PVR, drives the research throughout this chapter. 
The main criterion for the DDS is that it is soluble in SiO as the treatment will be 
administered via a SiO tamponade acting as a drug reservoir.  The use of a prodrug to 
control the release was investigated.  Poly(ethylene oxide) (PEO) was used as a 
hydrophilic non-drug component to drive the attached drug (Ibu and atRA which is 
hydrophobic) to the SiO/aqueous humour interface and into the aqueous humour, 
where the cleavage of the bond and the bio-activation occur, this then determines the 
release rate of the pharmacologically active drug (Figure 3.1).   
 
Figure 3.1 Proposed mechanism of the PEO prodrug approach and the bio-activation of the drug at 
the SiO/aqueous humour interface and within the aqueous humour. 
 
A lipophilic prodrug with PDMS as the promoiety was also studied in terms of the 
effect on solubility of drugs and release profiles from SiO.  The use of PDMS as the 
promoiety is advantageous due to the chemical similarity of side products and the 
SiO tamponade. 
 
3.2 PEO Prodrug  
 
3.2.1 Synthesis 
 
Throughout this section the synthesis of both PEO-atRA and PEO-Ibu prodrugs is 
described. Different number average molecular weight (Mn) PEO materials were 
used to tailor the degree of lipophilicity-hydrophilicity present within the prodrug.  
Both mono-functional and di-functional linear PEO were used, which allowed the 
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incorporation of either one or two drug molecules per polymer chain.  Initially a 
conjugation route using 1,1-carbonyl diimidazole (CDI) was undertaken to 
synthesise the prodrugs, and other strategies (such as the Steglich esterification 
method) were also evaluated.      
 
3.2.1.1 CDI Chemistry 
 
CDI chemistry is a useful method for the synthesis of esters1, 2 but was first used in 
peptide synthesis for the coupling of carboxylic acid and amine groups.3  CDI can 
also be used to prepare urethane, carbonate, amide and urea linkages.4 The different 
synthetic routes possible using CDI chemistry are shown in Scheme 3.1, with 
specific highlight for the route used within this project.  
 
Scheme 3.1 Possible chemistries using CDI as a coupling agent including esterification with a 
carboxylic acid (highlighted). 
 
The mechanism of esterification via CDI coupling is shown below in Scheme 3.2. 
CDI reacts with a carboxylic acid to give an imidazole carboxamide intermediate. 
This intermediate selectively reacts with primary alcohols or amines, due to steric 
hindrance around the carbonyl group, leading to the formation of an ester. This 
method was the original choice of esterification because the expected reaction time is 
much shorter than traditional routes (3 hours compared to over 24 hours), therefore 
minimising atRA exposure to conditions that may lead to degradation. 
 
Scheme 3.2 Mechanism of esterification via CDI coupling. 
 
 
CDI 
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A model reaction was carried out using benzoic acid (BA) and methyl terminated 
poly(ethylene oxide) (Me-PEO) (Mn 750 gmol
-1).  The desired poly(ethylene oxide) 
benzoate (PEO-BA) was successfully synthesised with an average yield of 61 % and 
fully characterised by 1H and 13C NMR and IR spectroscopies (see appendix Figure 
A26-28).  When BA was substituted by atRA, under the same conditions, the 
reaction failed.  The intermediate (Scheme 3.3) was successfully formed, as 
evidenced by the appearance of two peaks in 1H NMR spectroscopy at δ ppm 8.20 (s) 
and 8.09 (s), attributed to NCHN and NCHCHN respectively, with integration 
proportional to atRA (see appendix Figure A27).   
 
 
Scheme 3.3 Esterification of atRA and PEO reacting via a CDI intermediate. 
 
Usually the intermediate is readily reactive to an alcohol, however, this wasn’t the 
case with atRA.  p-Toluenesulfonic acid was added as a catalyst to try and drive the 
reaction, but even under these aggressive conditions the intermediate remained 
unreacted.  As the model reaction with BA was successful but the reaction with atRA 
was not, it was assumed that the structure/chemistry of atRA was causing the 
problem.  To get further confirmation, a reaction with atRA and benzyl alcohol was 
carried out, which was also unsuccessful.  It is possible that the conjugation in the 
atRA is stabilising the intermediate, making it unsusceptible to the reaction.  
 
3.2.1.2 Steglich Esterification 
 
Another approach to synthesise atRA and Ibu esters is the Steglich esterification 
method. This procedure offers a convenient method for the esterification of alcohols, 
thiols and carboxylic acids including very labile acids such as vitamin A.5  The 
reaction takes place at room temperature, under mildly basic conditions and its 
mechanism is shown in Scheme 3.4. 
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Scheme 3.4 Mechanism of a Steglich esterification. 
 
The Steglich esterification is a variation of a classic esterification, using 
dicyclohexylcarbodiimide (DCC) as a coupling reagent and 
4-dimethylaminopyridine (DMAP) as a catalyst.  DCC and the carboxylic acid form 
an O-acylisourea intermediate, which offers reactivity similar to the corresponding 
deprotonated carboxylic acid.  The alcohol can then be added to the activated 
carboxylic acid to liberate the stable dicyclohexylurea (DCU) and the ester; however 
this reaction is very slow in comparison to esterifications where strong nucleophiles 
such as amines are used.  The reaction with alcohol is slow enough that it allows the 
isolation of the O-acylisourea which then remains as a side product.  The reaction’s 
success comes from the addition of DMAP, a stronger nucleophile than an alcohol, 
which acts as an acyl transfer agent to form an activated amide (“active ester”).6 The 
alcohol then reacts quickly with this intermediate to form the desired ester. 
 
The synthesis of mono-substituted methyl terminated poly(ethylene oxide) retinoates 
(Me-PEO-atRA) via Steglich esterification was completed without any complications 
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of intermediate stabilisation, as previously seen with CDI chemistry. After filtration 
of the DCU by-product, and precipitation of the crude product (petroleum ether at 
approximately -70 °C), a yellow wax was recovered and fully characterised by NMR 
(1H, 13C and 2D) and IR spectroscopies,  all of which were in agreement with the 
desired product.  The 1H NMR spectra of a purified Me-PEO-atRA (1,050 gmol-1, 
n = 16) is presented in Figure 3.2.  The appearance of a peak at 4.31 ppm attributed 
to the CH2OCO from Me-PEO (labelled o) indicates the formation of an ester, also 
confirmed by the shifts of the peaks at 2.35 (m) and 5.82 ppm (n) corresponding to 
CH3CCHOO and CHCOO respectively. The attribution was confirmed by 2D NMR 
spectroscopy (1H-1H and 1H-13C); the correlation between the protons (o, m and n) 
and the carbonyl was observed, confirming the ester formation (see Appendix Figure 
A28 and A29). 
 
Figure 3.2 
1
H NMR (CDCl3, 400 MHz) of Me-PEO(16)-atRA. 
 
Mass spectroscopy was also carried out and displayed a shift of the Me-PEO MW 
distribution by a factor of 300 gmol-1 compared to unreacted Me-PEO, indicating the 
addition of an atRA molecule and the formation of the ester moiety (see Appendix 
Figure A30).  The IR spectrum confirmed the ester functionality with a peak at 
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1,707 cm-1, characteristic of a carbonyl in an ester (see appendix Figure A31).  Me-
PEO-atRA and Me-PEO-Ibu were successfully synthesised using Me-PEO of three 
different Mn values (750, 2,000 and 5,000 gmol
-1; DPn = 16, 45 and 113 monomer 
units respectively), all of which were fully characterised and determined to be the 
desired product.  Bi-functional PEO conjugates were also synthesised when hydroxyl 
groups were present at both ends of the PEO chain.  A summary of the prodrugs 
synthesised can be seen below in Scheme 3.5. 
 
Scheme 3.5 Schematic of prodrugs synthesised (A, B: atRA and C, D: Ibu) with different PEO 
functionality (A, C: Me-PEO and B, D: PEO) and conversions reached.  
 
When Me-PEO was the reactant, the peak at 3.38 ppm corresponding to the CH3 
from Me-PEO chain end (labelled q in Figure 3.2) could be used as a reference peak 
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to determine conversion via comparison of the new peak (o) and peak (q).  
Unfortunately, the conversion for di-substituted PEO prodrugs could not be 
determined by 1H NMR spectroscopy as the reference peak at 3.38 ppm was no 
longer available. Determination of conversion and drug content was attempted with 
UV-Vis analysis, however, it was concluded that this was not the appropriate 
technique to determine concentration of drug when it is bilaterally attached to PEO.  
This was due to varying trends of calibration curves when PEO/Me-PEO of different 
chain lengths are attached, possibly due to the micellisation of the hydrophobically-
modified water-soluble polymer chains.   
 
To determine the conversion by 1H NMR spectroscopy, an approximation of the PEO 
chain length close to the nominal reported value was taken; for example when an Mn 
of 600 gmol-1 was given, the number of ethylene oxide repeat units was determined 
to be 14, therefore the PEO peak at 3.45-3.85 ppm was calibrated to 56 protons (the 
number of hydrogens present within the PEO chain) then compared to the ester peak 
at 4.31 ppm. To confirm this, drug content within the prodrug was determined via a 
new methodology of 1H NMR spectroscopy using an external reference.  Anisole 
was chosen as its unique signals do not interfere with any of the PEO-drug peaks.  
Using precise volumes of NMR solvent (DMSO-d6), and an accurate concentration 
of anisole and drug, it was possible to determine the concentration of drug for all di-
substituted PEO materials.  Initially 1H NMR spectra of free atRA and Ibu were 
acquired with a known mass of materials present.  The signal at 7.1 ppm from anisole 
was normalised, and subsequently compared to the signal at approximately 1.0 ppm 
for atRA which corresponds to the protons of the methyl groups for both free and 
attached atRA (2 x –CH3) and 0.8 ppm for Ibu which represents the CH(CH3)2.  This 
allowed the precise concentration of drug to be calculated per mass of sample.  1H 
NMR analysis of all PEO retinoates and PEO-Ibu synthesised were carried out in the 
exact same conditions, i.e. volume of DMSO-d6 and concentration of anisole.  The 
concentration of drug could be calculated by comparing the amount of atRA and Ibu 
conjugated to PEO to the free atRA and Ibu reference spectra. This confirmed the 
correct conversions were calculated. 
 
The Ibu prodrugs were all successfully synthesised with high conversions, above 
90 %.  However, atRA prodrugs had lower conversion rates, between 50 and 74 %.  
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An explanation of the relatively low conversion (c.f. Scheme 3.5 A and B) comes 
from the conjugation of atRA.  Conjugation determines the electron distribution 
throughout the drug, therefore, affects the reactivity.  Computational modelling was 
performed by E. Eden (University of Liverpool) to investigate the reactivity of atRA 
with respect to the conjugated system, and confirmed this hypothesis by showing the 
size of the p(z) coefficient at the carbonyl carbon decreasing with increasing 
conjugation (see appendix Figure A38).  In other words, the space available for the 
hydroxyl group to attack decreased, therefore, caused the carbon to be less available 
to react throughout the esterification reaction.  The size of the PEO chain was also 
investigated; it was found that this was not expected to affect the reaction. 
 
3.2.2 Cleavage of Ester Bond 
 
The cleavage of the ester bond in vivo is anticipated to occur at the interface between 
the SiO and aqueous humour and within the aqueous humour (see Figure 3.1); 
therefore, the composition of the aqueous humour plays a key role. As discussed 
previously (section 1.7.2.1) this is not precisely characterised and the nature of the 
possible cleaving agents/factors is not known. Any cleavage experiment run in vitro 
won’t be a perfect model of the in vivo situation, therefore, will be carried out mainly 
as a proof of concept. 
 
Strong acidic or basic conditions were initially studied as conditions to cleave the 
ester bond. Table 3.1 summarises the different conditions used to cleave atRA from 
both mono- and di- substituted PEO and Ibu from di-substituted PEO.   The cleavage 
was performed in deuterated solvents, so it could be directly monitored by NMR 
spectroscopy. Controls were also measured in the solvents as well as with the 
addition of 0.2 equivalents of acid (deuterium chloride; DCl) and base (sodium 
deuteroxide; NaOD).  The decrease of the ester linkage is presented in terms of 
percentage of the original ester functionality. 
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Table 3.1 Different conditions used for the cleavage of PEO prodrugs in vitro with amount of cleaved 
drug given as a percentage.  
 
Experiments were initially planned to be carried out in deuterium oxide (D2O) to 
hydrolyse the ester bonds; however, due to poor solubility of drugs in D2O poor 
spectra were observed.  Therefore, although the decrease of ester functionality was 
observed, degradation of the drugs could not be accurately monitored. Porcine liver 
esterase (PLE) was used to determine if enzymatic release occurred, however, the 1H 
NMR spectra of PLE in D2O was also extremely complicated and no signals could be 
confidently assigned.   
 
Deuterated dioxane and acetone were finally chosen for these studies as both 
solubilised the prodrugs and gave clear spectra. Also, no degradation of the parent 
drugs was observed when solubilised at 37 °C (dark) for 3 and 1 day(s) respectively.  
Acidic conditions were observed to reduce the ester signals much more dramatically 
than basic conditions; however, both successfully cleaved the parent drug from the 
PEO effectively without degradation.  Figure 3.3 shows the assigned spectra of 
PEO(14) di-substituted with Ibu, before and after treatment with DCl for 24 hours.  
The complete disappearance of the ester signal (3) was observed as well as no 
degradation of Ibu. 
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Figure 3.3 
1
H NMR spectra (Acetone-d6, 400 MHz) of Ibu-PEO14-Ibu before (black) and after (blue) 
treatment with DCl (0.2eq.) at 37 °C for 1 day. 
 
Overall it was determined that atRA from both mono- and di- substituted PEO, and 
Ibu from di-substituted PEO, could be successfully cleaved without degradation of 
the parent drug. Acidic conditions at 37 °C were the most efficient particularly in 
dioxane-d8, however, these conditions were not indicative of actual physiological 
environments. 
 
3.2.3 Biological Evaluation  
 
Preliminary MTT and resazurin assays were conducted for cells treated with mono-
substituted PEO(48) attached to both atRA and Ibu because these incorporated the 
most PEO.  Metabolic activity of ARPE-19 cells was studied at multiple time-points 
resulting in both pre-confluent (1 day growth) and post-confluent (7 day growth) 
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cells being exposed to the prodrugs for 1 and 7 days.  MTT and resazurin assays 
were in concordance with one another and showed the same toxicity levels were 
observed as when cells are exposed to free drug (see appendix Figure A39 and A40).  
In the case of retinoates, cytotoxicity was observed at concentrations above 10 -5 M 
atRA content for pre- and post-confluent cells and 1 day prodrug exposure.  With 7 
days exposure, cytotoxicity for post-confluent cells was also observed at 
concentrations above 10-5 M, however, for pre-confluent cells the toxic limit 
decreased by a factor of ten to concentrations above 10-6 M.  In the case of Ibu 
prodrugs, cytotoxicity was observed at concentrations above 10-4 M Ibu content for 
pre- and post-confluent cells and 1 day Ibu exposure.  With 7 days exposure, 
cytotoxicity for post-confluent cells was also observed at concentrations above 10-4 
M, however, for pre-confluent cells the toxic limit decreased to concentrations above 
10-5 M.  Overall it was observed that PEO didn’t affect the metabolic activity of the 
cells, and that cytotoxicity was solely dependent on drug content. 
 
3.2.4 Solubility in SiO using UV-Vis Spectroscopy 
 
The solubilisation of PEO prodrugs in SiO is a crucial aspect to the project as the 
route of administration of this DDS to the eye is through a SiO tamponade.  The 
hydrophilic pro-moiety is necessary to help draw the hydrophobic drug to the 
SiO/aqueous interface and into the aqueous humour so cleavage of the ester bond and 
bio-activation of the prodrug can occur. While PEO is expected to have a limited 
solubility in SiO, it was anticipated that once a lipophilic drug was attached, the PEO 
conjugate solubility would increase in a hydrophobic environment such as SiO. 
SiO1000 was used throughout these investigations unless otherwise stated. 
 
3.2.4.1 atRA  
 
Initially, the saturation concentration of free atRA in SiO needed to be determined so 
the effect, if any, that the prodrug has on solubility can be deduced.  A protocol 
reported in the literature was used7  where a saturated solution of atRA in SiO was 
prepared and stirred gently in the dark at ambient temperature.  Samples were taken 
at different time-points over a 2 week period and filtered using a syringe pump 
(4 mL/h) through 0.45 µm PTFE filters to remove un-dissolved material.  To 
determine the amount of atRA dissolved in SiO, the drug was extracted from the SiO 
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three times with acetone (1:2 v/v).  The acetone layers were combined and the 
solvent was evaporated with the remaining solid dried at ambient temperature. The 
samples were solubilised in 2 mL of a mixture of DMSO/H2O (8/2) and subsequently 
analysed by UV-Vis spectroscopy. A standard curve previously determined for atRA 
(see Experimental 6.5.4.1) was used to determine the drug concentration.   
 
To test the accuracy of the extraction method, a known mass of atRA was solubilised 
in SiO and 93 % was recovered; this was deemed an acceptable error.  The 
experiment was repeated several times and an atRA solubility profile in SiO was 
determined under these conditions (Figure 3.44); the solubility reported in the 
literature (20 µg/mL, 6.66 x 10-5 M) is also depicted on the graph (red line).  After 14 
days, the average amount of atRA solubilised was 28.5 µg/mL (9.5 x 10-5 M), a value 
that is >40 % higher than literature values. Both of these saturation concentrations 
(literature and experimental) are lower than the cytotoxicity limits of ARPE-19 cells 
as investigated in Chapter 2.   
 
Figure 3.4 UV-Vis analysis of atRA solubility in SiO over 2 weeks (mean ± SD); n=3. 20 µg line 
shows solubility of atRA reported in the literature.
7
 
 
3.2.4.2 Ibu 
 
The same methodology exploited in atRA studies was used to determine the Ibu 
saturation concentration in SiO but phosphate buffered saline (PBS) was used as the 
solvent for UV-Vis spectroscopy analysis; Ibu saturation concentration in SiO was 
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determined to be 220 µg/mL (1.07 x 10-3 M) via this methodology.  While the 
concentration of atRA solubilised in SiO was not high enough to allow us to perform 
an NMR analysis directly on the oil sample, in order to confirm the number 
determined by UV-Vis, this was possible with Ibu. 0.2 mL of the saturated oil (after 
filtration) was solubilised in 0.7 mL CDCl3 containing 2 mg/mL anisole as an 
internal reference, allowing for the quantification of Ibu. The 1H NMR analysis 
showed that although UV-Vis and 1H NMR measurement of the extracted product 
gave similar values, the amount recovered by this technique was only 57 % of Ibu 
solubilised (~1 mg/mL, n = 3).  The solubility of Ibu in SiO was then determined by 
1H NMR of the SiO after filtration to be 2.05 mg/mL (9.94 x 10-2 M, n = 2), which 
was a much higher concentration than that determined by the UV-Vis method 
adapted from the literature.  Extraction of Ibu from SiO with acetone may, therefore, 
not be as effective as for atRA.    
 
Overall, the saturation concentration of both atRA and Ibu were determined to be 
28.5 µg/mL and 1.81 mg/mL respectively. Although the methodology in the 
literature led to an incomplete extraction of Ibu from SiO (57 %), atRA extraction 
was determined to be successful with a 93 % extraction.  This is possibly due to 
acetone acting as a better solvent for atRA than Ibu.   
 
3.2.4.3 PEO Prodrugs  
 
Saturated solutions of all the prodrugs synthesised in SiO were prepared, following 
the same methodology as for free drug (see experimental, Section 6.5.4).  Rather than 
extracting SiO and using UV-Vis to determine the amount of prodrug solubilised, the 
solutions were analysed by 1H NMR spectroscopy.  Anisole was used as an internal 
reference, and the prodrug saturation concentrations were determined using the 
resonance at 3.1 ppm assigned to the PEO chain; no drug peaks were visible because 
of the low concentration solubilised.   
 
The solubility profile of the prodrugs can be seen below in Figure 3.5.  There is a 
definite trend for both the mono- and di- substituted PEO prodrugs; as the PEO chain 
length increases, the solubility in SiO decreases.  There is also an increase in the 
amount of prodrug solubilised when PEO is di-substituted compared with Me-PEO 
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prodrugs. In all cases, the maximum solubility in SiO for both mono and di-
substituted materials was seen with the shortest chain length PEO (n = 14).     
 
Figure 3.5 Solubility of drug attached to PEO prodrugs , in SiO. atRA (x) and Ibu (●).  Measured 
value of free atRA in SiO (red line).   
 
The solubility of the different atRA prodrugs in SiO (i.e. either PEO-atRA or Me-
PEO-atRA), decreased with increased PEO chain length.  This led to the maximum 
concentration of atRA that was solubilised when attached to the pro-moiety being 
lower than the saturation concentration of the free drug in SiO, apart from for the two 
smaller di-substituted PEO prodrugs.  Therefore, these were no longer considered to 
be a good candidate to achieve prolonged drug delivery to treat PVR. The level of 
Ibu attached to the hydrophilic pro-moieties solubilised in SiO, particularly the di-
substituted low Mn PEO, was considered to be high enough to investigate the release 
from SiO.   
 
3.2.5 Release of Prodrugs from SiO into Culture Media 
 
The release of free Ibu as a control, along with Me-PEO16-Ibu and di-substituted 
PEO14, from SiO into culture media was investigated.  
1H NMR spectroscopy of Ibu 
remaining in the oil could be analysed to determine the concentration as 
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distinguishable peaks were visible within the spectra.  The release of Ibu, PEO-Ibu 
mono- and di-substituted from SiO was investigated with culture media being 
replenished daily or left stationary over 4 days. Figure 3.6 shows the cumulative 
percentage which was released under these conditions, however, it was not 
determined whether the Ibu was still attached to the pro-moiety or not; a percentage 
was used to allow Ibu and pro-drug comparison with ease as saturated solubility is 
much higher.  Figure 3.6A shows the release when the media is replenished daily; 
overall the release rate follows the trend Ibu>Me-PEO14-Ibu>PEO16-Ibu, however, 
more of the di-substituted prodrug is released initially than the mono-substituted 
prodrug but the amount is always lower than free Ibu.  Over the 4 day experiment, 93 
% of Ibu was released from the SiO compared to 73 % and 61 % of the mono- and 
di-substituted prodrugs respectively.  When the media is not changed over the 4 day 
experiment, the same trend is observed, again with a faster release of the di-
substituted initially than the mono-substituted prodrug, however, the overall 
difference of amounts released is much smaller.  The same 93 % of Ibu is released 
but this time more of the prodrugs are released than seen previously; 86 % and 78 % 
for the mono- and di-substituted respectively.   
 
Overall, the use of PEO prodrugs does slow down the release of Ibu from SiO into 
culture media with the di-substituted version being the most effective in prolonging 
release.  However, the majority of drug/prodrug is released after only 4 days, which 
does not meet the 4-6 week treatment period criteria aimed for.  
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Figure 3.6 Release of free Ibu (●), Me-PEO16-Ibu (▲) and PEO14-Ibu (■) from SiO into A: 
replenished media and B: unchanged culture media. 
 
3.3 PDMS PRODRUGS 
 
As the solubility of PEO prodrugs resulted in a much lower saturation concentration 
drug equivalent in SiO than free drug, the use of a hydrophobic pro-moiety was 
investigated.  End-functionalised poly(dimethylsiloxane) (PDMS) appears to be the 
ideal candidate as it is almost identical to the SiO tamponade.  This reduces solubility 
issues and also contributes to lowering the effect of side products, as the pro-moiety 
left after the cleavage would be chemically very similar to the surrounding SiO.   
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3.3.1 Synthesis – Steglich Esterification 
 
The PDMS-prodrugs were synthesised via the Steglich esterification method.  The 
commercially available bis(hydroxyalkyl) terminated poly(dimethylsiloxane) 
(PDMS-diOH, Figure 3.7) was reacted with both atRA and Ibu individually, at 
ambient temperature in dichloromethane (DCM).  These conditions had been 
investigated with respect to the degradation of atRA (see Chapter 2, Section 2.3) and 
found to be acceptable.  The working concentrations of reactants were based on the 
maximum solubility of atRA in DCM determined previously (i.e. 12 mg/mL, see 
Experimental 6.5.6.1 and 6.5.6.2).   
 
Figure 3.7 Poly(dimethylsiloxane), bis(hydroxyalkyl) terminated (4,700 gmol
-1
). 
 
The formation of prodrug was monitored by 1H NMR spectroscopy (see Figure 3.8) 
with the formation of the ester bond characterised by the appearance of a peak at 
4.31 ppm (labelled 2’), as well as a chemical shift of all the signals of the protons 
close to both the acid function of the drug (e.g. 11, 12, 13 and 14) and the hydroxyl 
function of PDMS-diOH (e.g. 3).  The chemical shifts after the reaction are 
highlighted by red arrows in Figure 3.8. In this particular case, the conversion 
reached 72 % after 4 days, therefore, the PDMS-atRA obtained contains 72 % of 
atRA as chain-ends. The remaining 28 % of available chain-ends remained as 
hydroxyl groups as seen by the residual signals labeled 2 and 3 in Figure 3.8.   
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Figure 3.8 
1
H NMR spectra (CDCl3, 400 MHz) of starting PDMS-diOH (blue) and atRA (black) along 
with PDMS-atRA (green) after purification.   
 
This classic esterification reaction usually requires no longer than 24 hours to 
achieve completion, as seen for the PEO-Ibu prodrug syntheses, but this depends on 
the nature of the acid and alcohol involved in the reaction.  For atRA the reaction 
was much slower, reaching only 40 % conversion after 2 days, and usually less than 
70 % after 4 days (n = 4). The conjugation throughout atRA stabilises the acid 
function by making the carbonyl function less available to react, as was observed via 
computational modelling of the Me-PEO-atRA prodrug.  Leaving the reaction for 
more than 4 days did not lead to higher conversions, therefore, all reactions were 
stopped at 4 days to limit degradation of atRA. Complete conversion was reached 
after 1 day in the case of PDMS-Ibu, further confirming that the limiting factor 
during the esterification between atRA and PDMS-diOH was the nature of the acid.   
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The final products were purified by repeated washes in methanol (MeOH), allowing 
for the removal of unreacted atRA or Ibu.  This purification process involves the loss 
of some of the shorter PDMS chains within the molecular weight distribution, 
therefore, leading to a higher average Mn within the final products than the initial 
starting material. PDMS prodrugs were fully characterised by 1H and 13C NMR 
spectroscopy (see Appendix Figure A42), as well as FT-IR spectroscopy which 
confirmed the formation of an ester bond, with the appearance of a characteristic 
ester signal at 1,714 cm-1. 
 
Figure 3.9 FTIR analysis of A: PDMS-diOH and B: PDMS-atRA after purification. 
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Table 3.2 summarises the characteristics of the different PDMS prodrugs prepared 
and used throughout the project. 
Table 3.2 Characteristics of the PDMS prodrugs synthesised and used throughout the project. 
 
 
3.3.1.1 Synthesis of PDMS-atRA - Anhydride Method 
 
Due to the Steglich esterification reaching only 40 % conversion after 2 days, and 
less than 70 % after 4 days for the synthesis of PDMS-atRA, an alternative route was 
investigated.  This involved the use of a two-step mechanism in which the first step 
consists of the synthesis of the atRA anhydride through a self-condensation reaction.  
The acid was mixed with 0.55 equivalents of the dehydrating agent DCC in DCM for 
2 days. The reaction was followed using both 1H and 13C NMR spectroscopy; 
however, 13C NMR analyses were more useful to monitor the reaction as there was a 
shift of the peak assigned to the carbonyl environment, which resonates at 173 ppm 
in the acid form and 163 ppm as the anhydride (see appendix Figure A43).  After 2 
days, 13C NMR confirmed the loss of the acid resonance and the crude product was 
filtered to remove the DCU by-product, prior to solvent removal in vacuo.  Yellow 
crystals were obtained with a 67 % yield and the solid was used immediately for the 
synthesis of PDMS-atRA to try and prevent any hydrolysis of the anhydride or atRA.  
The synthesis of PDMS-atRA was carried out by reacting PDMS-diOH in DCM with 
2 equivalents of anhydride-atRA, in the presence of 4 equivalents of pyridine and 0.2 
equivalents of DMAP per hydroxyl group, at ambient temperature in the dark for 4 
days.  The excess anhydride was quenched with water for 3 hours and the crude 
product diluted with DCM and extracted with 1 M NaHSO4 followed by 1 M 
NaHCO3 and brine to remove the DMAP and pyridine.   Precipitation in MeOH to 
remove the excess acid yielded a yellow oil with 65 % yield.  As this was similar to 
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the yields obtained with the steglich esterification method, all further reactions were 
carried out under the DCC/DMAP one-pot/one-step conditions described previously.  
 
3.3.2 Biological Evaluation of PDMS Prodrugs 
 
The metabolic activity and morphology of ARPE-19 cells was studied for pre-
confluent cells (1 day growth) which were exposed to SiO1000 and blends of PDMS-
atRA and PDMS-Ibu with SiO1000 at 10 % (v/v) for 1 day.  A resazurin assay was 
subsequently carried out, followed by phalloidin staining of the cells from the assay 
(see experimental Section 6.4.2). 
   
The resazurin assay contained positive (healthy cells) and negative controls (cells 
exposed to 20 % DMSO) as well as media with no resazurin present to determine 
background signals. As seen in Figure 3.10, these controls confirmed the validity of 
the assay, as there was a significant difference between the negative control and both 
the positive control and media without resazurin. However, no significant difference 
was observed between the positive control and cells exposed to SiO1000, PDMS-atRA 
and PDMS-Ibu blends at 10 % v/v in SiO1000, indicating that the oil and blends have 
no cytotoxic effect on the ARPE-19 cells.  
 
Figure 3.10 Resazurin assay with appropriate controls to determine the cytotoxicity of SiO1000 and 
blends of PDMS-atRA and PDMS-Ibu with SiO1000 at 10 % (v/v).  Pre-confluent ARPE-19 cells 
(grown for 1 d) were exposed to the oils for 1 d. (mean, error bars represent ± 1 standard deviation); 
n=3. *, Significance by ANOVA and Dunnett’s T3 post-hoc evaluation (p<0.05). 
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Phalloidin staining confirmed no cytotoxic effects with images of healthy 
cytoskeletons when cells were exposed to the oil and blends. Images of phalloidin 
stained cells exposed to SiO1000 and the 10 % blends, are presented in Figure 3.11, 
alongside negative control (healthy cells).  All four images represent healthy 
cytoskeletons.   
 
Figure 3.11 Fluorescent phalloidin (green) marking F-actin in ARPE-19 cells and DAPI (blue) stains 
the nuclei.  Negative control (A), cells exposed to SiO1000 (B), blends of PDMS-atRA (C) and PDMS-
Ibu (D) with SiO1000 at 10 % (v/v).  Scale bars represent 50 µm. 
 
3.3.3 Cleavage of Ester Bond 
 
Similarly to the PEO prodrugs, the cleavage of the ester bond was investigated under 
conditions that do not fully represent conditions in vivo and as a proof-of-concept 
study. 
 
PDMS is known to be sensitive to decomposition under strong acidic or basic 
conditions; however, these conditions were shown to cleave the ester bonds within 
PEO-prodrug systems previously and were investigated. PDMS is immiscible with 
water, but water is required when an acid or base is to be used, therefore, a good 
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solvent of PDMS that is miscible with water was required. While both acetone and 
THF are good solvents for PDMS, upon the addition of water, THF was the only 
solvent able to solubilise PDMS, providing that the ratio of water in THF did not 
exceed 8 % (v/v). Quantities of NaOH, KOH and HCl had to be adapted and 
solutions prepared in that respect. See Section 6.5.3 for an example of a typical 
experiment.  
 
3.3.3.1 Cleavage of PDMS-atRA 
 
To cleave atRA from PDMS, mild basic conditions were attempted using 2-5 
equivalents of base per ester function. DMAP was also evaluated, with or without 
water, with no difference being observed. Acidic conditions were also studied, using 
5-10 equivalents per ester function.  Table 3.3 provides a summary of the various 
conditions studied to cleave the atRA from the PDMS chains and the effects on 
PDMS and atRA under these conditions. 
Table 3.3 Conditions used to attempt the cleavage of the PDMS-atRA in vitro and their effects on 
PDMS and atRA. X = no cleavage or degrades PDMS/atRA.   = PDMS/atRA stable. 
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The use of both NaOH and KOH, even at low concentrations, led to the clear 
decomposition of the PDMS chains. While 1H NMR analyses displayed no change of 
the ester peak or atRA signals, the integration of the PDMS main chain signal 
diminished by a factor of 3-4 (integrations decreased from 507 to 165 protons when 
Si-CH2-CH2, labelled 6, was taken as a reference for integration) as illustrated in 
Figure 3.12.   
 
Figure 3.12 
1
H NMR spectra (CDCl3, 400 MHz) of PDMS-atRA before and after exposure to KOH in 
THF at 40 °C for 22 h. 
 
Gel permeation chromatography (GPC) was also used to characterise the prodrugs 
before and after exposure to NaOH and KOH.  The traces obtained (Figure 3.13) 
confirmed the decomposition of the main polymer chain.  
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Figure 3.13 GPC RI chromatogram overlays of PDMS-atRA (black) before and after exposure to 
KOH (2 and 5 equivalents) and NaOH (2 and 5 equivalents) in THF at 40 °C for 22 h.  
 
The use of DMAP as a base did not affect the PDMS chain and the atRA seemed to 
degrade partially under these conditions, but the ester linkage remained unchanged. 
Conducting the experiments with water or without water led to identical results.   
 
The use of acidic conditions (5-10 equivalents of HCl) in either THF or dioxane at 40 
°C led to comparable results. No decomposition of the PDMS chain was observed, 
the ester function remained unchanged, and no clear degradation of atRA was 
observed, as there was no change in the appearance of the 1H NMR spectra; 
however, there was a decrease of the signal intensities (see Appendix Figure A44 and 
A45). When the temperature of a cleavage study in dioxane was increased from 40 to 
60 °C, severe degradation of atRA was seen, shown by the complete disappearance 
of the signals in 1H NMR spectrum (see Appendix Figure A46); while the ester 
function remained unchanged and was still visible on the spectrum. In order to check 
that dioxane itself was not involved in side reactions due to the presence of peroxide, 
an inhibitor (methoxyphenol at 100 ppm) was added to the solvent. The reaction was 
repeated with 5 equivalents of HCl at 60 °C and samples were taken at 3, 6 and 9 
hours (9 hour time-point stated on Table 3.3), purified and analyzed by 1H NMR 
spectroscopy. The same results were obtained, with the degradation of atRA and the 
ester function remaining unchanged concluding it was not the solvent that led to 
degradation. Overall, conditions required for the cleavage of atRA from PDMS-atRA 
were not found and degradation of atRA was observed.   
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3.3.3.2 Cleavage of PDMS-Ibu 
 
As previously discussed, Ibu is not as susceptible to degradation as atRA, therefore, 
it was possible to further investigate the prodrug cleavage using stronger/harsher 
conditions in the particular case of PDMS-Ibu to determine whether cleavage of the 
drug from the PDMS pro-moiety was possible. Acidic conditions were used in either 
THF or dioxane, at various temperatures using concentrated HCl up to 40 equivalents 
per ester function. Table 3.4 summarises all conditions studied to cleave Ibu from the 
PDMS chain-ends. 
Table 3.4 Conditions used to attempt the cleavage of the PDMS-Ibu in vitro and their effects on the 
ester functionality, PDMS and Ibu. 
 
All three experiments led to no change of the chemical structure of the PDMS-Ibu; 
no cleavage of the ester function and no degradation of Ibu or the PDMS chain were 
observed.  Due to cleavage of ester functions being well established, and because the 
cleavage of the hydrophilic PEO prodrugs was successful, it was suspected that the 
hydrophilicity/hydrophobicity of the PDMS prodrugs with the cleavage conditions 
was the reason for this.  As PDMS is highly hydrophobic, the polymer chain is most 
probably in a collapsed configuration in the presence of water, even at ratios as low 
as 8 vol%. Due to the parent drug being attached at the chain ends, they are most 
likely to be inaccessible for reaction as illustrated in Figure 3.14. 
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Figure 3.14 Probable configuration of the PDMS-drug polymer chains in the presence of water. 
 
3.3.3.3 PDMS Prodrug with PEO Spacer 
 
Carl et al. introduced the concept of a tripartite prodrug design with a spacer in 
between the parent drug and pro-moiety to overcome stability issues of hydrolysis of 
the prodrug bond.8  As the cleavage of the drug from the polymer chain was 
successful using a hydrophilic polymer chain (PEO), the addition of a hydrophilic 
spacer between the PDMS chain and the drug molecule was considered. In this 
section, solely Ibu was used as the parent drug in order to prevent any possible 
interference arising from potential atRA degradation when harsh conditions were to 
be used for cleavage experiments. 
 
3.3.3.3.1 Synthesis of PDMS-PEO Prodrug 
 
PDMS-PEO-Ibu was synthesised following a 3-step procedure as shown in Scheme 
3.6. 
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Scheme 3.6 Preparation of PDMS-PEO-Ibu following a 3 step procedure.  
 
The first step involved the preparation of PDMS functionalized with acid groups 
(COOH), in order to react further with PEO via esterification. The reaction between 
the commercial bis(3-aminopropyl)-terminated poly(dimethylsiloxane)  (H2N-
PDMS-NH2, 3,000 gmol
-1) and succinic anhydride gives the expected HOOC-
PDMS-COOH with 100 % conversion in just a few hours (see Figure 3.15). The 
product can be used straight away, without any purification, in the next step which 
consists of an esterification with PEO (600 gmol-1, n = 14). The use of a large excess 
of PEO (approximately 20 equivalents per acid function) is combined with a very 
slow addition of acid onto the excess alcohol, allowing for the preparation of 
HO-PEO-PDMS-PEO-OH as the main product (see Figure 3.15). As both polymers 
(PDMS and PEO) are bi-functional, the excess PEO is necessary to prevent further 
reactions with any free HOOC-PDMS-COOH that would remain.  The purification 
of the obtained polymer, which is essential for further reactions with Ibu in a new 
esterification reaction, is the most challenging part of the synthesis. Finding a good 
protocol to eliminate the entire remaining unreacted PEO without losing too much 
product is very difficult as the different polymer chains are in the range of “low 
molecular weight” polymers, therefore, even purification based on solubility 
differences leads to the loss of an important amount of the final product (see 
experimental, Section 6.5.8).  HO-PEG-PDMS-PEG-OH was successfully 
synthesised and purified as highlighted by 1H NMR and the appearance of a new 
ester signal at 4.12 ppm attributed to COO-CH2-CH2-O (assigned 10 in Figure 3.15).  
The last step, the esterification with Ibu, was successful and led to the expected Ibu-
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PEG-PDMS-PEG-Ibu, confirmed by 1H NMR analyses (Figure 3.15).  The 1H NMR 
spectra display the appearance of a new ester signal at 4.15 ppm attributed to 
OCOCH(CH3) (14). 
 
Figure 3.15 
1
H NMR spectra (CDCl3, 400 MHz) of PDMS-PEO-Ibu at different steps of the synthesis: 
PDMS-COOH (green), PDMS-PEO (red) then PDMS-PEO-Ibu (black), along with Ibuprofen (purple) 
and PDMS-Ibu (blue) as a comparison. 
 
3.3.3.3.2 Cleavage of PDMS-PEO Prodrug 
 
PDMS-PEO-Ibu was treated with HCl (15 eq.) in dioxane at 85 °C. 1H NMR 
analyses of the crude product after 16 hours reaction (see Figure 3.16), displays the 
disappearance of both ester signals (10) and (14), as well as (9) and (8) which 
confirms the complete cleavage of the polymer chain between PDMS and PEO and 
between PEO and Ibu. A purification step (washing with aqueous solution to 
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neutrality) allowed for the recovery of isolated PDMS and Ibu without any trace of 
PEO, as shown in Figure 3.16. The overlay of PDMS-PEO-Ibu, and both starting 
PDMS-NH2 and Ibu spectra, clearly shows that the organic layer obtained after 
purification only contains free Ibu and PDMS-NH2. 
 
Figure 3.16 
1
H NMR spectra (CDCl3, 400 MHz) of PDMS-Ibu before (black) and after (red) exposure 
to 15 equivalents of HCl in dioxane at 85 °C for 16 h, as well as starting materials Ibuprofen (purple) 
and PDMS-NH2 (green). 
 
To summarise, the cleavage of the drug from the PDMS polymer chain was achieved 
in vitro, using strong acidic conditions, providing that a hydrophilic spacer was 
present between PDMS and the drug. The added PEO spacer appears to balance the 
hydrophobicity of the polymer chain and, therefore, allow access to the chain-ends in 
the presence of water. 
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3.4 PDMS-DRUG AND SIO BLENDS 
 
Due to the solubility of PDMS-atRA and PDMS-Ibu in SiO, the potential for these 
materials to act as “additives”, and modify the release and solubilisation behavior of 
SiO, was studied with free drug. 
 
As shown in Figure 3.17, when only free drug is present in SiO, release appears to be 
driven solely by diffusion through the oil, and has been reported to occur in an 
uncontrolled manner within a week in vivo.7  When using the newly synthesised 
PDMS-drug as a prodrug, the release of drug should be controlled by a combination 
of diffusion and the cleavage of the bond between the PDMS and the drug molecule. 
The latter is quite unpredictable in vivo, as the factors for cleavage are not identified, 
thereby leading to little control of the release. On the other hand, by mixing free drug 
in a blend of SiO and PDMS-drug, the release of drug may be modified as diffusion 
of the free drug and cleavage of the drug from the PDMS chain may be affected by 
the presence of the modified PDMS. Moreover, the presence of PDMS-drug may 
provide a positive effect on the solubility of the free drug and allow higher 
concentrations to be achieved in SiO. Both atRA and Ibu solubility in blends, 
containing different ratios of PDMS-drug, was investigated in addition to their 
release pattern from blends into culture media. 
 
Figure 3.17 Different possible routes of drug release from SiO tamponade. 
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The measurement of atRA by UV-Vis spectroscopy presents important limitations 
such as low accuracy of the extraction method and the inability to measure release 
into culture media directly as there is an overlap of absorption peaks of atRA and an 
essential media component, foetal calf serum (see Appendix Figure A47).  It is also 
not possible to measure solubility of atRA in SiO by 1H NMR spectroscopy of the oil 
directly, as achievable concentrations are too low.  As measuring atRA is essential to 
the project and analyses by traditional routes were not sufficient, the use of tritiated 
(3H) atRA was investigated.  Analysing the release of Ibu via 1H NMR of the oil 
directly also has its limitations when measuring small concentrations, and UV-Vis 
spectra of Ibu is distorted in media to the extent that no calibration curve could be 
obtained, therefore, the use of tritiated Ibu was also investigated.  The main 
advantages of using a radioactive isotope is the ease of detection, even at extremely 
small amounts, as well as the relatively simple protocol compared to other analyses; 
by selecting the 3H containing drug, the chemistry of the compound is essentially 
unchanged and the measured behaviour can be related to expected free drug 
behaviour in vivo. 
 
3.4.1 Introduction and use of Radioactive Isotopes 
 
Isotopes of an element have the same number of protons in the nucleus but a 
different number of neutrons, therefore, the same atomic number but a different mass 
number. Isotopes can either be stable or radioactive (radioisotopes) and unstable due 
to an imbalance of protons and neutrons which emit particles/energy to improve 
stability.  In 1889, Ernest Rutherford recognised that radioisotopes undergo nuclear 
decay/disintegration which involves the release of energy via emission of ionising 
radiation.9  Rutherford named two modes of radioactive decay based on their 
penetrating power (see Table 3.5): heavier alpha and lighter beta radiations.  A third 
type of radiation was discovered by Villard in 1900 and is called gamma rays,10 later 
recognised as electromagnetic radiation.  Table 3.5 shows some of the properties of 
these types of radiation. 
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Table 3.5 Types of radioactivity and their properties.  Adapted from ref:
11 
 
During nuclear decay of a radioisotope, more than one type of radiation may be 
emitted.  Alpha decay is a form of spontaneous fission, a reaction where a nucleus 
lowers its mass and atomic number by splitting and the emission of a large alpha 
particle (2 protons and 2 neutrons), equivalent to a helium nucleus. As such, alpha 
particles are relatively large, are likely to collide with surrounding atoms, do not 
travel far and do not require much shielding (see Table 3.5).   
 
Beta decay involves the transmutation of a neutron, which can occur via three routes 
represented in Figure 3.18. 
 
Figure 3.18 Illustrated representation of the different types of beta decay A: negatron emission, B: 
Positron emission and C: electron capture. 
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A. Negatron emission: Emits a negatively charged beta particle in the form of an 
electron. Negatron emission occurs in nuclei that contain more neutrons than 
stable isotopes of the same element. These "proton deficient" nuclides can be 
identified by their mass number being significantly higher than their atomic 
number, such as 3H and 14C. To regain some stability, the nucleus can 
transform one of its extra neutrons into a proton leading to the emission of an 
electron (negative beta particle) and an antineutrino (ν).  
B. Positron emission: Emits a positively charged beta particle in the form of a 
positron (the antiparticle of an electron, which has the same mass as an 
electron but with the opposite charge). Positron emission occurs in proton 
rich nuclei (nuclei which contain more protons than neutrons); nuclear decay 
takes place in order to restore balance by transforming a proton into a 
neutron.  This leads to the emission of a positron and a neutrino, which can be 
identified by the atonic number decreasing by 1 while the mass number 
remains constant. Positron emission may develop into gamma rays if the 
positron is annihilated by collision with an electron.  
C. Electron capture: Emits only a neutrino.  Electron capture occurs most often 
in the heavier neutron-deficient elements such as 231U.   A neutrino is emitted 
when an  orbital electron is captured by a proton in the nucleus and 
transformed into a neutron  
 
Gamma radiation is electromagnetic radiation and not particulate like alpha and beta 
emission, however, it is always sub-sequential to initial alpha or beta decay.  Gamma 
radiation involves the discharge of a high-energy photon from an over-excited 
nucleus, therefore, it does not change the identity of the atom from which it 
originates. As the gamma rays are not particulate they have only a small chance of 
colliding with surrounding atoms and, therefore, have a long range through air (see 
Table 3.5).  
 
Tritium Labelling 
 
Radioisotopes can be used to study the properties, behaviour and reactions of non-
radiolabelled compounds and throughout this project tritiated atRA and Ibu supplied 
by ARC were used (see Appendix Figure A50).  The tritium isotope was first 
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produced in 1934 by Rutherford and co-workers12 from deuterium and has the same 
properties as hydrogen with respect to charge and electrostatic repulsion with other 
atomic nuclei.  The only difference between tritium and hydrogen is that the nuclei 
contains an extra neutron and, therefore, undergoes beta decay to become stable. 
Tritium emits negative beta particles by negatron emission, and was chosen as it has 
a long half-life (12.43 years) and decay during experimental time periods would not 
need to be accounted for. Also tritium is a relatively safe beta emitter as it produces a 
maximum energy of 0.0186 MeV which only penetrates 4 mm of air and is incapable 
of passing through the dead outermost layer of skin (0.05 mm).  Due to this weak 
signal it can only be detected via liquid scintillation counting (see Section 6.17).     
  
3.4.2 Drug Solubility Measurement in SiO and Blends Utilising Radioisotopes 
 
The process of using radiolabelled drugs to determine solubility concentration within 
SiO is a much simpler protocol than that used when UV-Vis was utilised as there is 
no longer the need for the extraction step, see Figure 3.19. 
 
Figure 3.19 Process of determining solubility of drug in SiO when utilising radiolabelled drugs. 
 
3.4.2.1 atRA Solubility Studies 
 
The saturation concentration of free atRA in SiO was investigated using the tritiated 
atRA.  A saturated solution of atRA, spiked with tritiated atRA, in SiO was prepared 
and stirred gently.  Samples were taken at different time-points then filtered using a 
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syringe pump (4 mL/h) and 0.45 µm PTFE filters. To determine the amount of atRA 
dissolved in SiO, a 20 µL sample of oil was taken, which was insoluble in the 
scintillation cocktail, therefore, a co-solvent was needed to fully solvate the material 
for accurate analysis.  After several tests using a known activity of sample, it was 
determined that a ratio of diethyl ether/scintillation cocktail (8:10 mL) allowed 
accurate activity measurement by liquid scintillation.  
 
While the solubility reported for atRA in SiO in the literature is 20 µg/mL, higher 
concentrations, in the order of 28 µg/mL (9.5 x 10-5 M, s.d.= 1, n = 6). were 
measured when the same protocol was used.7 Using the tritiated atRA, the solubility 
measured was over 20 times higher than the previous values, reaching 450.6 µg/mL 
(1.5 x 10-3 M, s.d. = 39.9, n = 4).   
 
The solubility of atRA in SiO5000 was also investigated as a simpler protocol was 
now in place to deal with such a viscous substance. Saturation was determined to be 
higher than in SiO1000 at 610 µg/mL (2.03 x 10
-3 M, n=1) in SiO5000. 
 
Figure 3.20 Comparison of saturation concentration of atRA measured in SiO via UV-vis or 
radioactivity measurements. Literature value taken from Araiz et al.
7
  Error bars ±1 standard 
deviation. 
 
The use of radiolabelled isotopes has provided a much more accurate method to 
measure small drug concentration in SiO compared to the classic extraction 
combined with traditional instrumentation e.g. UV-Vis spectroscopy.  However, such 
a large difference between methods was not anticipated. When the literature value 
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was further analysed, it was noticed that the calibration curve used was in the range 
0.5 x 10-4 M to 1 x 10-6 M, with the reported 20 µg/mL (0.6 x 10-4 M) being on the 
cusp of the maximum value; therefore, higher concentrations need extrapolation from 
the curve, leading to potential errors.  Overall an accurate method to measure 
solubility of atRA in SiO has been established using radiolabelling techniques and a 
fundamental inaccuracy in the published literature has been identified.  
 
3.4.2.2 atRA in SiO Blends 
 
The same protocol used to determine accurate atRA solubility in SiO was employed 
to determine free atRA concentration in blends of PDMS-atRA in SiO at 1, 5 and 
10 % (v/v). As the amount of PDMS-atRA present in the blend increased so did the 
measured saturation concentration of atRA (see Table 3.6).  An increase from 
450.6 µg/mL to 812.7 µg/mL was observed when a blend of 10 % PDMS-atRA in 
SiO blend was used. This indicated the blends have a positive effect on the solubility 
of the free drug, increasing its saturation concentration in the oil possibly due to the 
presence of attached drug and its affinity towards free drug. 
Table 3.6 Saturation amounts of atRA (µg/mL) in SiO and SiO blended with PDMS-atRA at 1, 5 and 
10 % (v/v) for 2 weeks at ambient temperature, in air. 
 
 
The shear viscosity of SiO1000 and SiO5000, as well as the blends with end-modified 
PDMS, were measured at 37 °C (the temperature of cell culture within the project) 
and calculated from the gradient of the plot of shear stress against shear rate; graphs 
are shown below in Figure 3.21. 
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Figure 3.21 Graph of shear stress against shear rate for SiO5000 (●), SiO1000 (■), SiO1000 saturated with 
atRA ( ), SiO1000 blends with 1 (▲), 5(x) and 10 (▼)  % (v/v) PDMS-atRA from which the shear 
viscosity was calculated.  
 
The measured viscosities show that there is a negligible effect of saturating SiO1000 
with atRA, and the viscosity of the blends do not follow a trend of decreasing or 
increasing viscosity, therefore, it is not characteristic variation in viscosity that is 
affecting the observed saturation concentration change within the blends, Table 3.7. 
Table 3.7 Shear viscosities (mPa/s) calculated from the gradient of the plot of shear stress against 
shear rate at 37 °C.  
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3.4.2.3 Ibu Solubility Studies 
 
The same radiolabelling methodology was used to determine Ibu saturation in SiO, 
using tritiated Ibu, over 7 days and at ambient temperature. Ibu saturation in SiO was 
found to be 0.22 mg/mL via UV-Vis spectroscopy, and 1H NMR spectroscopy 
determined the saturation concentration to be 2.05 mg/mL (9.94.10-2 M, n = 2). When 
tritiated Ibu was used, a similar value was obtained via liquid scintillation counting 
(2.26 mg/mL). 
 
Figure 3.22 Comparison of saturation concentration of Ibu measured in SiO1000 via radioactivity and 
1
H NMR analyses.  Error bars ± 1 standard deviation. 
 
3.4.2.4 Ibu in SiO Blends 
 
The radiolabelling protocol used to determine Ibu solubility in SiO was used to 
determine Ibu concentration in blends of PDMS-Ibu in SiO at 1, 5 and 10 % (v/v).  
Unlike atRA, the amount of PDMS-Ibu present in the blend did not have any 
significant effect on the solubility of Ibu, see Table 3.8. 
Table 3.8 Saturation concentration of Ibu (mg/mL) in SiO and SiO blended with PDMS-Ibu at 1, 5 
and 10 % (v/v). 
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Although the solubility of Ibu had not increased when using the blends, the 
concentration solubilised was still high. Therefore, it was still important to 
investigate the blends further, as well as exploring the release of Ibu from SiO and 
see if release was affected in any way. 
 
3.4.3 Release of drug from SiO and Blends 
 
The effect of the presence of PDMS-drug on the release pattern of free drug was 
investigated within the Ibu and atRA systems, with the potential that the affinity of 
the blend to the drug would result in a slower release compared to the short time 
periods stated in the literature; that is  98 % clearance of atRA administered to the 
eye via a SiO tamponade, within a 7 day time period.7 This time period also needed 
to be confirmed, as the literature had already proven to be inaccurate in measuring 
atRA solubility in SiO and subsequent measurements could also be affected by 
inaccuracies. The optimum time period for release, targeted by this research, is 6 
weeks as this is the clinical treatment period for PVR.  Appropriate conditions of 
temperature, CO2 content, and presence/absence of cells for these experiments were 
investigated. 
 
3.4.3.1 Experimental Design for Drug Release Studies 
 
The release of atRA and Ibu from SiO1000 and SiO1000 blends with PDMS-drug (using 
solutions containing various initial concentrations) into culture media was monitored 
using tritiated versions of the drugs as prepared in Section 3.4.2.1.  The experiments 
were designed as follows: 1 mL of oil or blend containing free drug was placed over 
0.5 mL of culture media in a 24 well plate. The culture media was exchanged with 
fresh culture media when samples were taken (see Figure 3.23), and the amount of 
drug in the media determined directly via liquid scintillation counting. 
 
Figure 3. 23 Illustration of how media samples were taken throughout drug release studies. 
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3.4.3.1.1 Quenching Effect of Culture Media in Liquid Scintillation 
 
It is known that highly coloured samples can interfere with the scintillation counting 
process via quenching. The colour of the sample interferes with the light signals 
produced by the scintillant, therefore, leading to discrepancies in the data collected. 
To rule out potential inaccuracies, the effect of 250 µL of culture media within the 
scintillant cocktail (10 mL) was tested and showed no significant effect on the counts 
due to the solution being very dilute (see Table 3.9).  For each 0.5 mL culture media 
sample collected throughout the experiments, 250 µL was analysed, and the total 
amount of drug released deduced from that. 
Table 3.9 Decays per minute (DPM) of tritiated atRA solutions of both high and low concentration 
with and without media present. 
 
 
3.4.3.1.2 Effect of Temperature on SiO 
 
The shear viscosities of SiO1000 were measured at 20, 30 and 37 °C (the approximate 
temperature of the eye) to determine if temperature would alter the rheological 
properties of the oil. The shear viscosities were calculated from the gradient of the 
plot of shear stress against shear rate.  As a difference was observed (see Table 3.10), 
all release experiments were carried out at 37 °C as this is the temperature used to 
culture cells as well as a similar temperature observed in the eye. 
Table 3.10 Shear viscosities (mPa/s) of SiO1000 calculated from the gradient of the plot of shear stress 
against shear rate at 20, 30 and 37 °C. 
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3.4.3.1.3 Effect of CO2 on Release 
 
The effect of atmospheric CO2 content within the experiments on the release rate of 
atRA from SiO and blends into culture media was evaluated. A release experiment 
was carried out at 10 % CO2 (5 % CO2 is used to culture the cells) due to lack of 
availability of incubators that could hold radioisotopes. The same experiment was 
carried out in air, and the different release rates observed were compared.   
 
Figure 3.24 highlights differences in release from experiments conducted in air and 
within the presence of 10 % CO2.  On day 1, more atRA was observed to be released 
when the experiment was carried out in air, however, this difference decreased by 
day 2, and by day 8 the opposite effect was observed with more atRA released under 
a 10 % CO2 atmosphere.  Overall, this experiment showed that the atmospheric 
conditions for accurate release studies need to be kept constant to allow comparison.   
 
As a consequence of the investigations of optimum experimental conditions, all 
following experiments were carried out at 37 °C in a 5 % CO2 atmosphere (the same 
conditions used for ARPE-19 cell culture). 
 
Figure 3.24 Release of atRA at a concentration below 10 µg/mL from SiO (black) and 0.1(red), 1 
(blue), 5 (pink) and 10 % (green) blends (v/v) both in air (filled) and in a 10 % CO2 atmosphere 
(unfilled) into media.  All experiments were carried out at 37 °C. 
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3.4.3.1.4 Effect of the Presence of Cells 
 
A release experiment of atRA in SiO into media in the presence of pre- and post-
confluent cells (cultured for 1 day and 7 days respectively) was performed. This 
aimed to determine if the presence of cells had an impact on the drug release rate, as 
cells could act as a drain for released atRA and potentially affect the balance of 
concentrations. As seen in Figure 3.25 no obvious differences in release rates were 
observed, therefore, future experiments could be carried out in the absence of cells.   
 
Figure 3.25 Release of atRA at various concentrations from SiO1000 into media in the presence of pre- 
and post-confluent cells (filled and unfilled respectively) presented in a log+1 scale.  All experiments 
were carried out at 37 °C in a 5 % CO2 atmosphere. 
 
3.4.3.2 Release Studies of atRA  
 
The release into culture media of atRA from saturated SiO1000 and blends (PDMS-
atRA contents of 1, 5 and 10 % in SiO1000 (v/v)) was studied.  As stated earlier, the 
saturation concentration of atRA increases with increasing amounts of PDMS-atRA, 
therefore, all starting concentrations within the experiments were slightly different as 
saturation conditions were employed.  Figure 3.26 displays the amount of atRA 
released over a 50 day period, presented with a log plot + 1 scale; this scale was 
chosen so release points were easily comparable.  A rapid release of atRA is 
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observed within the first few days, after which the release gradually slows and then 
becomes steady over the remaining 20 days. More atRA appears to be released from 
the blends, probably due to initial saturation concentrations being higher.   
 
Figure 3.26 Release amounts of atRA from saturated SiO1000 (●), 1 (▲), 5 (■) and 10 ( ) % (v/v) 
blends of PDMS-atRA in SiO1000 into culture media presented on a log+1 scale. 
 
When looking at the amount of atRA released from SiO and the blends as a 
cumulative percentage (Table 3.11 and Appendix Figure A48), it is very interesting 
to notice the difference in time taken for 80 % of the solubilised atRA to be released: 
2 weeks for SiO1000 compared to nearly 7 weeks for the 10 % blend.  This is also 
interesting as the literature value of 7 days to clear 98 % atRA from a saturated 
SiO1000 solution has been disputed (although the 7 d time point was taken from a 
rabbit model rather than an in vitro model). 
 
Although promising release time periods were observed, the amounts of atRA being 
initially released was above the toxic range for ARPE-19 cells (10-4-10-5 M). It was 
important to ascertain if the use of blends of SiO with PDMS-atRA could impact the 
release rate for lower concentrations of atRA to avoid the potential of toxicity, and if 
the longevity of the release period was dependant on the amount of atRA initially 
solubilised.    
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Table 3.11 Number of days needed to reach a certain percentage (cumulative) of release of atRA from 
saturated solutions of SiO1000 and 1, 5 and 10 % PDMS-atRA blends Extrapolated values in italics. 
 
 
3.4.3.3 Release Studies Using Non-Saturation Concentrations of atRA Within 
SiO and Blends 
 
In the previous section it was observed that higher initial solubilised concentrations 
of atRA maintained the longest release profiles, however, the ability of the affinity of 
atRA to PDMS-atRA to slow the release rate was not shown conclusively. To 
investigate this further, a series of release experiments where varying but similar 
amounts of atRA were solubilised into SiO and blends with PDMS-atRA was carried 
out.  The cumulative percentage release values are presented in Table 3.12 (graph in 
Appendix Figure A49).  No noticeable release differences were observed between 
the SiO and the SiO/PDMS-atRA blends, apart from when 10 % PDMS-atRA was 
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present within the blend.  The time needed to release 80 % of the atRA solubilised in 
SiO1000 and the 1 and 5 % blends is on average 16 days (2 weeks) whereas for the 10 
% blend, this increases to nearly 51 days (>three times longer, ~7 weeks).  
Table 3.12 Number of days needed to reach a certain percentage (cumulative) of release o f atRA from 
SiO1000 and 1, 5 and 10 % blends containing approximately the same initial amount of atRA, i.e. 50 
µg/mL. Extrapolated values in italics. 
 
 
3.4.3.4 Different Amounts of atRA from SiO and Blends 
 
An underlying problem with the release observed for the desired time range (seven 
weeks) was that the initial burst release took the concentrations above the toxic range 
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for the ARPE-19 cells (10-4 – 10-5 M).  To ensure that the release period were 
definitely independent of the initial amounts of atRA, an experiment utilising varying 
amounts of atRA in SiO1000 (ranging from 13.2 to 412.5 µg/mL) was carried out.  
From this it was determined that the release period was independent of atRA starting 
concentration (see Table 3.13).  
Table 3.13 Number of days needed to reach a certain percentage (cumulative) of release of atRA from 
SiO1000 and 1, 5 and 10 % blends containing approximately various initial concentrations of atRA.  
Extrapolated values in italics. 
 
After determining that the release rates were independent of atRA starting 
concentration in SiO1000, the impact of the presence of PDMS-atRA blends was also 
studied.  When the release from saturated blends was compared with the release from 
a blend with an approximate starting concentration of 50 µg/mL, it appeared that the 
amount of PDMS-atRA present in the blend controlled the release time as shown in 
Table 3.14.  If we compare SiO1000 with a SiO1000 blend with PDMS-atRA 
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(10 vol %), 80 % of the atRA initially present within SiO1000 containing 40 or 
400 µg/mL was released in 10 and 14 days respectively, whereas 80 % of the atRA 
within a SiO1000/PDMS-atRA 10 % blend containing either 45 or 800 µg/mL was 
released in 51 and 48 days respectively.  This suggests that the presence of the blends 
may extend the release period into the 6 week period that is required clinically.         
Table 3.14 Table to show time (days) taken to reach certain percentages of cumulative release of 
atRA from solutions of 1, 5 and 10 % blends of PDMS-atRA in SiO1000 (v/v) with various initial 
concentration of atRA. Extrapolated values in italics. 
 
This is an exciting prospect as the potential to tailor the initial starting concentration 
to avoid the toxicity of the burst release ARPE-19 cells and maintain the sustained 
release amounts above the therapeutic level for an antiproliferative effect may be 
achievable.   
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3.4.3.5 atRA Release from SiO5000:SiO1000 Blends 
 
Whilst some surgeons prefer using SiO1000 as a tamponade agent, some prefer to use 
SiO5000 (see Chapter 1 Section 1.2.3.3.3).  Due to SiO5000 having a higher viscosity, it 
reduces the risk of emulsion formation within the eye after administration. A 
preliminary comparative experiment was carried out in which the release profile of 
atRA from a SiO1000 solution was evaluated against the release from a 50/50 
SiO1000/SiO5000 solution.   To achieve the same starting concentration of atRA in both 
of the oils, a solution of atRA in SiO1000 was prepared, stirred for 2 weeks and 
filtered following the same protocol as described previously. Once filtered, the 
solution was divided into two vials and the appropriate volume of SiO5000 was added 
to one to create a 50/50 blend of SiO1000/SiO5000, while the second one was diluted 
with SiO1000. The resulting oils had an initial concentration of 32 µg/mL of atRA.   
 
Figure 3.27 Release of atRA (starting concentration 32 µg/mL) from SiO1000 (●) and SiO1000/5000 blend 
(■) into culture media presented on a log+1 scale. Experiments were carried out at 37 °C in a 5 % CO2 
atmosphere. 
 
Figure 3.27 shows there is no apparent difference in atRA release from either SiO1000 
or a SiO1000/5000 50/50 vol % blend. It appears, therefore, that the viscosity of the oil 
does not seem to affect atRA release. 
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3.4.4 Release of Ibuprofen from SiO and Blends 
 
The release of Ibu from saturated SiO1000 and SiO/PDMS-Ibu blends, containing 1, 5 
and 10 vol % PDMS-Ibu, into culture media was investigated. Figure 3.28 shows the 
observed release rates determined by both 1H NMR spectroscopy and liquid 
scintillation measurements.   
 
While burst release is also observed within the first day, the majority of Ibu is 
released over several days, with 90 % being released after only 3 days.  The same 
release profiles were observed for SiO1000 and the 3 different blends, therefore, it can 
be concluded that the presence of PDMS-Ibu did not affect the release rates of Ibu 
from SiO1000 as seen for the atRA systems. 
 
Figure 3.28 Release of Ibu from saturated solutions of SiO1000 (black) and 1 (red), 5 (red) and 10 % 
(green) blends (v/v) measured both by 
1
H NMR spectroscopy (unfilled) and by liquid scintillation 
(filled) into culture media, presented on a log+1 scale.  All experiments were carried out at 37 °C in 5 
% CO2. 
 
3.5 CONCLUSION 
 
The synthesis of PEO prodrugs with atRA and Ibu was achieved, with successful 
cleavage without observable degradation of the drugs. Biological evaluation 
concluded PEO did not affect metabolic activity of ARPE-19 cells and cytotoxicity 
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was dependant on drug content.  Due to inefficient solubility of the PEO prodrugs in 
SiO compared to free drug, all investigations were ceased apart from studies using 
PEO14-Ibu which had the highest solubility in SiO.  Release studies of PEO14-Ibu 
with Me-PEO-Ibu and free Ibu from SiO into culture media concluded that the PEO 
prodrug did prolong release; however, the majority was released over 4 days which 
falls short of the target 4-6 week treatment period criteria. 
 
The synthesis of PDMS prodrugs with both drugs was successful; however, cleavage 
of drug via breakage of the ester bond was not readily achieved. It was hypothesised 
that this was due to a hydrophilicity/hydrophobicity issue of the prodrugs within the 
cleavage conditions.  The synthesis of a tripartite PDMS prodrug with a PEO spacer 
supported this as cleavage was then observed when this was present.  Biological 
evaluation of the PDMS prodrugs at 10 % (v/v) in SiO indicated no cytotoxicity 
occurred at this concentration.   
 
Due to the unsuccessful cleavage of the PDMS prodrugs, they were studied as 
additives to SiO to ascertain any impact on drug solubility and release.  Different 
methodologies were tested to investigate drug solubility in SiO; the development and 
use of radioisotope techniques was required to achieve accurate measurements, and a 
fundamental inaccuracy of atRA solubility in SiO reported in the literature was 
identified.  The presence of PDMS-atRA in SiO had a positive effect on atRA 
solubility, possibly due to the affinity of attached drug to free drug in the blend.  
PDMS-atRA also had a positive effect on release, with the release period being 
independent of atRA starting concentration and dependant on the PDMS-atRA 
concentration in the blend. Excitingly, a release period of atRA from a SiO blend 
with PDMS-atRA over 7 weeks was observed and it was found there would be a 
possibility to tailor initial starting concentrations of atRA so the burst release was 
below the toxic range but the sustained release was above the therapeutic level for an 
antiproliferative effect to be observed.  Unfortunately, the presence of PDMS-Ibu in 
a SiO blend did not have any significant effect on Ibu solubility nor did it affect the 
release rates of Ibu from SiO. 
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Branched Amphiphilic Polymer Architectures 
as Potential Additives for SiO Tamponades 
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4.1 INTRODUCTION 
 
The aim of this investigation was the evaluation of the synthesis of branched 
amphiphilic copolymers as additives for SiO tamponades and the potential for drug 
(atRA or Ibu) to be covalently bound to the hydrophilic component of the copolymer 
(Figure 4.1).   
 
Figure 4.1 A: Branched amphiphilic copolymer with drug attached to a hydrophilic component. B: 
Branched amphiphilic copolymer. 
 
The main criterion for the DDS envisaged within this Chapter is that it is soluble in 
SiO as any future therapy will employ a SiO tamponade acting as a drug reservoir.  
By incorporating both hydrophilic and hydrophobic monomers into a statistical 
copolymer, it was hypothesised that previous low solubilities of hydrophilic 
polymers in SiO (see Chapter 3) would be modified. Different degrees of 
polymerisation (chain length) of both the hydrophilic and hydrophobic components 
were studied and evaluated to establish their effects on solubility within SiO. 
 
4.1.1 Controlled Radical Polymerisation 
 
The development of controlled radical polymerisation (CRP) has provided materials 
chemists with a highly flexible approach to construct polymers via methods that 
allow the number of monomer units and the polymer architecture to be 
predetermined prior to synthesis.  Such techniques have led to a diverse range of 
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multifunctional polymers with well-defined Mn and low dispersity (Ð) across the 
molecular weight distribution.  The three leading CRP methods that have been 
adopted globally are atom transfer radical polymerisation (ATRP),1 nitroxide 
mediated polymerisation (NMP)2 and reversible addition-fragmentation chain 
transfer (RAFT).3   
 
All three CRP methods present a very similar mechanistic principle (see Scheme 4.1) 
where an active species (P●), capable of monomer addition, is in dynamic 
equilibrium with its dormant state (P-X) which is inert to polymerisation. Each 
method ensures that the concentration of the active species remains low throughout 
polymerisation thus minimising undesirable reactions such as chain transfer and 
chain termination.4 Only when this is achieved does the polymerisation react in a 
controlled manner; slow monomer addition is ensured allowing the polymer chains to 
grow in a more uniform manner, therefore, minimising dispersity within the 
molecular weight distribution. 
 
Scheme 4.1 A general representation of the reversible deactivation process responsible for 
maintaining a low radical concentration throughout controlled radical polymerisation processes  where 
(X-P) is the dormant species and (P●) is the active species .  
 
NMP, although a useful technique for some monomers, is limited to the functionality 
that it can tolerate,5  whereas ATRP and RAFT provide excellent techniques capable 
of polymerising a wide range of monomer functionalities within a range of solvent 
environments.6, 7  It is for this reason that they have been selected as the CRP 
methods to be used throughout this project.   
 
4.1.2 Atom Transfer Radical Polymerisation 
 
Following the discovery of ATRP at the end of the 20th century it has become a 
widely used CRP method around the world.6 As for all CRP methods, a controlled 
polymerisation is facilitated by ensuring a low concentration of the active species by 
establishing a dynamic equilibrium with a dormant state. The term ATRP comes 
from the atom transfer step which is the key elementary reaction responsible for the 
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controlled nature of the polymerisation. In ATRP the active species (R●) is generated 
by a reversible redox process catalysed by a transition metal complex (Mt
n-Y/Ligand 
with Y being another ligand or counter ion) which undergoes a one electron 
oxidation process by abstraction of a (pseudo)halogen atom from a dormant species 
(R-X).6 Initiators are typically alkyl halides, although the use of a number of 
(pseudo)halogen compounds has been reported.8-10  The reversible redox process 
occurs with an activation rate constant (kact) and deactivation constant (kdeact). A 
general mechanism for the ATRP process can be seen in Scheme 4.2. 
 
Scheme 4.2 The general mechanism of ATRP, as described by Matyjaszewski and Xia. Figure 
recreated from ref: 
6
. An alkyl halide (RX) is under dynamic equilibrium with its active species (R●), 
which can undergo propagation with monomer at a rate of kp to increase the length of the polymer 
chain, or termination processes at a rate kt. 
 
The active species (R●) undergoes monomer addition in a similar way to 
conventional free radical polymerisation, with the propagation rate constant (kp). 
Undesirable reactions such as chain termination (kt) also occur in ATRP, however, 
this is controlled due to the low concentration of the active species throughout the 
polymerisation. In the initial non-stationary stage of polymerisation a small number 
(<5 %) of growing chains will undergo termination while generation of a sufficient 
amount of the oxidised metal complex (X-Mt
n+1) is formed.11, 12  This ensures a low 
active radical species throughout the polymerisation, therefore, minimising 
termination reactions. Ideally an ATRP reaction will not only minimise the number 
of terminated polymer chains but ensure that surviving chains grow in a controlled 
and uniform manner.  
 
4.1.2.1 Reaction and Kinetics for ATRP 
 
ATRP allows a number average polymer chain length to be targeted via the 
concentration ratio of monomer:initiator in the initial stages of the polymerisation. 
This allows well defined polymers of Mn = 1,000 – 150,000 gmol
-1 to be synthesised 
with narrow dispersity (1.0 <Ð< 1.5).13, 14  However, as higher Mn polymers are 
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targeted, chain termination reactions become more prevalent, therefore, increasing 
polymer dispersity.15  ATRP also allows for the production of end-functionalised 
polymers by controlling initiator structure, which creates one chain end of each 
polymer formed.16 
 
The rate of polymerisation is dependent on the concentration of the active species 
throughout the polymerisation. This is governed by the magnitude of the equilibrium 
constant (Keq = kact / kdeact) of the reversible redox process by which the active 
species is generated.17  If Keq is very small then the active species concentration will 
be low, therefore, giving a slow polymerisation rate.18  In contrast, if Keq is high, the 
active species concentration will also be higher therefore giving a faster rate of 
polymerisation. However, an increased active radical concentration will also increase 
the probability of undesirable reactions such as chain termination which will 
negatively impact on the dispersity of the polymer chains.  
 
The propagation rate can be derived using the rate law outlined in Equation 4.1 
which makes the following two assumptions: firstly, the contribution of termination 
is negligible once steady state is achieved due to the persistent radical effect12 and, 
secondly, a fast equilibrium approximation is generated without which it would be 
impossible to obtain polymers of low dispersities.19 
  
Equation 4.1 Rate law of ATRP. The rate of propagation (Rp) is dependent upon the propagation rate 
constant (kp), monomer concentration ([M]) and the concentration of the active species ([R●]).  
Further derivation reveals that (Rp) is dependent upon the equilibrium constant of the reversible redox 
process (Keq), initial initiator concentration ([I]0) and the concentrations of both copper species 
([Cu
I
]/[X-Cu
II
]). 
 
A plot of monomer conversion against time on a semi-logarithmic scale reveals a 
linear plot which indicates that the polymerisation obeys first order kinetics with 
respect to monomer.20-22  This also shows that the concentration of the active species 
remains constant throughout the polymerisation. An example of a kinetic profile 
from an ATRP can be seen in Figure 4.2. Typically a small number of polymer 
chains will terminate during the early stages of polymerisation, however, this can be 
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greatly reduced by the addition of a small amount of the Cu(II) species which acts as 
a radical deactivator to minimise termination during the early stages.23 
 
Figure 4.2 A kinetic plot from a typical ATRP of p(OEGMA30) in IPA:H2O (92.5:7.5) at 55.5 % w/v 
(monomer:solvent) with CuCl:bipyridyl (bpy) as the catalytic system and ethyl α -bromoisobutyrate 
(EBriB) as the initiator. When plotted on a semi-logarithmic scale a linear increase in conversion over 
time is observed.  Conversion (■) and ln([M]0/[M]) (▲). 
 
Typically throughout an ATRP reaction a linear increase in the number average 
molecular weight (Mn) is observed when plotted against monomer conversion, as 
monomers add to growing polymer chains during propagation (see Figure 4.3).23  
During the early stages of ATRP there will be differences in chain lengths of 
growing polymer chains due to multiple monomer additions occurring each time the 
active species is formed.24  However, as the reaction progresses, chains will become 
more uniform due to continuous exchange reactions, thus a decrease in dispersity is 
normally observed with conversion.  
 
Figure 4.3 The evolution of Mn (●) and Ɖ (■) with monomer conversion of p(OEGMA30) in IPA:H2O 
(92.5:7.5) at 55.5 % w/v (monomer:solvent) with CuCl:bpy as the catalytic system and EBriB as the 
initiator. 
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4.1.2.2 Branched Polymers via ATRP 
 
One method of producing branched polymers by ATRP involves the incorporation of 
a divinyl monomer during the polymerisation of traditional vinyl monomers.25  The 
enhanced control offered by ATRP means that, ideally, all propagating chains grow 
at the same rate. Such branched polymerisations, therefore, proceed by an alternate 
mechanism to the formation of branched polymers using divinyl monomers via 
conventional free radical polymerisation mechanism, which utilise thiol chain 
transfer agents to provide a controlled and non-crosslinking reaction by what is 
known as the ‘Strathclyde route’.24, 26-28  The mechanism of  branched polymer 
synthesis using low concentrations of divinyl monomers in an ATRP polymerisation 
was investigated by Bannister et al.29  Three stages of polymerisation were identified 
from analysis of both monomer conversion and evolution of molecular weight during 
the copolymerisation of HPMA and EGDMA (Scheme 4.3). 
 
Scheme 4.3 The stages of polymerisation during the production of branched po lymers by ATRP as 
identified by Bannister et al.
29
  Stage 1 involves the initiation and propagation stages which are 
apparent in ATRP of traditional vinyl monomers. Statistical incorporation of the divinyl monomer 
occurs in stage 2 and stage 3 involves intermolecular branching of polymer chains to g ive a soluble 
branched polymer.  
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The first stage of the polymerisation includes the statistical copolymerisation of the 
mono and divinyl monomers at a ratio to give primary chains containing less than 
one potential branch point (i.e. pendant vinyl group) per chain. If there is more than 
one brancher per chain gelation can occur.  In this stage the monomer concentration 
is relatively high compared to the pendant vinyl groups therefore branching is 
negligible.  During the early stages of polymerisation, the evolution of Mn is identical 
to that of conventional CRP, showing a linear increase in Mn with monomer 
conversion. The number of branch points per chain increases in the second stage of 
the polymerisation, therefore, a deviation from CRP behaviour is observed.  This is 
due to the formation of covalent bonds between growing chains as the pendant vinyl 
group is consumed via reaction with propagating chain ends. The third stage is 
dominated by the intermolecular coupling of polymer chains via reaction of the 
pendant vinyl groups. This occurs at high monomer conversion when there is an 
increased probability of reaction of the pendant vinyl groups due to a dramatic 
decrease in monomer concentration. This stage can be identified by a characteristic 
large increase in Mn and Mw due to chain growth being dominated by polymer chains 
coupling through pendant vinyl groups.  
 
In order to produce soluble branched polymers it is important that the number of 
potential branch points is limited to less than one divinyl functionality per primary 
chain.30, 31  This is known as the gel-point criterion; above this primary chains 
become highly cross-linked leading to macrogelation. The degree of branching is 
also highly dependent upon the final monomer conversion which can be accounted 
for by the step-growth polymerisation behaviour during the final stage of the 
polymerisation mechanism.32 
 
4.1.3 Reversible Addition/Fragmentation Chain Transfer Polymerisation 
 
Reversible addition/fragmentation chain transfer is a form of CRP which relies on 
the use of a chain transfer agent (CTA) to control the process of monomer addition. 
RAFT CTAs utilise sulphur chemistry to interact with propagating radicals.  Due to 
recent advances in RAFT agent synthesis, a number of synthetic approaches are 
available to create CTAs.33, 34  The general structure of a CTA is based around a 
thiocarbonylthio group capped at each side with what is commonly referred to as the 
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R and Z groups. Following polymerisation the α-terminus of the polymer chain is 
capped with the R group, while the Z group is capping the ω-end of the polymer 
chain. A generic CTA structure, along with that of a number of commonly used 
CTAs can be seen in Figure 4.4. 
 
Figure 4.4 Structures of generic RAFT agents along with their compatible monomers.
35-40
  
 
The main functionalities of RAFT agents are dithioesters, trithiocarbonates, 
dithiocarbamates and xanthates. The chemical nature of the RAFT agent dictates the 
monomer functionality to which it is best suited to polymerise, for example, highly 
activated RAFT agents such as xanthates are used to polymerise less activated 
monomers such as vinyl acetate. Alternatively, more activated monomers such as 
methacrylates can be polymerised with good control by less activated RAFT agents 
such as trithiocarbonates and dithioesters.  
 
The mechanism of RAFT is yet to be fully understood, with a number of phenomena 
yet to be explained;7, 41, 42 however, the most widely accepted proposed RAFT 
mechanism has been outlined in Scheme 4.4. As with all polymerisations, the 
reaction starts with an initiation step, which may happen through auto-initiation (for 
example styrene above 110 °C), or more conventionally through the thermal 
decomposition of an initiating species such as 2,2’-azobis(2-methylpropionitrile) 
(AIBN). Whichever method of initiation is used, the initiating species forms a radical 
(I●) which combines with multiple monomer units to form short polymeric chains 
(Pn
●).  
 
Once the concentration of (Pn
●) has increased significantly, a pre-equilibrium is 
established with the RAFT agent (1) to form an intermediate species (2). Once 
formed, there are two ways that (2) can decompose: through a direct reversal to 
reform (1), or by fragmentation of the S-R bond to expel the R group as a radical 
species (R●), giving another intermediate species, (3). (R●) can then combine with 
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monomer units to form a second short polymeric chain (Pm
●). Once this has occurred 
it quickly leads to the formation of the main equilibrium. 
 
The main equilibrium is established following the addition of (Pm
●) onto (3) to give 
the radical intermediate (4), which contains both of the propagating moieties attached 
to either of the sulphur atoms. It can be argued that (4) represents the dormant state 
in the reaction with both growing polymer chains locked into the RAFT agent. This 
species can undergo one of two possible fragmentation reactions to expel either of 
the growing polymer chains thus reforming the thiocarbonyl group (3) or (5) and the 
active species, allowing further propagation.  As (3) and (5) are, in essence, 
indistinguishable, the decomposition of (4) has no preference as to which growing 
chain is released.  
 
The fact that the growing polymer chains spend most of the time locked into the 
dormant state explains the control offered by RAFT. The ability to maintain a low 
concentration of active radical species in solution at any one time prevents 
undesirable chain termination occurring by polymer-polymer coupling processes. 
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Scheme 4.4 The widely accepted mechanism of RAFT polymerisation.
7
 Initiator decomposition gives 
a radical species (I
●
) which quickly propagates with monomer (M) at the rate constant kpi to give short 
oligomer chains (Pn
●
). Addition of this species to (1) occurs under equilibrium with the addition 
occurring with a rate constant of (kadd1) to give (2) and the reverse process occurring with a rate 
constant of (k-add1). Expulsion of the R group from (2) is under dynamic equilibrium and occurs with a 
rate constant of kß1 and a reverse process occurring with a rate constant of kß-1. This gives (3) and 
another active radical species, which undergoes propagation at rate of kpr to give Pm
●
. Addition of Pm
●
 
into (3) occurs with a rate constant of kadd to give (4). (4) can decompose to reform (3) at a rate 
constant of k-add by expulsion of Pm
●
 or generate (5) by expulsion of Pn
●
 at a rate constant of kß, which 
has a reverse process occurring at k-ß. Active radical species can undergo termination processes either 
by polymer coupling at ktc or by disproportionation reaction with an hydrogen atom at a rate of ktd.  
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4.1.3.1 Branched Polymers by RAFT 
 
Branched copolymers have also been produced by RAFT polymerisation using a 
method known as the ‘grafting from approach’; which uses the polymer backbone as 
a scaffold from which polymer chains are grown. This process has been used to 
produce comb like structures via copolymerisation with a monomer that can easily be 
modified into a RAFT agent. This approach then allows for further polymerisation 
from the pendant RAFT functionality.43 The ‘grafting from approach’ has been used 
for the preparation of branched polymers of polystyrene, by copolymerisation of 
styrene with a styrenic monomer containing a dithiobenzoate modification. 
Polymerisation resulted in the production of branched polystyrene compared with the 
lower Mn polymers produced in the absence of the modified monomer.
44 
 
Alternatively, similar structures have been produced by a different method in which 
polystyrene reinitiated in the presence of maleic anhydride resulted in the 
incorporation of one maleic anhydride unit per polymer chain (the chemistry limits 
the reaction to the addition of only one unit). Chain extension of styrene with the 
same targeted DPn resulted in polystyrene-co-maleic anhydride with the maleic 
anhydride located in the middle of the polymer chain. Following multiple repetitions 
polystyrene-co-maleic anhydride was produced with maleic anhydride units spaced 
evenly along the polymer backbone. These functionalities were then targeted using 
poly(ethylene oxide) containing a terminal hydroxyl group, which yielded the graft 
copolymer.45 
 
Branched polymers have also been produced via the copolymerisation of vinyl and 
divinyl functionalised monomers in the presence of a RAFT agent.46  This method to 
synthesise branched architectures using RAFT involves the production of a macro 
RAFT agent from which chain extension can be carried out (see Figure 4.5). The 
production of branched polymers using this method was reported by Liu et al. who 
copolymerised MMA and EGDMA in the presence of 
2-(2-cyanopropyl)dithiobenzoate.47 The controlled nature of the polymerisation 
afforded preparation of controlled polymer architecture, furthermore end-group 
fidelity was proven through successful chain extension, yielding star like structures. 
Hyperbranched poly(MMA) polymers still containing their RAFT agent end groups 
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underwent chain extension with styrene to give star copolymers containing a 
branched PMMA core and styrene arms.  
 
Figure 4.5 Branched polymer architecture obtained by RAFT showing dual functionality of the 
polymer chains. 
 
4.2 COPOLYMERS OF OEGMA AND HEMA BRANCHED WITH 
PDMSDMA 
 
The synthesis of a range of branched polymers was considered as providing potential 
benefits for the formation of soluble polymeric additives for SiO when used as a 
tamponade agent.  Initially, ATRP was used to synthesise a linear statistical 
copolymer of the commercially available hydrophilic monomer oligo(ethylene 
glycol) methyl ether methacrylate (OEGMA, DPn = 3-4 ethylene glycol units / Mn = 
300 gmol-1), with 2-hydroxylethylmethacrylate (HEMA) which is also hydrophilic 
and bears a hydroxyl pendant group (to be used to covalently bond atRA or Ibu and 
form pro-drug prototypes). The polymerisations of both OEGMA and HEMA under 
aqueous solvent conditions have been reported in the literature and it was the 
presence of water has been shown to dramatically accelerate the ATRP of OEGMA 
and HEMA.48-50  Particularly, the use of mixtures of isopropanol/water (IPA:H2O, 
92.5:7.5 v/v) or methanol/water, (MeOH:H2O, 50:50 v/v) as the polymerisation 
solvent for OEGMA and HEMA respectively, at ambient temperature that have 
previously been reported to lead to controlled polymerisations.51, 52  The statistical 
copolymerisation of OEGMA and HEMA was targeted with an overall degree of 
polymerisation DPn = 30 monomer units (DP30) with molar ratios of the two 
monomers of 80/20 and 50/50 (Scheme 4.5).  Similar conditions to those reported in 
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the literature were used including a temperature of 30 °C and an IPA:H2O solvent 
mixture of 92.5:7.5 v/v at a concentration of 55.5 % w/v (monomer:solvent). A 
CuCl:bpy catalytic system was employed and the commercial EBriB was utilised as 
initiator. Removal of the copper was performed via a neutral alumina column and the 
polymers recovered by precipitation. The characteristics of the copolymers obtained 
are presented in Table 4.1. 
 
Scheme 4.5 Synthesis of statistical p(OEGMA-co-HEMA) via ATRP. 
 
The incorporation of a low concentration of dimethacrylate monomer into this 
polymerisation can lead to soluble polymers with high Mn and high Mw with a 
branched architecture.53 In an attempt to establish compatibility with the SiO 
tamponade, a hydrophobic dimethacryloxypropyl terminated PDMS (PDMSDMA) 
was utilised as the dimethacrylate branching agent (see Figure 4.6) and various 
chain-lengths of this macro-brancher (Mn) were used. In this initial scoping 
experiment, the shortest chain length (Mn 390 gmol
-1, m=1) was used.   
Table 4.1 Characteristics of the linear
 
p(OEGMA-co-HEMA) and the branched equivalents with 
PDMSDMA n=1. 
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Figure 4.6 Chemical structure of dimethacrylate monomer PDMSDMA. 
 
Gelation can occur during these reactions if the molar ratio of initiator to brancher is 
>1:1 due to cross-linking of polymer chains.  Therefore, all reactions were carried 
out at a ratio of 1:0.95 initiator:brancher to achieve the desired highly branched 
architectures. The concentration of the polymerisation also affects the branching; the 
more dilute the reaction, the more likely intramolecular looping will occur,54 
however, ultimately branching becomes diffusion controlled within the reaction.55 
Therefore, it was important to ensure all polymerisations were carried out at a 
constant concentration, here 55.5 % w/v (monomer:solvent). 
 
All the copolymers (linear and branched) were characterised by gel permeation 
chromatography (GPC) and 1H NMR, and the results are collated in Table 4.1.  The 
DPn for each monomer was calculated via 
1H NMR for both OEGMA and HEMA as 
the vinyl peaks for each monomer were distinguishable to analyse separately. Mn 
determined by GPC was higher than the targeted theoretical values, which is not 
uncommon for ATRP and possibly due to initiator efficiency being less than 100 % 
within the early stage of the equilibrium definition, leading to longer chains than 
predicted.  Effects of reduced initiator efficiency are well reported within the 
literature.56, 57  
 
When comparing the two linear copolymers, it was observed that the dispersity of 
p(OEGMA-co-HEMA) 50/50 is higher than the 80/20 copolymer; Ð = 1.43 
compared to Ð=1.27 respectively.  The higher dispersity could be due to HEMA 
initiating and propagating faster than OEGMA.  RI traces of the linear polymers 
presented in Figure 4.7 show a monomodal distribution; however, a slight shoulder 
can be seen on the lower retention volume (high Mw) side of the 50 % OEGMA 
copolymer.  This could be due to coupling of chain ends at high conversions.58  Both 
this and the higher Ð displayed in the 50/50 copolymer can be investigated by 
determining the kinetics of the polymerisations (see section 4.6.1).  The dispersity 
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calculated via GPC for the branched copolymers is much higher than their linear 
equivalents which is consistent with the attainment of branched architectures. 
 
The difference between the linear and branched polymers is clearly visible from the 
RI chromatograms shown in Figure 4.7: the incorporation of the PDMSDMA results 
in higher Mw branched polymers which elute at lower retention volumes.  However, 
a broad distribution is detected within the branched polymers due to the statistical 
incorporation within the ATRP mechanism, therefore, both highly branched and 
linear materials are present.   
 
Figure 4.7 GPC RI chromatogram overlays of the branched copolymers p(OEGMA-co-HEMA-co-
PDMSDMA) and their linear equivalents synthesised by ATRP. 
 
4.2.1 Kinetic Evaluation of ATRP branching reactions 
 
To determine if a polymerisation is controlled, time points are taken throughout the 
reaction and analysed to determine if the polymerisation follows first order kinetics 
with respect to the monomer concentration, and to observe the development of Mn 
compared to monomer conversion.   
 
The kinetic plots for both linear copolymers, (Figure 4.8), show that high conversion 
was reached within 4-6 hours (Figure 4.8 A and C) and followed first order kinetics. 
The conversion of both monomers was determined by 1H NMR spectroscopy with 
the use of an internal standard (anisole) with characteristic aromatic peaks at 7.21 
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and 6.84 ppm; these peaks remained constant throughout the polymerisation.  The 
vinyl peaks at 6.05 and 5.49 ppm attributed to HEMA and 6.12 and 5.54 ppm 
attributed to OEGMA decrease as the monomer is consumed (see Appendix Figure 
A34).  The ratio between the anisole aromatic peaks and monomer peaks therefore 
can be used to determine the conversion.  The HEMA monomer reacted faster than 
the OEGMA monomer, this also resulted in a faster polymerisation when the higher 
ratio of HEMA (50 %) was used.     
 
Figure 4.8 Kinetic plots for linear copolymers p(OEGMA24-co-HEMA6), (A and B) and 
p(OEGMA15-co-HEMA15), (C and D).  ■/■ = conversion OEGMA/HEMA; ▲/▲ = ln([M]0/[M]) 
OEGMA/HEMA; ● = Mn; ■ = Ð.   
 
When investigating the kinetics for the branched polymers, the incorporation of the 
PDMSDMA led to the vinyl peaks in 1H NMR spectra being indistinguishable from 
one another (i.e. they merged together as they are all in similar environments; see 
Appendix Figure A35).  This resulted in the conversion being determined for the 
total monomer concentration rather than for each individual monomer. The kinetic 
plots for both branched polymerisation are shown in Figure 4.9.   
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Figure 4.9 Kinetic plots for branched copolymers p(OEGMA24-co-HEMA6-co-PDMSDMA0.95) (A 
and B) and p(OEGMA15-co-HEMA15-co-PDMSDMA0.95) (C and D).  Conversion (■), ln([M]0/[M]) 
(▲), Mn (●), Ð (■).  
 
Again a faster polymerisation was observed when the ratio of HEMA was higher (50 
%), but both polymerisations followed first order kinetics (Figure 4.9 A and C).  The 
Mn values were observed to increase relatively linearly in both polymerisations until 
high conversions were reached (>80 %); this is a typical characteristic of branched 
polymerisations of this type. Once high conversion is reached, the Mn increases 
dramatically as large branched structures are being formed via intermolecular 
reactions joining individual linear polymers and structures containing many primary 
polymer chains. 
 
4.2.2 Linear and Branched Copolymer Solubility Studies in SiO 
 
The solubility of both OEGMA and HEMA monomers and copolymers were 
assessed in SiO1000.  It was determined that both monomers were practically 
immiscible with SiO, however, upon the incorporation of the hydrophobic 
PDMSDMA, both branched copolymers of p(OEGMA-co-HEMA), were soluble at 
20 % (v/v).  
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4.2.3 Drug Attachment to Branched Copolymers 
 
Once the branched amphiphilic copolymers were successfully synthesised and their 
solubility in SiO1000 confirmed, the functionalisation with drug molecules was 
investigated.  
  
4.2.3.1 Functionalised Monomer 
 
Both atRA and Ibu were successfully covalently bound to the HEMA monomer, 
however, polymerisation of the functionalised monomer resulted in some unexpected 
reactions. The Steglich esterification method (as described in Chapter 3) was utilised 
to react both atRA and Ibu to the HEMA monomer to form atRA-ethyl methacrylate 
(atRAEMA) and Ibu-ethyl methacrylate (IbuEMA) respectively, this is shown in 
Scheme 4.6.   
 
Scheme 4.6 Steglich esterification of both atRA and Ibu with HEMA monomer. 
 
Similarly to the observations made in Chapter 3, the esterification of atRA with 
HEMA resulted in a lower yield than the Ibu esterification, most probably due to the 
conjugated nature of atRA.  Both purified, modified monomers were analysed by 1H 
NMR spectroscopy and compared to their starting materials (Figure 4.10). The 
modified HEMA monomer, covalently bound to the drugs atRA (Figure 4.10 A) and 
Ibu (Figure 4.10 B), showed agreement across all integrations with expected values, 
confirming the attainment of atRAEMA and IbuEMA (see Appendix Figure A36 and 
A37). 
 
 
atRA 
(36 %) 
DCC, DMAP 
DCM Ambient T ,  
2 days 
Ibu 
(98 %) 
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Figure 4.10 
1
H NMR spectra (A:CDCl3, B: MeOD, 400 MHz) of starting HEMA and drug along with 
modified HEMA after purification.   
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4.2.3.1.1 atRAEMA Polymerisation and Copolymerisation by ATRP 
 
The synthesis of the 50/50 and the 80/20 linear copolymers of OEGMA and HEMA 
was repeated under the identical conditions to those described previously, but 
replacing the HEMA with atRAEMA, however, after 8 hours no reaction had 
occurred.  Following this, a linear homopolymerisation of the atRAEMA targeting a 
DP30 was carried out, again unsuccessfully. It appeared that the antioxidant nature of 
atRA was potentially acting as a terminator during the polymerisation, rendering this 
monomer-drug conjugate useless of the intended ATRP polymerisations.    
 
To test this hypothesis, the kinetics of HEMA homopolymerisation were carried out 
in the presence of added atRA within the system, at 1 and 10 % (w/w), the kinetic 
plots are presented in Figure 4.11. The rate of conversion decreased in the presence 
of 1 % (w/w) atRA and decreased further when 10 % (w/w) was present (see Figure 
4.11), confirming atRA was interacting with the radical concentration. Interestingly, 
the polymerisations still exhibited a linear semi-log plot, suggesting a slowing of the 
polymerisation rather than a loss of overall control. 
 
GPC analysis also confirmed that atRA was interfering with the polymerisation as 
broader distributions were observed when atRA was present and the elution of a very 
high molecular weight species appeared when atRA 10 % (w/w) was present (see 
Figure 4.12). As such, the control that was potentially indicated through the initial 
analysis (Figure 4.11) was not seen in the final products.  
 
CHAPTER 4 
164 
 
 
Figure 4.11 Kinetic plots for HEMA polymerisation in the presence of atRA 1 and 10 % (w/w) (red 
and blue respectively), and in the absence of atRA (black). Conversion (circles), ln([M]0/[M]) 
(triangles).  
 
 
Figure 4.12 GPC RI chromatogram overlays of p(HEMA30) synthesised in the presence and absence 
of atRA. 
 
The interference of atRA with the ATRP reaction led to the conclusion that the use of 
a pre-functionalised monomer was not appropriate for the preparation of atRA 
functionalised amphiphilic branched p(OEGMA-co-atRAEMA-co-PDMSDMA). 
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4.2.3.1.1 Polymerisation and Copolymerisation of IbuEMA Using ATRP 
 
Solubility issues arose with the Ibu-modified monomer whilst investigating the 
ATRP polymerisation in the IPA:H2O solvent system previously used.  A solvent 
system of MeOH:H2O (92.5:7.5 v/v), which displays controlled ATRP reaction for 
pHEMA,52 was successfully used while all other parameters were kept consistent 
with regards to the previous ATRP reactions. Polymerisations of HEMA targeting a 
chain length of DP30 were carried out under these conditions, in the presence of 1 and 
10 % (w/w) Ibu and kinetic studies showed that, unlike atRA, Ibu did not affect the 
polymerisation (see Figure 4.13).  
 
Figure 4.13 Kinetic plots for p(HEMA30) (black) in the presence of Ibu 1 (red) and 10 % (blue) 
(w/w). Conversion (squares), ln([M]0/[M]) (triangles) Mn (circles), Ð (squares). 
 
The measured Mn values for all polymerisations were again higher than the targeted 
Mn as may be expected, however, the  polymers obtained were consistent and almost 
identical when characterised by GPC and 1H NMR spectroscopy (see Table 4.2), 
despite the varying concentrations of Ibu. The GPC RI chromatograms of the 
different polymers are overlaid in Figure 4.14. 
Table 4.2 
1
H NMR and GPC data for all pHEMA synthesised in MEOH:H2O (92.5:7.5) with and 
without the presence of Ibuprofen. 
Target Polymer 
Composition 
Ibu Content        
(% w/w) 
Theoretical 
Mn     
(gmol
-1
) 
GPC
a
 
1
H NMR
b
 
Mn 
(gmol
-1
) 
Mw     (gmol
-
1
) 
Ð DPn DPn 
p(HEMA30) - 4,100 5,100 8,605 1.44 38 30 
p(HEMA30) 1 4,100 5,750 8,205 1.43 43 30 
p(HEMA30) 10 4,100 5,628 7,931 1.41 42 30 
a
Determined using GPC (DMF eluent at 60 ºC) 
b
 Determined by 
1
H NMR in  MeOD. 
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Figure 4.14 GPC RI chromatogram overlays of p(HEMA30) synthesised in the presence or absence of 
Ibu. 
 
The copolymerisation of OEGMA with IbuEMA in the presence of PDMSDMA 
brancher was attempted under the conditions described above, however, the brancher 
was not soluble in the MeOH:H2O (92.5:7.5) solvent. A new solvent system in which 
all three components and the catalytic system was soluble needed to be found.  
Acetone was investigated as the solvent of choice, with the initial synthesis of 
p(IbuEMA30).   
 
The polymerisation of IbuEMA was carried out in MeOH:H2O and in acetone in 
parallel, as a comparison and the ATRP reaction was observed to be uncontrolled in 
acetone.  The GPC traces of the two polymers obtained are presented in Figure 4.15 
and the RI chromatogram broadened considerably when acetone was employed as 
the reaction solvent, and high molecular weight species were apparent within the 
right angle light scattering (RALS) detector chromatograms (Figure 4.15 B).   The 
difference between the two detectors is that the RI detector is dependent on the 
concentration of analyte, whereas the RALS detector response is dependent on the 
size in solution of the polymeric species under investigation (the larger the material 
the more light will be scattered).  Therefore, although the RI response detected no 
material at an elution volume of 14 mL, the RALS detector response clearly indicates 
the presence of this impurity.  The lack of control observed with acetone suggests 
that it is not an appropriate solvent to use for the synthesis of the targeted 
amphiphilic branched architectures. 
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Figure 4.15 GPC chromatogram overlays of p(IbuEMA30) polymerised in MeOH:H2O (92.5:7.5) 
(black) and Acetone (red). A: RI chromatograms and B: RALS chromatograms. 
 
The lack of a useful solvent system in which all monomers, brancher and catalytic 
system were soluble, leading to a controlled ATRP reaction, post functionalisation of 
the copolymers comprising HEMA was investigated. 
 
4.2.3.2 Drug Incorporation via Post-Functionalisation of Polymers 
 
As described earlier, linear p(HEMA30) was synthesised via an ATRP reaction in a 
MeOH:H2O solvent mixture to yield a polymer that was analysed by 
1H NMR 
spectroscopy  (CDCl3) and GPC (DMF eluent at 60 °C)  to give an Mn = 9,100    
gmol-1, Ð = 1.40.  A Steglich esterification was carried out for both atRA and Ibu as 
before (see Chapter 3, Section 3.3.2), but on the pre-polymerised polymer using 
toluene at 40 °C (previously DCM at ambient temperature) to ensure solubility of 
p(HEMA).  The reactions were left for 4 days, in the dark when using atRA, 
followed by dicyclohexylurea (DCU) by-product removal. The purified polymer was 
analysed by 1H NMR spectroscopy (MeOD), as shown in Figure 4.16.  
 
From the 1H NMR spectra in Figure 4.16, it can be seen that atRA did not react with 
p(HEMA30), while Ibu was successfully conjugated to the p(HEMA30); but only with 
a yield of 14 % in 4 days. It is possible that this is due to steric hindrance between 
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p(HEMA30) and the drug molecules. The successful p(IbuEMA) esterification is 
characterised by the merging of peaks at 4.16 and 3.90 ppm which represent the CH2 
groups within p(HEMA) (c and d in Figure 4.16 B) merging together at 4.06 ppm as 
they become part of the same environment, i.e. next to –O-C=O.   
 
Figure 4.16 
1
H NMR spectra (MeOD, 400 MHz) of starting p(HEMA30) and drug (A: atRA and 
B:Ibu) along with modified p(HEMA30).  A: p(atRAEMA30) and B:p(IbuEMA30).   
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Due to the unsuccessful post-modification of p(HEMA) with atRA and the low 
yields obtained for p(IbuEMA30) after 4 days, the direct conjugation of drugs to 
p(HEMA) was abandoned. 
 
4.3 BRANCHING OF OEGMA WITH PDMSDMA USING ATRP 
 
Attaching atRA to the HEMA monomer led to poor polymerisation, whilst 
modifying HEMA with Ibu was successful; however, polymerisations with the Ibu-
modified monomer became problematic when trying to find an appropriate solvent to 
carry out a controlled ATRP in which all components were soluble.  Finally post 
modification of p(HEMA30) with both atRA and Ibu could not obtain viable yields.  
Therefore, the synthetic strategy was modified to evaluate the formation of 
amphiphilic branched copolymers with the aim to investigate the improvement of 
drug solubility using the hydrophilic and hydrogen-bonding environment (in this 
case OEGMA) within SiO.  The subsequent release of free drug and an analogous 
approach to that described in PDMS-drug blends in Chapter 3 will also be studied. 
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Scheme 4.7 Schematic representation of initiator, monomer and brancher and the different targeted DP branched polymers synthesised with different Mn branchers. 
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4.3.1 Kinetic Studies of Linear and Branched OEGMA ATRP Polymerisation  
 
The absence of a strategy requiring covalent attachment of drugs to a SiO-soluble 
polymer removed the need for the HEMA segment which, although hydrophilic, has 
a much simpler structure than OEGMA.  Studies, therefore, aimed to understand the 
homopolymerisation of OEGMA, a commercially available hydrophilic monomer 
with a DPn = 3-4 monomer units (Mn = 300 gmol
-1).  The main aim was to form a 
branched amphiphilic architecture of OEGMA at various DPn values (15, 30 and 60 
monomer units) for the primary structural polymer chains, but using four different 
chain lengths of  PDMSDMA as the brancher, ranging from 390-21,250 gmol-1 (m = 
1, 12, 55 and 282), Scheme 4.7. The polymerisation of OEGMA under aqueous 
solvent conditions have been reported in the literature, particularly the use of 
isopropanol:water, IPA:H2O mixtures (92.5:7.5 % v/v).
51
  Similar conditions to those 
reported in the literature for the homopolymerisation of OEGMA were employed for 
the following reactions, namely 30 °C using the IPA:H2O mixture (92.5:7.5 % v/v) at 
a concentration of 55.5 % w/v (monomer:solvent) with CuCl: bpy as the catalytic 
system and EBriB as the initiator.  Kinetic studies were investigated when a low 
molecular weight PDMSDMA (Mn 386 gmol
-1, m = 1), was employed in the 
branched copolymerisation.  All polymers synthesised were characterised by 1H 
NMR spectroscopy and GPC, Table 4.3. 
Table 4.3 
1
H NMR and GPC data for all linear p(OEGMA) and branched equivalents with 
PDMSDMA (Mn 390 gmol
-1
, n = 1) synthesised.  
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The GPC chromatogram overlays (RI Figure 4.17A; RALS Figure 4.17B) highlight 
the difference between linear and branched copolymerisations. As seen previously, 
the incorporation of PDMSDMA results in higher molecular weight branched 
polymers eluting at lower retention volumes with broad distributions.  
 
Figure 4.17 Overlaid GPC chromatograms showing linear and branched p(OEGMA) A: RI traces and 
B: RALS traces. 
 
The kinetics of linear p(OEGMA) was also monitored by 1H NMR spectroscopy,  
Figure 4.18, and overlaid spectra were obtained in the case of p(OEGMA30) at 
different time points. As previously, the presence of an external reference, anisole, 
aided this analysis. 
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Figure 4.18 
1
H NMR (D2O, 400 MHz) overlay of kinetic samples at hourly time points for 
p(OEGMA30) synthesised using ATRP. 
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The kinetic plots for linear p(OEGMA) polymerisation, with different targeted DPn 
values (Figure 4.19) show that each polymerisation reached a high conversion in less 
than 8 hours and followed first order kinetics. As would be expected, the targeting of 
shorter chains showed more rapid polymerisation. 
 
Figure 4.19 ATRP kinetic plots for linear p(OEGMA). A and B: p(OEGMA15), C and D: 
p(OEGMA30), E and F p(OEGMA60).  Conversion (■), ln([M]/[M]0) (▲), Mn (●) and Ð (■). 
 
The kinetics of OEGMA branched polymerisations using the divinyl PDMSDMA 
(Mn = 390 gmol
-1, n=1), with various targeted DPn values for the primary chains (15, 
30 and 60) were also investigated.  First order kinetics were, again, observed as 
depicted in Figure 4.20 A, C and E.  The plots of Mn and Mw are shown in Figure 
4.20 B, D and F, initially both increase linearly, however, when conversion reaches 
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80-90 % the Mn and Mw rapidly increases due to formation of a branched structure 
when linear chains join together. 
 
Figure 4.20 ATRP Kinetic plots for branched p(OEGMA) with PDMSDMA (Mn=390 gmol
-1
, n=1).  
A and B: p(OEGMA15), C and D: p(OEGMA30), E and F p(OEGMA60).  Conversion (■), ln([M]/[M]0) 
(▲), Mn (●), Mw (o) and Ð (■). 
 
4.3.2 Synthesis of p(OEGMA)/PDMSDMA Branched Copolymers 
 
After the kinetics of the branched ATRP copolymerisation of p(OEGMA) with 
PDMSDMA were determined to be controlled and first order, a range of materials 
were synthesised.  Primary chains of p(OEGMA) with targeted DPn values of 15, 30 
and 60 monomer units were synthesised in the presence of PDMSDMA of varying 
Mn  390 (m = 1), 1,275 (m =12), 4,460 (m = 55) and 21,250 (m = 282) gmol
-1. The 
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different materials with various combinations of p(OEGMA) and PDMSDMA are 
summarised in Scheme 4.8.  These materials were analysed by 1H NMR spectroscopy 
and GPC (DMF eluent at 60 °C) and their characteristics are presented in Table 4.4.   
 
Table 4.4 
1
H NMR and GPC data for all branched p(OEGMA) synthesised. 
 
 
It was observed the higher Mn PDMSDMA (4,460 and 21,250 gmol
-1) failed to 
produce high molecular weight branched materials seen when employing the shorter 
chain PDMSDMA (see Figure 4.21), and dispersity values < 1.5 were seen.  The 
GPC chromatogram overlays of the different p(OEGMA) branched copolymers with 
the different PDMSDMA branchers are presented in Figure 4.21, and clearly show 
that the use of longer branchers failed to give highly branched materials. 
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Figure 4.21 GPC chromatogram overlays of branched p(OEGMA) DP 15 (red), 30 (blue) and 60 
(green).  A: p(OEGMA) branched with PDMSDMA (Mn 390 gmol
-1
 m = 1). B: p(OEGMA) branched 
with PDMSDMA (Mn 1,275 gmol
-1
 m = 12). C: p(OEGMA) branched with PDMSDMA (Mn 4,460 
gmol
-1
 m = 55). D: p(OEGMA) branched with PDMSDMA (Mn 21,250 gmol
-1
 m = 282).  
 
Following the unsuccessful branched polymerisations with high molecular weight 
PDMSDMA, despite high conversion (<90 %) of the OEGMA monomer units, THF 
was added to the solvent system with the aim to remove any potential solubility 
issues of the longer  PDMSDMA branchers that may inhibit the  branching between 
chains.  To ensure this new solvent system (IPA:H2O:THF; 74.5:7.5:18) did not 
affect the ATRP polymerisation, kinetic studies of the p(OEGMA30) branched ATRP 
copolymerisation, using the shortest PDMSDMA, were conducted and compared 
with the previous solvent system (see Figure 4.22). The addition of THF did not 
inhibit the polymerisation and first order kinetics were seen, suggesting a controlled 
polymerisation, however, the polymerisation was noticeably faster.  Using this short 
brancher, branched architectures were obtained, as shown by the rapidly increase of 
Mn and Mw at high conversion. 
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Figure 4.22 ATRP kinetic plots of p(OEGMA30) branched with PDMSDMA (Mn 390 gmol
-1
) in 
IPA:H2O (92.5:7.5) (black) and IPA:H2O:THF (74.5:7.5:18) (red).  A: Conversion (squares), 
ln([M]/[M]0) (triangles). B: Mn (filled circles), Mw (unfilled circles) and Ð (squares). 
 
As the kinetics confirmed that a controlled first order polymerisation was taking 
place with the addition of THF, ATRP reactions of the previously failed branched 
copolymerisations (primary p(OEGMA) DPn = 15, 30 and 60) with PDMSDMA 
branchers of  Mn = 4,460 and 21,250 gmol
-1 were repeated.  Table 4.5 summarises 
the characterisation of the resulting materials as analysed by 1H NMR spectroscopy 
and GPC (DMF eluent at 60 °C).   
 
Despite the addition of THF, the formation of high molecular weight, branched 
copolymers was not seen, as evidenced by the absence of high molecular weight 
materials and despite high conversions being obtained. 
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Table 4.5 
1
H NMR and GPC data for all branched p(OEGMA) synthesised using IPA:H2O:THF 
(74.5:7.5:18) solvent system. 
 
 
4.3.3 Solubility Study of p(OEGMA-co-PDMSDMA) in SiO 
 
Despite the lack of success with long PDMSDMA branchers, the solubility of the 
different p(OEGMA-co-PDMSDMA) branched architectures in SiO1000 was 
investigated. Initially, a solubility study was carried out with linear homopolymers of 
p(OEGMA15) which revealed that p(OEGMA) and SiO1000 were practically 
immiscible. Blends of the amphiphilic copolymer of OEGMA (DPn = 15) branched 
with both PDMSDMA Mn 390 and 1,275 gmol
-1 (n =1 and 12 respectively) at 0.1, 1, 
5 and 10 % (v/v) in SiO1000 were prepared and stirred at ambient temperature for 2 
days without any observable change. The samples were then placed at 37 °C for 2 
days and stirred at ambient temperature for a further 3 days without appreciable 
dissolution of the branched polymers. To overcome the initial interfacial interactions 
which must happen for solids to solubilise in solvents the polymers were solubilised 
with SiO in THF by stirring overnight. The blends were then stirred and left open for 
7 days at ambient temperature to allow the THF to evaporate.  This process resulted 
in the formation of a homogeneous 0.1 % (v/v) blend of the p(OEGMA15-co-
PDMSDMA0.95(12)) in SiO1000, however, no other combinations were successful. Due 
to the observed immiscibility of the branched amphiphilic structures in SiO, a series 
of alternative polymer structures were considered. 
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4.4 ATRP COPOLYMERISATION OF OEGMA AND PDMSMA  
 
To increase the solubility of the targeted amphiphilic polymer architectures within 
SiO, a higher ratio of the hydrophobic/lipophilic component was considered to be 
required when compared to the hydrophilic p(OEGMA).  The divinyl monomer 
PDMSDMA, used as a brancher previously, was clearly not sufficient to induce 
solubility within these structures, therefore, the statistical linear copolymerisation of 
OEGMA with monomethacryloxypropyl PDMS (PDMSMA, Figure 4.23) was 
chosen for study .  
 
Figure 4.23 Chemical structure of monomethacryloxypropyl PDMS (PDMSMA). 
 
Two different molecular weights of PDMSMA were selected (985 and 4,600 gmol-1, 
r = 9 and 57 respectively), and the synthesis of a variety of copolymers was 
investigated. The target within this section was to statistically copolymerise OEGMA 
and PDMSMA with an overall targeted DP60 monomer units and 
OEGMA/PDMSMA ratios of 80/20 and 50/50, Scheme 4.9. 
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Scheme 4.9 Synthesis of statistical p(PDMSMA-co-OEGMA) via ATRP and schematic 
representations of the targeted amphiphilic polymeric materials. 
 
4.4.1 ATRP Copolymerisation of OEGMA and PDMSMA 
 
The polymerisation of PDMSMA in tertiary butanol (tBuOH) using a PEO 
macroinitiator has been reported in the literature via ATRP at 30 % v/v and 90 °C.59   
The PEO macroinitiator would have similar hydrophilic properties to the OEGMA 
monomer, therefore, comparable conditions to those reported in the literature were 
employed, namely 90 °C in tBuOH at a concentration of 30 % w/v 
(monomer:solvent) with CuCl:bpy as the catalytic system and EBriB as the initiator. 
Initially the linear polymers p(PDMSMA(9)60), p(OEGMA60) and the 80/20 and 50/50 
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ratio copolymers were synthesised and analysed by 1H NMR spectroscopy and GPC 
(THF eluent at 35 °C), Table 4.6. 
Table 4.6 
1
H NMR spectroscopy and GPC data of homopolymers and copolymers  of OEGMA and 
PDMSMA synthesised via ATRP in 
t
BuOH. 
 
Copolymers prepared by the ATRP of PDMSMA and OEGMA gave materials with a 
large dispersity which indicates a lack of control when using ATRP under these 
conditions.  The catalytic system was also seen to precipitate once the complex had 
been formed (Figure 4.24) and, therefore, was not efficient in controlling the reaction 
leading to premature termination of chains.   
 
 
Figure 4.24 Picture of precipitate formation within the ATRP polymerisation of OEGMA and 
PDMSMA  (9) DP60 50/50 ratio in 
t
BuOH. 
 
4.4.2 RAFT Polymerisation of OEGMA and PDMSMA 
 
Due to the insolubility of the catalytic system within the ATRP solvent, an 
alternative polymerisation method was employed; the non-catalytic controlled radical 
polymerisation technique RAFT.  Matching the exact conditions of an ATRP with 
RAFT polymerisation is not possible, as discussed in Section 4.1.3, as this method of 
polymerisation requires a chain transfer agent (CTA).  2-cyano-2-propyl 
benzodithioate (CPBD) was selected as the RAFT CTA due to the excellent 
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compatibility with methacrylate monomers. 2,2’-azobis(2-methylpropionitrile) 
(AIBN) was also selected as the free radical initiator due to excellent solubility 
within tBuOH. and copolymerisations were conducted at 30 wt.% monomer with 
respect to solvent and at 70 °C,  Figure 4.25. 
 
Figure 4.25 Controlled radical polymerisation of OEGMA and PDMSMA conducted in 
t
BuOH at 
70 °C via RAFT with 4,4′-azobis(4-cyanopentanoic acid) and 2-cyano-2-propyl benzodithioate. 
 
4.4.2.1 Linear Amphiphilic Copolymers of OEGMA and PDMSMA via RAFT  
 
Homopolymerisations of OEGMA and the two different chain length PDMSMA 
monomers, targeting DPn = 60 monomer units, and copolymers of PDMSMA and 
OEGMA with identical targeted degrees of polymerisation at 80/20 and 50/50 ratios 
were synthesised.  As previously, the resulting materials were analysed by 1H NMR 
spectroscopy and GPC (THF eluent at 35 °C), Table 4.7. 
 
Table 4.7 
1
H NMR and GPC data of all polymers synthesised via RAFT in 
t
BuOH. 
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All materials synthesised have low dispersities (<1.25) indicating control within the 
polymerisation, and the difference between ATRP and RAFT was readily obvious 
when comparing the RI traces of p(OEGMA) and p(PDMSMA) (Mn 985 gmol
-1, r = 
9) homopolymers, prepared by each technique (Figure 4.26).  High conversions 
could not be reached with the longer chain PDMSMA monomers (45-47 % after 7 
days), probably due to steric hindrance as RAFT requires a close proximity of two 
separate propagating polymer chain ends to undergo CTA exchange; however, these 
materials were still suitable for study after purification.   
 
Figure 4.26  GPC RI chromatogram overlays of A) p(OEGMA60) and B) p(PDMSMA (9)60) 
synthesised by ATRP (black) and the RAFT synthesised equivalents (red). 
 
4.4.2.2 Branched Amphiphilic Terpolymers of OEGMA, PDMSMA and 
PDMSDMA via RAFT  
 
Due to the successful synthesis of the linear homopolymers and copolymers via 
RAFT, the introduction of the divinyl PDMS branchers (Mn = 1,275 and 4,460  
gmol-1; m = 12 and 55 respectively) to form branched terpolymers was reconsidered. 
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The brancher to CTA ratio was kept at 0.95: 1 for each attempt to ensure gelation did 
not occur.   
 
p(OEGMA15) was successfully branched with PDMSDMA(55), which was not 
possible when previously attempted by ATRP.  The attainment of a branched 
architecture is clearly evidenced by the GPC (THF eluent at 35 °C) analysis of the 
copolymer (see Figure 4.27). This successful copolymerisation led to the synthesis of 
branched p(PDMSMA-co-OEGMA-co-PDMSDMA) terpolymer architectures with 
varying compositions, Table 4.8. 
 
Figure 4.27 GPC chromatogram overlays of A) RI chromatograms and B) RALS chromatograms for 
linear p(OEGMA60) (black) and branched p(OEGMA15-co-PDMSDMA(55)0.95) (red). 
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Table 4.8  
1
H NMR and GPC data of all branched polymers synthesised via RAFT. 
 
When branched terpolymer architectures were targeted using PDMSDMA(12) (only 
PDMSMA(9) was used in this case due to obvious steric constraints), low dispersities 
were achieved, and no high molecular weight materials were obtained, suggesting 
that the branching had, again, been unsuccessful.  The use of the PDMS 
monofunctional monomer and bifunctional brancher of similar sizes (r = 9 and m = 
12) may be expected to lead to steric constraints that prevent branching.  When using 
the longer brancher, PDMSDMA(55), high molecular weight branched materials were 
obtained when the smaller monomer (PDMSMA(9)) was used, which appears to 
confirm this assumption.  Similar problems were evident when branched 
architectures of p(PDMSMA(57)-co-OEGMA) were targeted, even with the longer 
PDMSDMA(55) branchers. Again, having PDMS monomer and brancher of similar 
sizes (r = 57 and m = 55) appears to lead to steric hindrance. 
 
The GPC chromatograms of the different architectures synthesised using RAFT are 
presented in Figure 4.28. It can clearly be seen that only the combination of a small 
PDMS monomer (r = 9) and a long PDMS brancher (m = 55) leads to successful 
branching. The only architectures which display branching consist of 
p(PDMSMA(9)48-co-OEGMA12-co-PDMSDMA(55)0.95) and p(PDMSMA(9)30-co-
OEGMA30-co-PDMSDMA(55)0.95) as evidenced by the very high molecular weights 
and Ð values obtained.  
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In an attempt to obtain branched polymers using the long chain (PDMSMA(57)) 
monomer, the longer (PDMSDMA(55)) brancher was used. Unfortunately, after 
leaving this reaction for 30 days, a high enough conversion was not reached in order 
to obtain highly branched materials (see Figure 4.29).   
 
 
Figure 4.28 GPC chromatogram overlays of A) RI and B) RALS signals for linear 
p(PDMSMA(9)47-co-OEGMA12) (black) and branched equivalents with either PDMSDMA(12)0.95 (red) 
or PDMSDMA(55)0.95 (blue) and p(PDMSMA(57)20-co-OEGMA5-co-PDMSDMA(55)0.95) (green). GPC 
analysis C) RI and D) RALS for linear p(PDMSMA (9)30-co-OEGMA30) (black) and branched  
equivalents with either  PDMSDMA(12)0.95 (red) or PDMSDMA(55)0.95 (blue) and 
p(PDMSMA(57)20-co-OEGMA20-co-PDMSDMA(55)0.95) (green). 
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Figure 4.29  GPC chromatogram overlays of A) RI and B) RALS signals for linear p(PDMSMA(9)15-
co-PDMSMA(57)15-co-OEGMA30) (black) and  p(PDMSMA(9)24-co-PDMSMA(57)24-co-OEGMA12) 
(red) with their branched equivalents with PDMSDMA (55)0.95 (blue and green respectively). 
 
4.4.2.3 Solubility of Amphiphilic Copolymers and Terpolymers in SiO 
 
As the aim of these studies was to investigate the ability to solubilise a hydrophilic 
polymer within SiO and evaluate drug release from the resulting mixture, it was 
essential to investigate the solubility of the amphiphilic co- and terpolymers, both 
linear and branched, in SiO.  Table 4.9 summarises the materials tested for solubility 
in SiO and the results obtained. 
 
 
 
 
 
 
CHAPTER 4 
189 
 
Table 4.9  Solubility of the synthesised polymers in SiO (% v/v). 
 
The branched p(OEGMA15-co-PDMSDMA(55)0.95) had minimal SiO solubility (< 1 % 
v/v) and, as this contained the largest hydrophobic component possible through 
branching alone, co- and terpolymers of OEGMA with PDMSMA were clearly 
needed to increase solubility.   
 
All other polymers were soluble at 40-50 % (v/v) apart from when a 50/50 ratio of 
OEGMA:PDMSMA(9) was copolymerised which represents the smallest content of 
hydrophobic monomer. This success represents a major increase in solubility 
compared to less than 1 % (v/v) that had been seen without the incorporation of 
PDMSMA. 
 
4.4.2.4 Removal of CTA from Amphiphilic Co- and Terpolymers synthesised via 
RAFT 
 
As the amphiphilic copolymers were soluble in SiO at high levels, the removal of the 
RAFT chain end was required as the CTA-end group is known to be highly coloured 
and the solutions were a bright pink colour (Scheme 4.10A).  In some cases, gelation 
was also observed when the amphiphilic copolymers and linear homopolymers of 
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PDMSMA were stored, suggesting the presence of difunctionalised monomer 
impurities within the commercial PDMSMA.  The removal and recovery of  CPBD 
following RAFT polymerisations of PMMA has been reported by Perrier et al.60  
Excess AIBN was added to a solution of the purified polymer and subsequent AIBN 
thermal decomposition yields cyanoisopropyl radicals which react with the C=S 
bond of the thiocarbonyl-thio group.  This results in an intermediate radical which 
can either fragment back to the previous state or free the thiocarbonyl-thio moiety 
from the polymer chain-end.  The excess cyano-isopropyl radicals drive the 
equilibrium towards a radical chain end which is capped by additional cyano-
isopropyl groups.  It has been reported that too little AIBN under these conditions 
can lead to disproportionation and subsequent reactions between polymer chains.61  
The temperature and length of the reaction are important for the complete removal of 
the thiocarbonyl-thio end group and should follow the half-life time of the radical 
initiator used (in this case AIBN).   
 
Similar conditions to those previously reported were employed for the removal of 
CPBD from p(PDMSMA(9)48-co-OEGMA12).  The purified polymer was dissolved in 
toluene and a 20 molar excess of AIBN added to the solution which was degassed 
and heated to 80 °C for 150 minutes (the half-life time of AIBN in these conditions is 
80 minutes).  The polymer was isolated by precipitation into cold MeOH which 
afforded a white solution (Scheme 4.10 B).  
 
Scheme 4.10  Scheme of CPBD removal and pictures of p(PDMSMA(9)48-co-OEGMA12) synthesised 
via  RAFT polymerisation A: before and B: after reaction with AIBN. 
 
The colour change indicated removal of the CPBD and the recovered polymer was 
analysed by 1H NMR spectroscopy (Figure 4.30) which confirmed the CTA removal 
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as the peaks at 7.30, 7.38, and 7.93 ppm, characteristic of the dithiobenzoate moiety, 
were no longer present. 
 
Figure 4.30 
1
H NMR spectra (CDCl3, 400 MHz) of CPBD (red) and p(PDMSMA(9)48-co-OEGMA12) 
after CTA removal drug (black). 
 
4.5 CONCLUSION 
 
The initial strategy investigated within this Chapter involved the synthesis of 
copolymers of OEGMA and HEMA with branching via PDMSDMA. These 
terpolymers were to act as scaffolds for conjugation of atRA or Ibu via the HEMA 
component either to the monomer or after polymerisation. The synthesis of the 
amphiphilic branched terpolymer p(OEGMA-co-HEMA-co-PDMSDMA(9)) was 
successfully achieved and the copolymer was soluble in SiO at 20 % (v/v).  HEMA 
monomer was successfully functionalised with atRA and Ibu via Steglich 
esterifications; however, the ATRP of atRA-functionalised monomers failed due to 
retardation of the polymerisation by the antioxidant nature of atRA. A copolymer of 
p(IbuEMA-co-OEGMA) was successfully synthesised, however, when a branched 
structure was targeted, no appropriate solvent system could be found to solubilise all 
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the different components of the ATRP reaction and provide a controlled 
polymerisation.  Post-functionalisation of p(HEMA) was then attempted but was 
unsuccessful in the case of atRA and only yielded 14 % product in the case of Ibu 
after 4 days. 
 
Following the unsuccessful attempts to generate SiO-soluble polymer prodrugs, a 
focus on blends of SiO and amphiphilic polymers, as shown with the SiO blends 
containing PDMS-drug additives, was targeted. Branched architectures of 
p(OEGMA-co-PDMSDMA) were attempted via ATRP, but only the low molecular 
weight PDMSDMA branchers (Mn 395 and 1,275 gmol
-1) successfully led to 
branched architectures. This was initially considered to be a solubility issue when 
using of the longer PDMSDMA branchers, however, upon addition of THF to the 
ATRP polymerisation no improvement was observed. The solubility of the branched 
polymer architectures that had been successfully synthesised was investigated, but 
only low solubility within SiO was achieved (0.1 % v/v) even with p(OEGMA15-co-
PDMSDMA(12)0.95) which contains the largest lipophilic component. To improve the 
content of PDMS within these target polymers, a new series of co- and terpolymer 
architectures were developed which incorporated the monofunctional PDMSMA 
within the OEGMA chains.  Due to solubility issues of the catalytic system needed 
for ATRP, RAFT was employed and both linear and branched amphiphilic 
architectures were successfully synthesised which were highly soluble within SiO 
(40-50 % v/v).  Unfortunately due to time constraints the solubility and release of 
atRA and Ibu in these amphiphilic polymer/SiO blends were not conducted.   
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5.1 CONCLUSIONS 
 
The aim of this research was to investigate different methodologies to develop a 
sustained and controlled DDS to treat PVR via the use of a SiO tamponade acting as 
a drug reservoir.  This was investigated by modifying the chemistries of both the 
drug and the SiO.  The drugs chosen to be investigated throughout were atRA and 
Ibu.   
 
The cytotoxic limits of both drugs were determined via MTT, resazurin, phalloidin 
and BrdU assays on ARPE-19 cells.  The cytotoxic threshold was observed to be 
dependent on level of confluence and time of exposure.  When both pre- and post-
confluent cells were exposed to the drugs for 1 day the cytotoxic limit for atRA was 
determined to be 10-5 M, whilst the Ibu cytotoxic limit was higher and toxicity was 
observed at concentrations above 10-4 M.  Upon 7 days exposure, cytotoxicity in the 
case of post-confluent cells was observed at the same concentrations; however, for 
pre-confluent cells the toxic limit decreased by a factor of ten for both atRA and Ibu 
to concentrations above 10-6 M and 10-5 M respectively.  Subsequently, the cytotoxic 
limits determined were used to decide concentrations of drug used for loading and 
release studies.   
 
To achieve a prolonged release of approximately 6 weeks, the desired clinical 
treatment period for PVR, prodrugs were investigated and solubilised in SiO with the 
aim that cleavage of the ester linkages, which bonded the drugs to the pro-moiety, 
would control the release.  Initially a hydrophilic promoiety, PEO, was investigated 
and a number of prodrugs were successfully synthesised with various molecular 
weights and substitution number.  The cytotoxicity of these prodrugs was 
investigated and it was found that PEO did not affect the cytotoxicity limits 
previously established. The cleavage of the drug from PEO was successfully 
completed without degradation of the drug; however, these studies were carried out 
in harsh conditions not representative of in vivo conditions. Due to SiO being a 
lipophilic environment, prodrug solubility was known to be a considerable challenge, 
however, the attachment of a lipophilic drug the PEO chain-ends was expected to 
modify solubility.  Unfortunately this was not the case, and it was observed that the 
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drug concentrations that could be successfully achieved within SiO were not 
sufficient for a DDS to treat PVR. 
 
A change of pro-moiety to PDMS was investigated in an attempt to improve 
solubility to provide post-cleavage side products that were chemically very similar to 
the surrounding SiO tamponade. The synthesis of PDMS prodrugs with both drugs 
was successful; however, drug cleavage via degradation of the ester bond was not 
readily achieved. It was hypothesised that this was due to a 
hydrophilicity/hydrophobicity issue of the prodrugs within the cleavage conditions 
and the synthesis of a tripartite PDMS prodrug with a PEO spacer between drug and 
PDMS supported this view.   
 
Due to the unsuccessful cleavage of the PDMS prodrugs, they were then studied as 
additives to SiO to attempt to modify drug solubility and release.  Biological 
evaluation of the PDMS prodrugs blended at 10 % (v/v) into SiO indicated no 
cytotoxicity at this concentration. Different methodologies were tested to investigate 
drug solubility in SiO; a protocol from the literature was followed which involved 
extraction of drug from the oil followed by UV-Vis spectroscopy analysis.  While the 
solubility reported for atRA in SiO in the literature is 20 µg/mL, higher 
concentrations, in the order of 28 µg/mL, were measured when the same protocol 
was used.  It was observed that the calibration curve used for UV-Vis spectroscopic 
analysis was in the range of 0.5 x 10-4 M to 1 x 10-6 M, with the reported 20 µg/mL 
saturation concentration of atRA (0.6 x 10-4 M) being on the cusp of the maximum 
value; therefore, higher concentrations need extrapolation from the curve, leading to 
potential errors.  There were also issues with insufficient extraction of Ibu from SiO 
which was confirmed by 1H NMR spectroscopy of the SiO, however 1H NMR 
spectroscopy also has sensitivity limits at such low concentrations. The use of 
tritiated drugs allowed accurate solubility concentrations to be determined via liquid 
scintillation and a saturation concentration of atRA in SiO was established to be 20 
times higher than that reported in the literature. Overall an accurate method to 
measure solubility of atRA and Ibu in SiO has been established using radiolabelling 
techniques and a fundamental inaccuracy in the published literature has been 
identified.  
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The presence of PDMS-atRA in SiO had a positive effect on atRA solubility, 
possibly due to the affinity of attached drug to free drug in the blend.  PDMS-atRA 
also had a very positive effect on release, with the release period being independent 
of atRA starting concentration but dependant on the PDMS-atRA concentration in 
the blend.  Excitingly, a prolonged release of atRA from a SiO blend with PDMS-
atRA was observed for over 7 weeks.  Unfortunately, the presence of PDMS-Ibu in a 
SiO blend did not have any significant effect on Ibu solubility, nor did it affect the 
release rates of Ibu from SiO. 
 
Another strategy to develop a DDS for PVR that was investigated involved the 
synthesis of amphiphilic branched copolymers of OEGMA and HEMA with 
PDMSDMA. These polymers were to act as scaffolds for conjugation of atRA or Ibu 
via the HEMA component, by either pre-functionalisation of the monomer or post-
functionalisation of the polymer. HEMA monomer was successfully functionalised 
with atRA and Ibu, however, the ATRP of atRA-functionalised monomers failed due 
to retardation of the polymerisation by the antioxidant nature of atRA. A linear 
copolymer containing IbuEMA and OEGMA was successfully synthesised, however 
no appropriate solvent system could be found to solubilise all the different 
components of the ATRP reaction and provide a controlled polymerisation when a 
divinyl monomer, PDMSDMA, was added.  Post-functionalisation of p(HEMA) was 
then attempted but was inefficient for both drugs. 
 
Amphiphilic branched copolymers were studied as additives to SiO with the aim to 
investigate the improvement of drug solubility using the hydrophilic and hydrogen-
bonding environment (in this case OEGMA) within SiO. Branched architectures of 
p(OEGMA-co-PDMSDMA) were attempted via ATRP, but only the low molecular 
weight PDMSDMA branchers (Mn 395 and 1,275 gmol
-1) successfully led to 
branched architectures. The solubility of these branched polymer architectures was 
investigated, but only low solubility within SiO was achieved (0.1 % v/v) even with 
p(OEGMA15-co-PDMSDMA(12)0.95) which contains the largest lipophilic component. 
To improve the content of PDMS within these target polymers, a new series of co- 
and ter-polymer architectures were developed which incorporated the 
monofunctional PDMSMA within the OEGMA chains.  Due to solubility issues of 
the catalytic system needed for ATRP, RAFT was employed and both linear and 
CHAPTER 5 
201 
 
branched amphiphilic architectures were successfully synthesised which were highly 
soluble within SiO (40-50 % v/v).  Unfortunately, due to time constraints, studies of 
the solubility and release of atRA and Ibu in these amphiphilic polymer/SiO blends 
were not conducted.   
 
5.2 FUTURE WORK 
 
Further study into the cytotoxicity limits of the drugs could be carried out on ARPE-
19 cells to determine a more precise toxicity limit with smaller increments than the 
ones studied within this project.  The cell line chosen to evaluate the cytotoxic drug 
effects was ARPE-19, which is somewhat representative of RPE cells in vivo, 
however, there are many other cell types that the drug would come into contact with 
if the tamponade releasing DDS were to be used clinically.  In the future it would be 
vital to carry out cytotoxicity studies on other cell types present within the eye, 
particularly those in the retina and involved in PVR such as retinal glial cells, but 
also others that would contact the DDS such as corneal endothelium cells. The use of 
primary cells, which may, in certain aspects, behave more like those in vivo, should 
also be used to confirm the important findings. In vivo studies using animal models 
would be the next step in moving the DDS towards the clinic.   
 
Alternate linkers to ester bonds between drug and the pro-moiety of the pro-drug 
could be used.  Anhydride bonds may be a good alternative, as they are more 
sensitive to hydrolysis and cleavage would be expected to occur more readily.  
Investigations on cleavage could be carried out for all linkages in more biologically-
relevant conditions. 
 
An exciting prospect of distinguishing a starting concentration of atRA within a 10% 
PDMS-atRA in SiO (v/v) which may lead to the burst release being below the toxic 
range but also allow the sustained release to be above the therapeutic level for an 
antiproliferative effect, was determined to be possible.  Therefore, investigations into 
this starting concentration of atRA are required. 
 
Whilst the synthesis of the modified HEMA monomer, IbuEMA, was successful, it 
was the lack of a suitable solvent system, capable of solubilising the different 
components of the ATRP reaction, which restricted this strategy.  Later in the project 
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an alternate polymerisation method, RAFT, was utilised.  Polymerisation of branched 
architectures of IbuEMA may be possible via the RAFT mechanism. 
 
Finally, investigations into the synthesised amphiphilic branched copolymers which 
were successfully solubilised at a high concentrations (40-50 % v/v) within SiO 
could be conducted. An analogous approach to that described in PDMS-drug blends 
with respect to drug solubility and release may lead to options for further study.  
Biological evaluation of these polymers would also be crucial if they were to be used 
within a DDS for PVR. 
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6.1 CHARACTERISATION 
 
6.1.1 NMR Spectroscopy 
 
NMR spectra were recorded using a Bruker DPX-400 spectrometer operating at 400 
MHz for 1H NMR and 100 MHz for 13C NMR in CDCl3, D2O, EtOH-d6, DMSO-d6, 
1,4-Dioxane-d8 and Acetone-d6. 
 
6.1.2 Mass Spectrometry 
 
Chemical ionisation (CI) and electrospray (ES) mass spectrometry data was recorded 
in the Mass Spectrometry Laboratory at the University of Liverpool.  The CI-MS 
was obtained on an Agilent GCQTOF 7200 using methane CI gas.  ES-MS was 
analysed using a MicroMass LCT mass spectrometer using electron ionisation and 
direct infusion syringe pump sampling. 
 
6.1.3 Melting Point 
Melting points were measured on an Optimelt Automatic Melting Point System 
(Stanford Research Systems) with 90 mm × 1 mm sample tubes.  
 
6.1.4 High-Performance Liquid Chromatography (HPLC) 
All solvents were analytical grade and purchased from Fisher.  HPLC was run on a 
Dionex HPLC using an ODS 2 C18 column (100 mm x 4.6 mm i.d., 5 µm), sample 
size: 5 µL. The mobile phase consisted of 95 % ACN, 5 % MeOH and 0.6 % acetic 
acid. Elution peaks were monitored with a UV-Vis detector at 364 nm and 
subsequently analysed using Chromeleon v.6.8.software. 
 
6.1.5 UV-Vis Spectroscopy 
UV-Vis spectra were collected using a Thermo Fisher NanoDrop 2000c 
spectrophotometer, either with a quartz cuvette or directly with the nanodrop 
functionality of the equipment depending on the solvent used.  Data was analysed 
using the NanoDrop2000 software. 
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6.1.6 Rheometry 
All rheological measurements were carried out using a TA Instruments Rheolyst AR 
1000 N controlled-stress rheometer (TA Instruments, Elstree, United Kingdom). A 
40 mm diameter, 2° acrylic cone geometry was used.  Temperature control of the 
rheometer is achieved via a plate that utilises the Peltier effect to control the 
temperature of the sample within ±0.1 °C. Shear viscosity was calculated from the 
gradient of the plot of shear stress against shear rate. 
 
6.1.7 Scintillation Counter 
ProSafe+ scintillation cocktail (Meidian Biotechnologies Ltd.) was used as received. 
All radiation measurements were carried out using a liquid scintillation counter 
(Packard Tri-carb 3100TR; Isotech).  
 
Liquid scintillation counting relies upon the use of a scintillation cocktail which 
contain scintillators (materials which exhibit luminescence when excited by ionising 
radiation).  The solvent molecules absorb energy emitted from beta particles (see 
Chapter 3 Section 3.4.1) and transfer this energy until it is transferred to a scintillant.  
The scintillant then emits photons following the energy absorption which are 
detectable by the scintillation counter. 
 
6.1.8 Gel Permeation Chromatography (GPC) 
Triple detection GPC was performed to measure molecular weights and molecular 
weight distributions using Malvern Viscotek instruments.  One instrument was 
equipped with a GPCmax VE2001auto-sampler, two Viscotek D6000 columns (and a 
guard column) and a triple detector array TDA305 (refractive index, light scattering 
and viscometer) with a mobile phase of DMF containing 0.01 M lithium bromide at 
60 °C and a flow-rate of 1 mL min-1.  
 
The second instrument was equipped with a GPCmax VE2001 autosampler, two 
Viscotek T6000 columns (and a guard column), a refractive index (RI) detector 
VE3580 and a 270 Dual Detector (light scattering and viscometer) with a mobile 
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phase of THF containing 2 v/v % of trimethylamine at 35 °C with a flow rate of  1 
mL min-1.  
 
GPC determines molecular weight and molecular weight distributions by separating 
different polymeric chain length within a molecular weight distribution.  This is 
performed by the use of columns which contain porous beads with different pore 
sizes.  Larger polymeric materials cannot pass through the pores which results in a 
shorter path-length through the column and elute at earlier retention volumes.  
Whereas smaller polymeric materials pass through the porous beads so have a longer 
path-length through the column which results in later retention volumes.  The triple 
detection system then uses RI, differential viscometry and light scattering detectors 
to calculate the absolute molecular weight of the polymer. 
 
6.2 MATERIALS USED THROUGHOUT THE THESIS 
 
atRA was purchased from Xian Bosheng Biological Technology Co., Ltd. and used 
as received.  Ibu was purchased from Tokyo Chemical Industry UK Ltd. and used as 
received. SiO (technical grade, SiO1000 and SiO5000) was donated to the project by 
Fluron GmbH and used as received. All deuterated solvents were purchased from 
Aldrich apart from DMSO-d6 which was purchased from Goss Scientific.  All 
deuterated solvents were used as received except CDCl3 where 0.1 % TMS was 
added.  All solvents used were analytical grade and purchased from Fisher.  
Resazurin and (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
(MTT) were purchased from Sigma and used as received.  Alexa Fluor® 488 
Phalloidin (Phalloidin) was purchased from Invitrogen and used as received. 
 
6.3 CELL CULTURE 
 
All cell culture was carried out under strict aseptic conditions in a class II laminar 
flow biological safety cabinet. All the cells cultured were incubated at 37 °C with a 
5 % CO2 atmosphere unless stated otherwise.   
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6.3.1 Cell Source 
ARPE-19 cells are an established human cell line from a healthy 19 year old male 
donor which show many functional and characteristic properties of RPE cells in vivo.  
These cells were previously bought from American Type Culture Collection, 
Manassas, VA, USA, catalogue number CRL 2302, but were obtained from frozen 
stocks stored in-house for these experiments. 
 
6.3.2 Media Preparation 
 
The solutions used for media preparation throughout cell culture for this project are 
summarised in Table 6.1.  
Table 6.1 Solutions used to prepare culture media for ARPE-19 cells.  
 
 
Cells were cultured in a 1:1 (vol/vol) mixture of DMEM/F12 containing 1 % L-Glut , 
1 % Pen-Strep, 1 % Fungizone and supplemented with 10 % FCS. 
 
6.3.3 Cell Retrieval 
 
ARPE-19 cells were stored in cryovials under liquid nitrogen in complete media with 
10 % DMSO.  To retrieve the cells, a cryovial was placed in a water bath at 37 °C 
then emptied into a universal tube containing pre-warmed media (15 mL), therefore, 
diluting the amount of DMSO. This was split evenly into 3x T75 flasks each 
containing an additional 7 mL of fresh media.   
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6.3.4 Cell Culture Maintenance/Seeding 
 
Cells were fed twice weekly by replacing approximately 7 mL old media with 8 mL 
fresh medium, ensuring to examine cells using light microscopy to check for any 
abnormalities or preliminary infections. For these studies, cells were used between 
passages 8 and 24. 
 
Cell subculture was carried out at around 80 % confluence, which usually occurred 
after 1 week.  Culture medium, sterile Dulbecco’s calcium and magnesium free 
phosphate buffered saline catalogue number P1447 from Sigma-Aldrich (PBS) and 
Trypsin-EDTA containing 5 g porcine trypsin and 2 g ethylenediaminetetraacetic 
acid from Sigma-Aldrich catalogue number T4174 (Tryspin) were all pre-warmed to 
37 °C in a water bath.  All media was removed from the flask then rinsed briefly with 
PBS (5 mL) to remove any serum which would inhibit trypsin activity. Trypsin-
EDTA (5 mL) was added, and incubated at 37 °C for approximately 3 minutes until 
all the cells had lifted off the flask. Cells that were rounded but still attached were 
removed by gently agitating the flask. Media (5 mL) was added to inactivate and 
neutralise the trypsin reaction.  For subculture 2.5 mL of this cell suspension was 
placed in a fresh flask with 9 mL fresh culture media. To seed samples for 
experiments, the cell suspension was pipetted into a centrifuge tube and spun at 1200 
rpm/ 259 g for 5 minutes.  The supernatant was removed and the cell pellet 
resuspended in media (1 mL).   A haemocytometer was prepared by cleaning all 
surfaces with 70% ethanol and dried before the coverslip was centred.  20 µL of cell 
suspension was pipetted onto the top edge of the coverslip to allow the cells to enter 
the counting chamber.  After cells were counted calculations were made to determine 
the volumes needed to obtain the desired seeding density for experimental 
procedures. 
   
6.3.5 Cell Storage 
 
The surplus ARPE-19 cells were frozen and stored in liquid nitrogen until needed.  A 
cell pellet was obtained by following the procedure described in Section 6.2.4 then 
suspended in a solution of media with 10% DMSO.  The cell suspension was 
transferred into a cryovial and placed in a Nagene freezing container at -80 °C 
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overnight then transferred into liquid nitrogen dewars where they were stored until 
required.   
 
6.4 CHAPTER 2 
 
6.4.1 Extraction of atRA from Media 
 
0.3 mL of 1 M sodium acetate buffer (pH 4.0) was added to a culture medium and 
atRA solution (2 mL); samples were immediately vortex-mixed.  Acetonitrile (3.6 
mL) was added and samples centrifuged (5 minutes at 3,000 g and 4 ºC); 100 µL of 
the clear supernatant was transferred to an auto-sampler vial and HPLC mobile phase 
(900 µL) added. 
 
6.4.2 Cellular Assays 
 
Multiple assays were carried out on ARPE-19 cells to study toxicity and 
antiproliferative effects of different drug concentrations.  8,000 cells/well were 
seeded in a 96 well tissue culture plate and left for 1 or 7 days to adhere to the plate 
and generate a cell monolayer.  The 7 day samples were fed once within the week by 
replacing 150 µL old medium with 180 µL fresh culture medium.  After the 
predetermined time period, the media was aspirated from all wells and replaced with 
spiked media (either 10-3 M to 10-10 M atRA, 10-3 M to 10-10 M Ibu or 1 – 20 % 
DMSO) then incubated for 1 to 7 days. Following this cell set-up the following 
assays could be performed. 
 
6.4.2.1 MTT Assay  
 
MTT was dissolved in PBS at 5 mg/mL, sterilised by filtration and stored at -20 °C. 
Stock MTT solution (10 L per 100 L medium) was added to wells of the assay 
apart from control wells of media alone and cells with media, plates were incubated 
at 37 C for 4 hours. Acidified isopropanol (100 l of 0.04 M HCl in isopropanol) 
was added to all wells and mixed thoroughly to dissolve the formazan crystals.  After 
15 minutes of further incubation cells plates were read on a Quant 
spectrophotometer (Measured = 570 nm; Reference = 690 nm).  The amount of 
absorbance is proportional to the mitochondrial activity of the cells; therefore, 
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toxicity can be deduced.  All values were normalised to control wells on each plate 
which contained cells and culture medium.   
 
6.4.2.2 Resazurin Assay 
 
Resazurin was dissolved in PBS at 0.1 mg/mL and filtered to sterilize, stored at 4 °C 
in the dark. Stock resazurin solution (10 L per 100 L medium) was added to wells 
of the assay apart from control wells, plates were incubated at 37 C for 4 hours. 
Media was removed and put in black 96-well plastic plates; resorufin fluorescence 
was read using a Biotek FLx800 spetrofluorometer (Excitation = 530 nm; Emission = 
590 nm).  All values were normalised to control wells on each plate which contained 
culture medium from cells. 
 
6.4.2.3 Detecting Cell Morphology 
 
In a 24 well tissue culture plate, cells were seeded at 25,000 cells/well then the same 
protocol as in Section 6.4.2 was followed.  After incubation the media was discarded 
and the cells washed with PBS (500 µL) then fixed for 10 minutes in 10 % neutral 
buffered formalin (NBF; 10 % formalin, approximately 4 % formaldehyde).  NBF 
was discarded and the cells washed again with PBS.  A phalloidin solution was used 
to stain the F-actin of the cytoskeleton of the cell.  A phalloidin solution was 
produced at 1 mg powder in 1.5 mL MeOH according to manufacturer’s instruction.  
The solution was then diluted 1 in 100 (in fresh PBS) and 75 µL was placed in each 
well followed by 30 minutes of incubation at 4 °C.  Phalloidin solution was removed 
and the cells washed with PBS.   
 
4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI, purchased from Invitrogen) 
was used to stain the nuclei of the cell.  A stock solution of DAPI was made at 
1:1,000 with PBS, then further diluted to a working solution of 1:10 PBS, 75 µL was 
placed in each well and incubated for 10 minutes at 4 °C.  Cells were washed with 
PBS and placed under 500 µL PBS. 
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6.4.2.4 Cell Proliferation/Cell Counting 
Table 6.2 Solutions required for BrdU incorporation. 
 
Approximately 25,000 cells/well were seeded in a 24 well tissue culture plate and 
then the same protocol as Section 6.4.2 was followed.  After incubation the media 
was removed and cells washed (3xPBS, 200 µL; 2 minutes/wash).  This wash step 
was repeated after each incubation unless otherwise stated.  BrdU (200 µL) was 
placed on cells and incubated at 37 °C for 4 hours.  Cells were fixed for 10 minutes 
in 10% NBF then Triton-X (200µL) was added to cells followed by 15 minutes 
incubation at 4 °C. HCl (500 µL) was added to the cells and incubated for 30 minutes 
at 37 °C then washed 5xPBS (200 µL).  The following steps were carried out on an 
orbital shaker in the dark at ambient temperature; again wash steps were carried out 
after each incubation period unless otherwise stated.  Goat serum (200 µL) was 
added and incubated for 30 minutes, removed without washing, primary anti-body 
solution (200 µL) added and left for 2 hours.  This was removed and the secondary 
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antibody solution (200 µL) added and incubated for 1 hour.  Finally Hoechst (200 
µL) was added and incubated for 30 minutes followed by a final wash.  These 
samples were then stored under PBS (500 µL) in the dark at 4 °C for up to 7 days.  
 
6.5 CHAPTER 3 
 
6.5.1 Materials 
Sodium sulphate (Na2SO4), sodium chloride (NaCl), sodium hydrogen sulphate 
(NaHSO4), magnesium sulphate (MgSO4), sodium hydrogen carbonate (NaHCO3), 
potassium hydroxide (1 M) (KOH), sodium hydroxide (1 M) (NaOH) and 
hydrochloric acid (1 M) (HCl) were purchased from Fischer and used as received. 
Benzoic Acid (99.5 %), 1,1-carbonyl diimidazole (>97 %) (CDI), 4-(dimethylamino) 
pyridine (>99 %) (DMAP), N,N’ – dicyclohexylcarbodiimide (>99 %) (DCC), 
poly(ethylene glycol) methyl ether (average Mn 750, 2,000 and 5,000 gmol
-1) (Me-
PEO), poly(ethylene glycol) (average Mn 600, 1,000 and 2,000 gmol
-1), 
bis(hydroxyalkyl) terminated poly(dimethylsiloxane) (average Mn 4,700 gmol
-1), 
bis(3-aminopropyl) terminated poly(dimethyl siloxane) (average Mn 3,000 gmol
-1) 
and succinic anhydride (97%) were purchased from Sigma Aldrich and used as 
received. All solvents used were of analytical standard, obtained from Fischer and 
used as received.  
 
6.5.2 PEO Prodrug Synthesis 
 
6.5.2.1 General CDI Synthesis of Esters  
 
Dry toluene (50 mL) was added to a 100 mL round-bottom flask containing a 
magnetic stirrer bar and fitted with a reflux condenser and N2 inlet.  CDI (1.459 g, 9 
mmol) and either benzoic acid or atRA (10 mmol) were added and the mixture 
heated to 60 C, purged with N2 and stirred for 30 minutes.  Alcohol either butanol or 
PEO (18 mmol) was added and the reaction mixture was stirred for a further 3 hours. 
The reaction mixture was then concentrated in vacuo and the remaining oil dissolved 
in DCM (5 mL) and washed three times with water (3x10 mL) and once with brine 
(10 mL).  The solution was dried over Na2SO4, filtered and concentrated in vacuo to 
give the final product.   
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6.5.2.2 CDI Synthesis of PEO-atRA with Catalyst 
 
Dry Toluene (7.5 mL) was added to a 100 mL round-bottom flask containing a 
magnetic stirrer bar and fitted with a reflux condenser and N2 inlet.  CDI (0.486 g, 3 
mmol) and atRA (1 g, 3.33 mmol) were added and the mixture heated to 60 C, 
purged with N2 and stirred for 30 minutes.  PEO
 (Mn 750 gmol
-1
,  0.75 g, 1 mmol) 
and p-toluenesulfonic acid (0.19 g, 1 mmol) were added and the reaction mixture was 
stirred for a further 3 hours. The reaction was followed by TLC. The reaction 
mixture was concentrated in vacuo and the remaining oil dissolved in DCM (5 mL) 
and washed three times with water (3x10 mL) and once with brine (10 mL).  The 
final solution was dried over Na2SO4, filtered and concentrated in vacuo.  
 
6.5.2.3 Synthesis of PEO Prodrugs via a Steglich Esterification 
 
PEO* (10 mmol OH) and DCM (20 mL) were added to a 50 mL round-bottom flask 
containing a magnetic stirrer bar and fitted with a N2 inlet.  12 mmol of either atRA 
(0.33 g) or Ibu (0.247 g), along with DMAP (0.2 g, 1.67 mmol) were dissolved in 
degassed DCM (10 mL), then added to the mixture.  DCC (2.75 g, 13 mmol) was 
dissolved in DCM (5 mL) then added dropwise to start the reaction under N2.  The 
mixture was stirred at ambient temperature for 22 hours for Ibu and up to 4 days for 
atRA in the dark. The DCU precipitate was removed by filtration and the solution 
was concentrated in vacuo. The resulting ester was isolated by precipitation from the 
minimum amount of THF into cold petroleum ether; yields above 50 % and above 90 
% were observed for atRA and Ibu respectively. 
PEO*: Me-PEO Mn 750, 2,500 and 5,000 gmol
-1 and PEO Mn 600, 1,000, 2,000 
gmol-1. 
PEO prodrugs were analysed by 1H NMR. 1H NMR (400 MHz, CDCl3):  
PEO-atRA: d 7.01 (dod, 1H, CH-CH=CH), 6.31 (m, 1H×2, C-CH=CH and C=CH-
C(CH3)), 6.15 (m, 1H×2, C=CH-C(CH3)=CH-CH, 5.80 (s, 1H, C(CH3)=CH-
C(O)O), 4.27 (m, 2H, O-CH2-CH2-OCO), 3.73 (q, 2H, O-CH2-CH2),  3.64 (t, 2H×3, 
CH2-O-CH2-CH2-O), 3.56 (t, 2H, CH2-CH2-O), 3.38 (s, 3H O-CH3), 2.35 (s, 2H, CH-
C(CH3)=CH)  2.02 (m, 1Hx2, CH-CH-C(CH3)=C), 1.72 (s, 3H, CH-C(CH3)=C), 
1.62 (dod, 2H, CH2-CH2-CH2), 1.47 (d, 2H, CH2-CH2-C(CH3)2), 1.03 (s, 3H×2, CH2-
C(CH3)2-C). 
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PEO-Ibu: d 7.21/7.10 (d, 2H×2, CH from aromatic ring), 4.21 (m, 2H×2, O-CH2-
CH2-OCO), 3.82 (q, 1H×2, OC(O)-CH(CH3)-C), 3.64 (t, 2H×3, O-CH2-CH2-OCO), 
3.38 (s,3H O-CH3), 2.44 (d, 2H×2, C-CH2-CH(CH3)2), 1.84 (m, 1H×2, C-CH2-
CH(CH3)2), 1.49 (d, 3H×2, OC(O)-CH(CH3)-C), 0.89 (d, 6H×2, C-CH2-CH(CH3)2). 
atRA-PEO-atRA: d 7.01 (dod, 1Hx2, CH-CH=CH), 6.31 (m, 1H×4, C-CH=CH and 
C=CH-C(CH3)), 6.15 (m, 1H×4, C=CH-C(CH3)=CH-CH, 5.80 (s, 1Hx2, 
C(CH3)=CH-C(O)O), 4.27 (m, 2H, O-CH2-CH2-OCO), 3.73 (q, 2H, O-CH2-CH2),  
3.64 (t, 2H×3, CH2-O-CH2-CH2-O), 3.56 (t, 2H, CH2-CH2-O), 2.35 (s, 2Hx2, CH-
C(CH3)=CH)  2.02 (m, 1Hx4, CH-CH-C(CH3)=C), 1.72 (s, 3Hx2, CH-C(CH3)=C), 
1.62 (dod, 2Hx2, CH2-CH2-CH2), 1.47 (d, 2Hx2, CH2-CH2-C(CH3)2), 1.03 (s, 3H×4, 
CH2-C(CH3)2-C). 
Ibu-PEO-Ibu: d 7.21/7.10 (d, 2H×2, CH from aromatic ring), 4.21 (m, 2H×2, O-
CH2-CH2-OCO), 3.82 (q, 1H×2, OC(O)-CH(CH3)-C), 3.64 (t, 2H×3, O-CH2-CH2-
OCO), 2.44 (d, 2H×2, C-CH2-CH(CH3)2), 1.84 (m, 1H×2, C-CH2-CH(CH3)2), 1.49 
(d, 3H×2, OC(O)-CH(CH3)-C), 0.89 (d, 6H×2, C-CH2-CH(CH3)2). 
 
6.5.2.4 Analysis of PEO Esterification by External NMR Reference 
 
1H NMR samples of atRA and Ibu were prepared at a concentration of 10 mg/mL in 
a 2 mg/mL solution of DMSO-d6 and anisole.  Integrals were calibrated against 
anisole (7.23-7.35 ppm; aromatic CH next to C-O). Upon integration of the retinoates 
signal at 0.9-1.1 ppm (s, 3H×4, CH2-C(CH3)2-C) and the Ibu ester signal at 0.89 ppm 
(d, 3H×2, C-CH2-CH(CH3)2), the concentration of drug in ester was calculated. 
Concentration of drug in ester = (Integral of CH3 ester x concentration of free drug 
NMR) / Integral of CH3 in free drug. 
 
6.5.3 Cleavage of PEO Prodrugs 
 
In an NMR tube, 1 mL sample of PEO prodrug (0.20 mmol) in either D2O, dioxane-
d8 or acetone-d6 was prepared.  NaOD or DCl was added at 0.01 to 0.2 equivalents 
per ester function.  The mixture was incubated at 37 C for up 7 days.  1H NMR 
spectroscopy was used to follow cleavage progress. 
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6.5.4 Solubility of Drugs in SiO 
 
6.5.4.1 atRA  
 
A saturated solution of atRA (10-12 mg) in SiO (30 mL) was prepared and stirred 
gently in the dark, in a sealed flask, for approximately 2 weeks.  Samples were taken 
at different time points over the 2 week period, filtered using a syringe pump (4 
mL/h) and 0.45 µm PTFE filters.  The drug was extracted from the SiO three times 
with acetone (1/2 v/v).  The acetone layers were combined, the solvent was 
evaporated and the remaining solid was dried at ambient temperature.  2 mL of 
DMSO/H2O (8/2) were used to solubilise the remaining solid.  The samples were 
then analysed by UV-Vis.  A standard curve previously determined for atRA (see 
Figure 6.1) was used to determine concentration values. 
 
Figure 6.1 Calibration curve of atRA in DMSO/H2O 8:2 from 5 x 10
-5
 – 5 x 10
-7 
M. 
 
6.5.4.2 Ibu 
 
A saturated solution of Ibu (60 mg) in SiO (30 mL) was prepared and stirred gently 
in a sealed flask for approximately 3 – 4 days.  Samples were filtered using a syringe 
pump (4 mL/h) and 0.45 µm PTFE filters.  The drug was extracted from the SiO 
three times with acetone (1/2 v/v).  The acetone layers were combined, the solvent 
was evaporated and the remaining solid was dried at ambient temperature.   
 
UV-Vis: 2 mL of PBS were used to solubilise the remaining solid.  A standard curve 
previously determined for Ibu (see Figure 6.2) was used to determine concentration 
values. 
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Figure 6.2 Calibration curve of Ibu in from 5 x 10
-3
 – 1 x 10
-4 
M. 
 
1H NMR: 0.2 mL of filtered oil was solubilised in 0.7 mL of CDCl3 containing 
anisole (2 mg/mL), in a sample vial, then vortexed for 20 seconds.  The mixture was 
then left to stand for approximately 30 minutes before being pipetted into a NMR 
tube.  
 
6.5.5 Release of PEO-Ibu Prodrugs into Media 
 
1 mL samples of oil saturated with Ibu ester (PEO-Ibu or Ibu-PEO-Ibu) was placed 
in several wells in a 24 well plate over 0.5 mL media.  0.2 mL of oil were  taken 
daily from different wells using a 1mL syringe and analysed by 1H NMR 
spectroscopy in CDCl3 following the same protocol as in Section 6.5.2.4.  Media was 
either left throughout the experiment or changed daily using a 1 mL syringe and 26 
gauge needle as this was narrow enough not to take up any oil. 
 
6.5.6 PDMS Prodrug Synthesis 
 
6.5.6.1 atRA-PDMS-atRA 
 
Bis(hydroxyalkyl) terminated poly(dimethylsiloxane), (Mn = 4,700 gmol
-1, 4 g, 1.7 
mmol OH) was dissolved in degased DCM (10 mL), followed by the addition of a 
degased solution of atRA (0.6 g, 2 mmol) and DMAP (64 mg, 0.5 mmol) in DCM 
(30 mL). Finally 10 mL of a degased solution of DCC (0.41 g, 2 mmol) in DCM was 
added. This mixture was stirred at room temperature, under argon (Ar), in the dark, 
for 4 days. After filtration of the residual DCU, the solvent was eliminated under 
reduced pressure. The residual yellow oil was washed three times with cold methanol 
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then dried in vacuo. The purified yellow oil was filtered through a 0.45 µm PTFE 
filter, then stored under Ar in dark conditions at ambient temperature. atRA-PDMS-
atRA was analyzed by 1H NMR and FTIR. 1H NMR (400 MHz, CDCl3): d 7.00 (q, 
1H×2, =CH-CH=CH), 6.29-6.11 (4H×2, =CH-C-CH3, -CH=C-CH3 and C-CH=CH-
C-CH3), 5.82/5.69 (s, 1H×2, -OCOCH=C), 4.26 (t, 2H×2, O-CH2-CH2-OCO), 3.66 
(t, 2H×2, O-CH2-CH2-OCO), 3.44 (t, 2H×2, Si-CH2-CH2-CH2-O), 2.35 (s, 3H×2, 
C(CH3)=CH-C(O)O), 2.02 (t, 2H×2, CH2-C(CH3)=C), 2.00 (s, 3H×2, C(CH3)=CH-
CH=CH), 1.71 (s, 3H×2, CH2-C(CH3)=C), 1.61 (m, 2H×2, 2H×2, Si-CH2-CH2-CH2-
O, CH2-CH2-CH2-C(CH3)=C), 1.47 (m, 2H×2, CH2-CH2-CH2-C(CH3)=C), 1.02 (s, 
6H×2, CH2-C(CH3)2-C), 0.54 (qt, 2H×2, Si-CH2-CH2-CH2-O), 0.07 (s, 6H×n, 
Si(CH3)2-O). IR: 1,738 cm
-1 υ(C=O) in ester. 
 
6.5.6.2 Ibu-PDMS-Ibu 
 
Bis(hydroxyalkyl) terminated Poly(dimethylsiloxane)(Mn = 4,700 gmol
-1, 4 g, 1.7 
mmol OH), ibuprofen (0.4 g, 1.9 mmol) and DMAP (30 mg, 0.24 mmol) were 
dissolved in DCM (15 mL), followed by addition of a 10 mL DCC (0.4 g, 1.9 mmol) 
solution in DCM. This mixture was stirred at room temperature for 24 hours. After 
filtration of the residual DCU, the solvent was eliminated under reduced pressure. 
The residual colourless oil was washed two times with room temperature methanol 
then dried in vacuo. The purified oil was filtered through a 0.45 µm PTFE filter. Ibu-
PDMS-Ibu was analyzed by 1H NMR and FTIR. 1H NMR (400 MHz, CDCl3): d 
7.21/7.08 (d, 4H×2, CH from aromatic ring), 4.21 (m, 2H×2, O-CH2-CH2-OCO), 
3.73 (q, 1H×2, OC(O)-CH(CH3)-C), 3.57 (t, 2H×2, O-CH2-CH2-OCO), 3.35 (t, 
2H×2, Si-CH2-CH2-CH2-O), 2.43 (d, 2H×2, C-CH2-CH(CH3)2), 1.83 (m, 1H×2, C-
CH2-CH(CH3)2), 1.57 (m, 2H×2, Si-CH2-CH2-CH2-O), 1.49 (d, 3H×2, OC(O)-
CH(CH3)-C), 0.89 (d, 6H×2, C-CH2-CH(CH3)2), 0.50 (t, 2H×2, Si-CH2-CH2-CH2-
O), 0.07 (s, 6H×n, Si(CH3)2-O). IR: 1,738 cm
-1 υ(C=O) in ester. 
 
6.5.6.3 Anhydride Route 
 
6.5.6.3.1 Preparation of atRA Anhydride 
 
atRA (2 g, 66 mmol) and DCC (1 g, 34 mmol) were dissolved in DCM (20 mL) and 
the reaction mixture was gently stirred at ambient temperature in the dark for 2 days.  
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After filtration of the mixture and removal of the DCM in vacuo, the final product 
was isolated with a 67 % yield and analysed by 1H and 13C NMR spectroscopy. 1H 
NMR (400 MHz, CDCl3): d 7.00 (q, 1H×2, =CH-CH=CH), 6.29-6.11 (4H×2, =CH-
C-CH3, -CH=C-CH3 and C-CH=CH-C-CH3), 5.82/5.69 (s, 1H×2, -OCOCH=C), 2.35 
(s, 3H×2, C(CH3)=CH-C(O)O), 2.02 (t, 2H×2, CH2-C(CH3)=C), 2.00 (s, 3H×2, 
C(CH3)=CH-CH=CH), 1.71 (s, 3H×2, CH2-C(CH3)=C), 1.61 (m, 2H×2, 2H×2, CH2-
CH2-CH2-O, CH2-CH2-CH2-C(CH3)=C), 1.47 (m, 2H×2, CH2-CH2-CH2-C(CH3)=C), 
1.02 (s, 6H×2, CH2-C(CH3)2-C).  
13C NMR (100 MHz, CDCl3): d 163 (C=O), 156 
(CH2-C(CH3)=C), 141 (-C-C(CH)=C-), 138 (C=C(H)-C-), 137 (CH-C(CH3)=C-), 
135 (CH=C(H)-C-), 132 (C-C(CH3)=C-), 130 (C=CH-C-, C), 118 (C=CH-C(O)), 40 
(C-CH2-C), 35 (C-C(CH3)2), 34 (C-CH2-C=C), 29 (2 x CH3 off ring), 22 (CH3 off 
ring), 20 (CH2-CH2-CH2), 14 (CH3 chain), 13 (CH3 chain near C=O). 
 
6.5.6.3.2 Preparation of atRA-PDMS-atRA 
 
Poly(dimethylsiloxane) bis(hydroxyalkyl) terminated (Mn = 4,700 gmol
-1, 3 g, 1.2 
mmol OH) was dissolved in degased DCM (10 mL), followed by the addition of a 
degased solution of atRA anhydride synthesised in the previous step (1.06 g, 1.8 
mmol) and DMAP (37 mg, 0.25 mmol) in DCM:Pyridine (30 mL 1:1 v/v). This 
mixture was stirred at room temperature, under Ar and in the dark for 4 days. After 
this time approximately 2 mL of water was added to quench the excess anhydride 
and the mixture was stirred for a further 2 hours.  The product was purified by 
diluting the mixture with DCM (150 mL) and washing it with 1 M NaHSO4 (3 x 150 
mL), 1 M NaHCO3 then brine (2 x 150 mL).  The organic layer was dried over 
MgSO4 and the solvent was removed in vacuo.  The remaining oil was washed with 
MeOH (5 x 30 mL) to remove unattached atRA then dried in vacuo. The purified 
yellow oil was filtered through a 0.45 µm PTFE filter, then stored under Ar in dark 
conditions. atRA-PDMS-atRA was analyzed by 1H NMR. 1H NMR (400 MHz, 
CDCl3): d 7.00 (q, 1H×2, =CH-CH=CH), 6.29-6.11 (4H×2, =CH-C-CH3, -CH=C-
CH3 and C-CH=CH-C-CH3), 5.82/5.69 (s, 1H×2, -OCOCH=C), 4.26 (t, 2H×2, O-
CH2-CH2-OCO), 3.66 (t, 2H×2, O-CH2-CH2-OCO), 3.44 (t, 2H×2, Si-CH2-CH2-
CH2-O), 2.35 (s, 3H×2, C(CH3)=CH-C(O)O), 2.02 (t, 2H×2, CH2-C(CH3)=C), 2.00 
(s, 3H×2, C(CH3)=CH-CH=CH), 1.71 (s, 3H×2, CH2-C(CH3)=C), 1.61 (m, 2H×2, 
2H×2, Si-CH2-CH2-CH2-O, CH2-CH2-CH2-C(CH3)=C), 1.47 (m, 2H×2, CH2-CH2-
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CH2-C(CH3)=C), 1.02 (s, 6H×2, CH2-C(CH3)2-C), 0.54 (qt, 2H×2, Si-CH2-CH2-CH2-
O), 0.07 (s, 6H×n, Si(CH3)2-O). 
 
6.5.7 Cleavage of PDMS Prodrugs 
 
6.5.7.1 Basic Conditions 
 
PDMS-drug (70 mg) was dissolved in THF (2.3 mL). 0.2 mL of an aqueous solution 
of either KOH, NaOH or DMAP, containing either 2 or 5 equivalents per ester 
function was added. The solution was stirred at 40°C for up to 13 days. Then the 
reaction was stopped, DCM was added and the solution was washed with distilled 
water until neutral pH was obtained. The organic phase was recovered, dried over 
Na2SO4 and filtered. The solvent was eliminated under reduced pressure, and the 
recovered product was dried for few hours in a vacuum oven (40ºC), then analysed 
by 1H NMR spectroscopy using CDCl3.  
 
6.5.7.2 Acidic Conditions 
 
PDMS-drug (70 mg) was dissolved in either THF or dioxane (2.5 mL). The 
appropriate volume of a 1M HCl solution was added (5 to 10 equivalents per ester 
function). The solution was stirred at either 40°C or 60ºC in an oil bath, for up to 24 
hours. Then the reaction was stopped, DCM was added and the solution was washed 
with distilled water until neutral pH was obtained. The organic phase was recovered, 
dried over Na2SO4 and filtered. The solvent was eliminated under reduced pressure, 
and the recovered product was dried for few hours in a vacuum oven (40ºC), then 
analyzed by 1H NMR spectroscopy using CDCl3. 
 
6.5.8 Synthesis of PDMS-PEO Prodrug 
 
HOOC-PDMS-COOH. Poly(dimethylsiloxane) bis(3-aminopropyl) terminated 
(H2N-PDMS-NH2) (3,000 gmol
-1, 1 g, 0.33 mmol) and succinic anhydride (84.5 mg, 
0.84 mmol, 1.2 eq. per NH2 function) were solubilized in DCM (10 mL). The 
reaction mixture was stirred at room temperature for 2 hours. HOOC-PDMS-COOH 
was obtained with 100% conversion as confirmed by 1H NMR analysis (CDCl3) of 
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the crude product. The crude solution was used straightaway without any treatment 
in the next step.  
 
HO-PEO-PDMS-PEO-OH. DCC (137.5 mg, 0.66 mmol) was added to the HOOC-
PDMS-COOH solution before it was added dropwise to a solution of PEO (600 
gmol-1, 8 g, 13.2 mmol, 20 eq. per COOH function) and DMAP (10 mg, 0.082 mmol, 
1/8 eq) in DCM (20 mL). Once the slow addition was completed, the reaction was 
left to stir at room temperature. After 2 days, the DCU by-product was removed by 
filtration, the solvent was removed under vacuum and a white oil was recovered. The 
excess PEO was removed by extraction using diethyl ether and water. The extraction 
was repeated 3 times, then the organic phase was dried with Na2SO4, filtered, the 
solvent was then evaporated and the recovered product was dried under vacuum at 
40°C for few hours. 1H NMR (CDCl3) confirmed the obtaining of the HO-PEO-
PDMS-PEO-OH with 75% conversion and 18% yield.  
 
Ibu-PEG-PDMS-PEG-Ibu. HO-PEO-PDMS-PEO-OH (5,350 gmol-1 and 1.5 OH 
function per chain, determined from 1H NMR analysis) (0.12 g, 0.018 mmol) was 
solubilised in DCM (2 mL). Both Ibu (9 mg, 0.043 mmol, 1.2 eq per OH function) 
and DMAP (2 mg, 0.016 mmol) were added to the solution that was then stirred at 
room temperature. A solution of DCC (9 mg, 0.043 mmol) in DCM (1 mL) was 
added dropwise, and the reaction mixture was left to stir at room temperature. After 
20 hours, the DCU by-product was removed by filtration, the solvent was removed 
under vacuum and a white solid was recovered. The obtained product was purified 
by extraction using DCM and water. The extraction was repeated 3 times, then the 
organic phase was dried with Na2SO4, filtered, the solvent was then evaporated and 
the recovered product was dried under vacuum at 40°C for few hours. 1H NMR 
(CDCl3) confirmed the obtaining of the Ibu-PEO-PDMS-PEO-Ibu final product with 
100% conversion and 40% yield. 
 
6.5.9 Cleavage of PDMS-PEO Prodrug 
 
PDMS-PEG-Ibu (50 mg) was dissolved in dioxane-d8 (1 mL).  0.2 mL of 
concentrated HCl were added to the solution which was then left to stir at 80 °C for 
16 hours. 1H NMR of the crude solution in dioxane-d8 confirmed the complete 
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cleavage of both ester functions (between PDMS and PEO, and between PEO and 
Ibu). DCM was added and the solution was washed with distilled water until neutral 
pH was obtained. The organic phase was recovered, dried over Na2SO4 and filtered.  
The solvent was eliminated under reduced pressure, and the recovered product dried 
for a few hours in a vacuum oven (40 °C), then analysed by 1H NMR using CDCl3, 
which evidenced the complete disappearance of PEO upon washings. 
 
6.5.10 PDMS-atRA/PDMS-Ibu SiO Blends 
 
Blends of PDMS-atRA or PDMS-Ibu and SiO1000 at 0.1, 1, 5 and 10% vol content of 
PDMS-drug were prepared and mixed in a sealed container (in the dark for PDMS-
atRA blends) for approximately 4 days.  Saturated solutions of either atRA or Ibu in 
their respective blends, i.e. PDMS-atRA/SiO1000 and PDMS-Ibu/SiO1000, were then 
prepared as described below, using radiolabeled atRA and Ibu. 
 
6.5.11 Radiolabeled Drugs 
 
6.5.11.1 atRA Solubility in SiO  
 
Saturated solutions of atRA in SiO were prepared by mixing atRA (11.6 mg) with 
tritiated atRA (10 µCi) in EtOH (2 mL); after evaporation of the solvent  at ambient 
temperature, SiO1000 (5 mL) was added to the residual solid and the solution was 
stirred for 2 weeks.  The sample was filtered using a syringe pump (4 mL/h) and 0.45 
µm PTFE filters. Samples of the filtered oils (20 µL) were then solubilised in diethyl 
ether (8 mL) before scintillation cocktail (10 mL) was added. Radiation was then 
measured on the scintillation counter and saturation concentrations were determined.   
 
Amounts of atRA added to the samples were altered depending on targeted final 
concentrations .  Solutions of 100 µg/mL: atRA (0.5 mg) and tritiated atRA (3 µCi) 
were mixed in EtOH (2 mL) and the same protocol was followed.  Solutions of 20 
µg/mL: atRA (0.1 mg) and tritiated atRA (2 µCi) were mixed in EtOH (2 mL) and 
the same procedure was carried out. 
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6.5.11.2 Ibu Solubility in SiO 
Saturated solutions of Ibu in SiO were prepared by mixing Ibu (32 mg) with tritiated 
Ibu (10 µCi) in EtOH (2 mL); after evaporation of the solvent at ambient 
temperature, SiO1000 (5 mL) was added to the residual solid and the solution was 
stirred for 1 week.  The sample was filtered using a syringe pump (4 mL/h) and 0.45 
µm PTFE filters. Samples of the filtered oils (20 µL) were then solubilised in diethyl 
ether (8 mL) before scintillation cocktail (10 mL) was added. Radiation was then 
measured on the scintillation counter and saturation concentrations were determined.  
 
Solutions of 100 µg/mL: Ibu (0.5 mg) and tritiated Ibu (3 µCi) were mixed in EtOH 
(2 mL) and the same protocol was followed.  Solutions of 20 µg/mL: Ibu (0.1 mg) 
and tritiated Ibu (2 µCi) were mixed in EtOH (2 mL) and the same procedure was 
carried out. 
 
6.5.11.3 atRA/Ibu Solubility in PDMS-atRA/PDMS-Ibu SiO Blends 
The same protocol as in the previous sections (6.5.11.1 and 6.5.11.2) was followed 
for the preparation of both atRA and Ibu solutions in their respective blends, i.e. 
PDMS-atRA/SiO1000 and PDMS-Ibu/SiO1000 (0.1, 1, 5 and 10% vol content of 
PDMS-drug). Saturated solutions were prepared as well as solutions with alternate 
concentrations.  
 
6.5.11.4 Release of Drug from SiO and SiO Blends into Media 
 
1 mL of SiO or blend with determined concentration of drug was placed in a 24 well 
plate over 0.5 mL media.  Samples of media (0.5 mL) were taken and replaced daily 
using a 1 mL syringe and 26 gauge needle. Media (250 µL) was mixed with 
scintillation cocktail (10 mL) and analysed by liquid scintillation counting.   
 
6.6 CHAPTER 4 
 
6.6.1 Materials 
 
Poly (ethylene glycol) methyl ether methacrylate (average Mn 300 gmol
-1) (98%) 
(OEGMA), (hydroxyethyl) methacrylate (98%) (HEMA), α-bromoisobutyryl 
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bromide (98%) (EBrIB), 2,2’-bipyridyl (>99%) (bpy), Copper (I) Chloride (Cu(I)Cl) 
(97%), 2-cyano-2-propyl benzodithioate (97%) (CPBD) and 2,2’-azobis(2-
methylpropionitrile) (98%) (AIBN) were purchased from Sigma Aldrich and used as 
received. Mono methacryloxypropyl polydimethylsiloxane methacrylate (molecular 
weight 985 and 4,600 gmol-1) (PDMSMA) and methacryloxypropyl 
polydimethylsiloxane dimethacrylate (molecular weight 390, 4,460 and 21,250 gmol-
1) (PDMSDMA) were purchased from Gelest and used as received. Activated 
aluminum oxide (neutral) was also purchased from Sigma Aldrich and used as 
received.  
6.6.2 ATRP 
 
All ATRP polymerisations were conducted at a constant ratio to initiator bromine 
atoms of [Br]:[Cu(I)Cl]:[Bpy] =  1:1:2.   
 
6.6.2.1 Linear Polymerisation: p(OEGMA) 
 
In a typical synthesis, targeting DPn = 30 monomer units, OEGMA (5 g, 17 mmol), 
EBrIB (0.11 g, 0.55 mmol) and bpy (0.17 g, 1.09 mmol) were added to a 25 mL 
round-bottomed flask equipped with a magnetic stirrer bar.  IPA/H2O (92.5/7.5, 5.1 
mL, 55 wt.% with respect to monomer; deoxygenated via Ar purge) was added and 
the resulting solution was purged with Ar for 15 minutes.  Cu(I)Cl (54.99 mg, 0.55 
mmol) was rapidly added to the flask whilst maintaining a positive Ar flow, instantly 
forming a brown mixture.  The reactor was submerged into an oil bath pre-heated to 
30 °C, and left to stir.  The polymerisation was stopped by cooling the flask to 
ambient temperature, exposing its contents to air and diluting the reaction medium 
with THF forming a blue mixture.  The polymer solution was passed through a 
neutral alumina column to remove the catalyst using THF as the mobile phase.  The 
solution was concentrated by rotary evaporation and precipitated into cold 
petroleum-ether (40-60) to give a white solid.  The sample was dried under vacuum 
at 40 °C for 24 hours and analysed by 1H NMR in D2O and GPC with a mobile phase 
of DMF.  
 
 
6.6.2.2 Linear Copolymerisation: p(OEGMA-co-HEMA) 
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In a typical synthesis, targeting DPn = 30 monomer units (50/50 OEGMA/HEMA), 
OEGMA (2.5 g, 8.33 mmol), HEMA (1.09 g, 8.33 mmol), EBrIB (0.11 g, 0.55 
mmol) and bpy (0.17 g, 1.09 mmol) were added to a 25 mL round-bottomed flask 
equipped with a magnetic stirrer bar.  IPA/H2O (92.5/7.5, 3.6 mL, 55 wt % wrt. 
monomer; deoxygenated via Ar purge) was added and the resulting solution was 
purged with Ar for 15 minutes.  Cu(I)Cl (54.99 mg, 0.55 mmol) was rapidly added to 
the flask whilst maintaining a positive Ar flow, instantly forming a brown mixture.  
The reactor was submerged into an oil bath pre-heated to 30 °C, and left to stir.  The 
polymerisation was stopped by cooling the flask to ambient temperature, exposing its 
contents to air and diluting the reaction medium with MeOH forming a blue mixture.  
The polymer solution was passed through a neutral alumina column to remove the 
catalyst using MeOH as the mobile phase.  The solution was concentrated by rotary 
evaporation and precipitated into cold petroleum-ether (40-60) to give a white solid.  
The sample was dried under vacuum at 40 °C for 24 hours and analysed by 1H NMR 
in MeOH-d3 and GPC with a mobile phase of DMF.  
 
6.6.2.3 Branched Polymerisation: p(OEGMA-co-HEMA-co-PDMSDMA) 
 
In a typical synthesis, targeting DPn = 30 monomer units (50/50 OEGMA/HEMA), 
OEGMA (2.5 g, 8.33 mmol), HEMA (1.09 g, 8.33 mmol), PDMSDMA (Mn 390 
gmol-1, 0.21 g, 0.53 mmol; 0.95 equiv. relative to initiator), EBrIB (0.11 g, 0.55 
mmol) and bpy (0.17 g, 1.09 mmol) were added to a 25 mL round-bottomed flask 
equipped with a magnetic stirrer bar.  IPA/H2O (92.5/7.5, 3.6 mL, 55 wt % wrt. 
monomer; deoxygenated via Ar purge) was added and the resulting solution was 
purged with Ar for 15 minutes.  Cu(I)Cl (54.99 mg, 0.55 mmol) was rapidly added to 
the flask whilst maintaining a positive Ar flow, instantly forming a brown mixture.  
The reactor was submerged into an oil bath pre-heated to 30 °C, and left to stir.  The 
polymerisation was stopped by cooling the flask to ambient temperature, exposing its 
contents to air and diluting the reaction medium with CHCl3 forming a blue mixture.  
The polymer solution was passed through a neutral alumina column to remove the 
catalyst using CHCl3 as the mobile phase.  The solution was concentrated by rotary 
evaporation and precipitated into cold petroleum-ether (40-60) to give a white solid.  
The sample was dried under vacuum at 40 °C for 24 hours and analysed by 1H NMR 
spectroscopy in CDCl3 and GPC with a mobile phase of THF.  
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6.6.2.4 Kinetic Studies 
 
Kinetic studies (i.e. plots ln([M]0/[M]) = f (conversion)) were performed by taking 
samples from the reaction medium under positive pressure of Ar and analysing them 
by 1H NMR spectroscopy (with anisole as an internal reference) and GPC.  The 
monomer conversion was determined by 1H NMR; the vinyl protons of the residual 
monomer located at 6.08 and 5.65 ppm were integrated and compared to the 
integrated values of the anisole aromatic peaks (6.97 and 7.32 ppm).  This allowed 
the conversion to be estimated using the following equation: 
Conversion = [1 – (2*I1/I2)]*100 
where I1 and I2 are the integrals of the NMR signals at 5.6 (or 6.08 ppm) and 6.97 
ppm.  The catalytic system was removed from the kinetic samples prior to GPC 
analysis by passing them through a neutral alumina column. 
 
6.6.3 Monomer Functionalisation  
 
DCM (20 mL) and HEMA (5 g, 38.42 mmol) were added to a 50 mL round-bottom 
flask containing a magnetic stirrer bar and fitted with a N2 inlet.  atRA or Ibu (42.26 
mmol) and DMAP (0.94 g, 7.68 mmol) were dissolved in DCM (10 mL) and added 
to the mixture.  DCC (8.72 g, 42.26 mmol) was dissolved in DCM (5 mL) and added 
to start the reaction.  The mixture was stirred at ambient temperature for 48 hours, in 
the dark for atRA. The precipitated DCU by-product was removed by filtration.  The 
product was isolated by diluting the mixture with DCM and washing it twice with 
water to remove the unreacted HEMA and twice with 1 M NaHSO4 to remove the 
DMAP catalyst.  The organic layer was dried over MgSO4 and evaporated to dryness.  
A purified product was then obtained following column chromatography (silica gel, 
eluting hexane increasing to hexane/ethyl acetate 50/50) and analysed by 1H NMR 
(400 MHz, CDCl3 atRAEMA and MeOD IbuEMA). 
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Scheme 6.1 Steglich esterification of both atRA and Ibu with HEMA monomer. 
 
atRAEMA: d 7.01 (dod, 1H, CH-CH=CH), 6.29 (m, 1H×2, C-CH=CH and C=CH-
C(CH3)), 6.14 (m, 1H×2, C=CH-C(CH3)=CH-CH and 1H, CH2=C(CH3) 5.79 (s, 1H, 
C(CH3)=CH-C(O)O), 5.59 (s, 1H CH2=C(CH3)), 4.37 (m, 2Hx2, O-CH2-CH2-OCO), 
2.35 (s, 3H, CH-C(CH3)=CH)  2.02 (m, 1Hx2, CH-CH-C(CH3)=C), 1.95 (s, 3H, 
CH2=C(CH3)) 1.72 (s, 3H, CH-C(CH3)=C), 1.62 (dod, 2H, CH2-CH2-CH2), 1.47 (d, 
2H, CH2-CH2-C(CH3)2), 1.03 (s, 3H×2, CH2-C(CH3)2-C). 
IbuEMA: d 7.08/6.97 (d, 2H×2, CH from aromatic ring), 5.88/5.46 (s, 1Hx2, 
CH2=C(CH3)), 4.74 (m, 2Hx2, O-CH2-CH2-OCO), 3.63 (q, 1H, OC(O)-CH(CH3)-C), 
2.32 (d, 2H, C-CH2-CH(CH3)2), 1.74 (m, 1H, C-CH2-CH(CH3)2) and 3H, 
CH2=C(CH3)), 1.34 (d, 3H×2, OC(O)-CH(CH3)-C), 0.79 (d, 6H, C-CH2-CH(CH3)2). 
 
6.6.4 Postfunctionalisation of p(HEMA) 
 
Toluene (20 mL) and p(HEMA) (0.5 g, 0.13 mmol) were added to a 50 mL round- 
bottom flask containing a magnetic stirrer bar, fitted with a N2 inlet and heated to 40 
°C.  atRA or Ibu (4.55 mmol) and DMAP (0.159 g, 1.3 mmol) were dissolved in 
degased toluene (10 mL) and added to the mixture.  DCC (0.939 g, 4.55 mmol) was 
dissolved in degased toluene (5 mL) and added dropwise to start the reaction.  The 
mixture was stirred at ambient temperature for 4 days, in the dark for atRA. The 
precipitated DCU by-product was removed by filtration.  The liquid was 
concentrated in vacuo and the resulting ester was isolated by precipitation from the 
minimum amount of MeOH into ethyl acetate and analysed by 1H NMR (400 MHz, 
CDCl3). 
 
atRA 
(36 %) 
DCC, DMAP 
DCM Ambient T ,  
2 days 
Ibu 
(98 %) 
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6.6.5 RAFT 
 
All RAFT polymerisations were conducted at a constant ratio of chain transfer agent 
to initiator [CPBD]:[AIBN] = 1:0.2.  
  
6.6.5.1 Linear Polymerisation: p(OEGMA) 
 
In a typical synthesis, targeting DPn = 60 monomer units, AIBN (2.7 mg, 0.016 
mmol), CPBD (18.4 mg, 0.083 mmol) and OEGMA (1.5 g, 5 mmol) were added to a 
25 mL Schlenk tube equipped with a magnetic stirrer bar.  tBuOH (4.5 mL, 30 wt % 
wrt. monomer, deoxygenated via N2 purge) was added and the resulting solution 
degassed by five cycles of freeze/pump/thaw.  After the final thaw cycle, the flask 
was backfilled with N2.  The reaction flask was placed into a pre-heated oil bath 
(70 °C) and stirred for 8 hours, after which the reaction medium was observed to be 
slightly turbid.  The polymerization was stopped by cooling the flask to ambient 
temperature, exposing its contents to air and diluting the reaction medium with 
tBuOH.  The solution was concentrated by rotary evaporation and precipitated into 
cold petroleum-ether (40-60) to give a pink solid.  The sample was dried under 
vacuum at 40 °C for 24 hours and analysed by 1H NMR in D2O and GPC with a 
mobile phase of DMF.  
 
6.6.5.2 Linear Polymerisation p(OEGMA-co-PDMSMA) 
 
In a typical synthesis, targeting DPn = 60 monomer units (OEGMA/PDMSMA 
50/50), AIBN (2.7 mg, 0.016 mmol), CPBD (18.4 mg, 0.083 mmol), OEGMA (0.148 
g, 0.492 mmol) and PDMSMA (Mn 985 gmol
-1, 1.5 g, 1.524 mmol) were added to a 
25 mL Schlenk tube equipped with a magnetic stirrer bar.  tBuOH (4.96 mL, 30 wt % 
wrt. monomer, deoxygenated via N2 purge) was added and the resulting solution 
degassed by five cycles of freeze/pump/thaw.  After the final thaw cycle, the flask 
was backfilled with N2.  The reaction flask was placed into a pre-heated oil bath 
(70 °C) and stirred for 24 hours, after which the reaction medium was observed to be 
slightly turbid.  The polymerisation was stopped by cooling the flask to ambient 
temperature, exposing its contents to air and diluting the reaction medium with 
tBuOH.  The solution was concentrated by rotary evaporation and precipitated into 
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cold MeOH to give a pink liquid.  The sample was dried under vacuum at 40 °C for 
24 hours and analysed by 1H NMR in CDCl3 and GPC with a mobile phase of THF.  
 
6.6.5.3 Branched Polymerisation: p(OEGMA-co-PDMSMA-co-PDMSDMA) 
 
In a typical synthesis, targeting DPn = 60 monomer units (OEGMA/PDMSMA 
50/50), AIBN (5.6 mg, 0.034 mmol), CPBD (37.5 mg, 0.169 mmol), OEGMA (1.524 
g, 5 mmol), PDMSMA (Mn 985 gmol
-1, 5 g, 5 mmol) and  PDMSDMA (Mn 1,275 
gmol-1, 0.205g, 0.158 mmol) were added to a 100 mL Schlenk tube equipped with a 
magnetic stirrer bar.  tBuOH (20.3 mL, 30 wt % wrt. monomer, deoxygenated via N2 
purge) was added and the resulting solution degassed by five cycles of 
freeze/pump/thaw.  After the final thaw cycle, the flask was backfilled with N2.  The 
reaction flask was placed into a pre-heated oil bath (70 °C) and stirred for 24 hours, 
after which the reaction medium was observed to be slightly turbid.  The 
polymerization was stopped by cooling the flask to ambient temperature, exposing its 
contents to air and diluting the reaction medium with tBuOH.  The solution was 
concentrated by rotary evaporation and precipitated into MeOH) to give a pink 
liquid.  The sample was dried under vacuum at 40 °C for 24 hours and analysed by 
1H NMR spectroscopy in CDCl3 and GPC with a mobile phase of THF.  
 
6.6.5.4 CTA Removal from p(PDMS(9)48-co-OEGMA12) 
 
A ratio of polymer:AIBN = 1:20 was used.  p(PDMS(9)48-co-OEGMA12) (5.3811 g, 
0.112 mmol) was dissolved in toluene (73 mL, deoxygenated via Ar purge) in a 100 
mL schlenk flask equipped with a stirrer bar.  AIBN (369 mg, 2.24 mmol) was added 
to the reaction flask and purged with Ar.  The temperature was raised to 80 °C for 
2.5 hours.  After the reaction with AIBN, the polymer was precipitated in cold 
MeOH and a white liquid was isolated by decanting the MeOH.  The product was 
dried in vacuo then analysed by 1H NMR spectroscopy in CDCl3. 
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6.6.6 Solubility of Polymers in SiO 
 
6.6.6.1 p(OEGMA-co-HEMA) Linear and Branched  
 
In a typical solubilisation experiment, p(OEGMA-co-HEMA) copolymer (1 mL) and 
SiO1000 (1 mL) were syringed into a glass vial to create a 50 v/v % mixture and 
placed on a roller for 3 days.  The solutions were diluted systematically by adding 
SiO1000 to decrease the amount of polymer by 10 v/v%, rolled for 3 days each time, 
until a soluble concentration was reached (i.e. 40, 30, 20, 10 and also 5 and 1 v/v% 
were tested). 
    
6.6.6.2 p(OEGMA-co-PDMSDMA) Branched 
 
Blends of the amphiphilic p(OEGMA15) branched with both PDMSDMA Mn 390 and 
1,275 gmol-1 (m = 1 and 12 respectively) at 0.1, 1, 5 and 10 % (v/v) in SiO1000 were 
made.  The blends were stirred at ambient temperature for 2 days without any 
change, then placed at 37 °C for 2 days and stirred at ambient temperature for a 
further 3 days.  No change occurred, no solubility was observed.  THF (5 mL) was 
added to solubilise the mixtures which were then left covered overnight.  THF was 
allowed to evaporate over 7 days by stirring the blends in a fume cupboard at 
ambient temperature.   
 
6.6.6.3 p(OEGMA-co-PDMSMA) Linear and Branched 
 
Same methodology as 6.6.4.1 was used.  
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Figure A1 
1
H NMR (CDCl3, 400 MHz) of atRA. 3.5 years after receipt. 
 
Figure A2 HPLC of atRA stored at -20 °C in the dark under Argon. 
 
Figure A3 HPLC of atRA stored at ambient temperature in light under Argon after 1 and 7 days. 
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Figure A4 CI-MS of atRA stored at ambient temperature in light under Argon after 7 days. 
 
Figure A5 
1
H NMR (CDCl3, 400 MHz) of atRA stored at ambient temperature in light under Argon 
after 1 and 7 days with atRA reference spectra. 
 
Figure A6 HPLC of atRA stored at ambient temperature in light and air after 1 and 7 days. 
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Figure A7 CI-MS of atRA stored at ambient temperature in light in air after 7 days. 
 
Figure A8 
1
H NMR (CDCl3, 400 MHz) of atRA stored at ambient temperature in air after 1 and 7 
days with atRA reference spectra. 
 
Figure A9 HPLC of atRA stored in EtOH at -20 °C in the dark under Argon after 1, 7 and 28 days. 
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Figure A10 ES-MS of atRA stored in EtOH at -20 °C in the dark under Argon after 28 days. 
 
 
Figure A11 
1
H NMR (EtOH-d6, 400 MHz) of atRA stored in EtOH at -20 °C in the dark under Argon 
at t=0 and after 1, 7 and 28 days. 
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Figure A12 HPLC of atRA stored in EtOH at -20 °C in the dark in air after 1, 7 and 28 days. 
 
Figure A13 ES-MS of atRA stored in EtOH at -20 °C in the dark in air after 28 days. 
 
Figure A14 
1
H NMR (EtOH-d6, 400 MHz) of atRA stored in EtOH at -20 °C in the dark in air at t=0 
and after 1, 7 and 28 days. 
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Figure A15 HPLC of atRA stored in EtOH at ambient temperature in the light in air after 1 and 7 
days. 
 
Figure A16 ES-MS of atRA stored in EtOH at ambient temperature in the light in air after 7 days. 
 
Figure A17 
1
H NMR (EtOH-d6, 400 MHz) of atRA stored in EtOH at ambient temperature in the light 
in air at t=0 and after 1 and 7 days . 
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Figure A18 HPLC of atRA stored in DMSO at -20 °C in the dark in air after 1 and 7 days. 
 
Figure A19 ES-MS of atRA stored in DMSO at -20 °C in the dark in air after 7 days. 
 
Figure A20 
1
H NMR (DMSO-d6, 400 MHz) of atRA stored in DMSO at -20 °C in the dark in air after 
1 and 7 days. 
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Figure A21 HPLC of atRA stored in DMSO at 37 °C in light, in air after 1 and 7 days. 
 
Figure A22 ES-MS of atRA stored in DMSO at 37 °C in light, in air after 7 days. 
 
Figure A23 
1
H NMR (DMSO-d6, 400 MHz) of atRA stored in DMSO at 37 °C in light, in air after 1 
and 7 days. 
APPENDIX 
239 
 
 
Figure A24 
1
H NMR (DCM-d2, 400 MHz) of atRA stored in DCM at ambient temperature in the dark, 
under argon after 1, 4 and 7 days . 
 
 
Figure A25 
1
H NMR (CDCl3, 400 MHz) of atRA and atRA in SiO after autoclave.  
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Figure A26 
1
H NMR (CDCl3, 400 MHz)of  Me-PEO Benzoate. 
 
Figure A 27 
1
H NMR (CDCl3, 400 MHz)of  Me-PEO Retinoate with CDI intermediate. 
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Figure A28 
1
H-
1
H NMR (CDCl3, 400 MHz) of  Me-PEO Retinoate 
 
Figure A29 
1
H-
13
C NMR (CDCl3, 400 MHz) of  Me-PEO Retinoate. 
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Figure A30 CI-MS of Me-PEO-atRA. 
 
Figure A31 IR spectroscopy of Me-PEO-atRA. 
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Figure A32 
13
C NMR (CDCl3, 100 MHz), of Me-PEO Benzoate. 
 
Figure A33 IR Spectroscopy of Me-PEO Benzoate. 
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Figure A34 
1
H NMR (CDCl3, 400 MHz) p(OEGMA24-co-HEMA6) at hourly time points throughout 
polymerisation. 
 
Figure A35 
1
H NMR (CDCl3, 400 MHz) Polymerisation of p(OEGMA24-co-HEMA6-co-
PDMSDMA0.95) at T=0. 
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Figure A36 
1
H NMR (CDCl3, 400 MHz) atRAEMA with integrations. 
 
Figure A37 
1
H NMR (MeOD,, 400 MHz) IbuEMA with integrations. 
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Computational modelling was performed by E. Eden (University of Liverpool) using 
the following: ground state geometries of conjugated esters were optimised at the 
HF/6-31G(d) level of theory using the Spartan ’10 v1.1.0 software package. 
Calculations were conducted in vacuo using default parameters in Spartan ’10. 
Orbital energies and coefficients were calculated at the same level of theory. 
Coefficients, associated with the contribution of the pz orbital at the carbonyl carbon 
to the HOMO, were used to estimate reactivity of the carbonyl moiety.  
 
Double Bonds 
Present (m) 
Ethylene Glycol 
units (n) 
ELUMO (eV) EHOMO (eV) P(z) 
1 4 3.07 -8.95 1.00 
2 4 1.67 -8.67 0.86 
3 4 1.98 -7.95 0.73 
4 4 1.78 -7.55 0.67 
 
 A38 Computational Modelling Parameters  
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Figure A39 MTT and resazurin assay to determine the cytotoxicity of Me-PEO48-atRA at different 
concentrations from 10
-3 – 10-8 M, and control cells without exposure and with 20 % DMSO. ARPE-
19 cells were grown and treated for different time scales.  Pre-confluent cells (grown for 1 d) were 
exposed to Me-PEO48-atRA for 1 d (black) and 7 d (red).  Post-confluent cells (grown for 7 d) were 
also exposed to Me-PEO48-atRA for 1 d (blue) and 7 d (green).  (mean, error bars represent ± 1 
standard deviation ); n=3. *, Significance by ANOVA and Dunnett’s T3 post- hoc evaluation 
(p≤0.05). 
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Figure A40 MTT and resazurin assay to determine the cytotoxicity of Me-PEO48-Ibu at different 
concentrations from 10
-3 – 10-8 M, and control cells without exposure and with 20 % DMSO. ARPE-
19 cells were grown and treated for different time scales.  Pre-confluent cells (grown for 1 d) were 
exposed to Me-PEO48-Ibu for 1 d (black) and 7 d (red).  Post-confluent cells (grown for 7 d) were also 
exposed to Me-PEO48-Ibu for 1 d (blue) and 7 d (green).  (mean, error bars represent ± 1 standard 
deviation ); n=3. *, Significance by ANOVA and Dunnett’s T3 post- hoc evaluation (p≤0.05). 
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Figure A41 
1
H NMR (CDCl3, 400 MHz) atRA-PDMS. 
 
Figure A42 
13
C NMR (CDCl3, 100 MHz) atRA-PDMS. 
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Figure A43 
13
C NMR (CDCl3, 100 MHz) atRA(black) and atRA anhydride (blue). 
 
Figure A44 
1
H NMR (CDCl3, 400 MHz) PDMS-atRA before (black) and after treatment with 10 
equivalents HCl in THF at 40 °C (blue). 
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Figure A45 
1
H NMR (CDCl3, 400 MHz) PDMS-atRA before (black) and after treatment with 10 
equivalents HCl in dioxane at 40 °C (blue). 
 
Figure A46 
1
H NMR (CDCl3, 400 MHz) PDMS-atRA before (black) and after treatment with 10 
equivalents HCl in dioxane at 60 °C (blue). 
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Figure A47 UV-Vis Spectra of atRA in media at various concentrations, showing overlap of FCS 
peak with atRA at 364 nm. 
 
Figure A48 Cumulative percentage release of atRA from SiO and blends from saturation 
concentration. 
 
Figure A49 Cumulative percentage release of atRA from SiO and blends from a starting 
concentration of approximately 50 µg/mL. 
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Figure A 50 Technical data sheet supplied by ARC with 
3
H atRA of HPLC using Zorbex ODS 
column and the mobile phase: ACN 1 % triethylammonium acetate PH 4, (70:30). 
